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Abstract
H um an cytomegalovirus (HCMV) is the m ost com m on viral infection 
com plicating stem  cell transplantation, and if untreated  frequently results 
in a  fatal outcome. In order to identify the  main risk factors for HCMV 
infection, a retrospective study of all allogeneic stem  cell transplants 
perform ed over a five year period at a  single centre w as undertaken. The 
main risk factors for HCMV infection following transplantation were 
identified a s  a  HCMV seropositive donor and/or recipient and in-vivo use  
of th e  monoclonal antibody, anti-CD52 (alem tuzum ab). A prospective 
s tudy  of HCMV viral loads determ ined by real time PCR using a  Taqm an 
p ro b e  w as undertaken, and  the viral load dynam ics of 57 patients were 
an a ly sed . Despite the use  of aciclovir prophylaxis, PCR monitoring and 
pre-em ptive therapy, the peak  viral load, viral replication rate and  the  total 
duration of viraemia remain significant risk factors for sym ptom atic HCMV 
infection. Peak  viral load w as th e  m ost significant predictor of time to viral 
c lea ran ce . A prospective longtitudinal study of the reconstitution of the 
HCMV specific immune re sp o n se  following allogeneic stem  cell 
transplantation  was perform ed in 20 patients using intracellular interferon 
g am m a staining and flow cytom etry. HCMV infection w as asso c ia ted  with 
a  significantly reduced HCMV specific CD4+ T cell response.
Furtherm ore, in patients receiving in-vivo anti-CD52, HCMV specific 
CD 4+ T cell immune recovery w as significantly delayed. An HLA class II 
ep itope mapping study w as undertaken in stem  cell transplant recipients 
and  healthy controls using peptide pools consisting of 15 m er overlapping
p ep tid es  spanning the entire amino acid se q u e n ce  of the HCMV proteins, 
pp65 and  IE1. Using intracellular cytokine detection in CD4+ T cells, a  
num ber of novel HCMV specific c lass II ep itopes w ere identified. 
T ransp lan t recipients responded to a  broader range of epitopes than 
HCMV seropositive controls. T h ese  results have important implications 
for HCMV specific immunotherapy in allogeneic stem  cell transplantation.
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ADCC = Antibody dependent cell-mediated cytotoxicity
AML = Acute myeloid leukaemia
APC = Allophycocyanin
APC = Antigen presenting cell
ATG = Anti-thymocyte globulin
BAL = Bronchoalveolar lavage
BEAM = Carmustine, etoposide, cytosine arabinoside and melphalan
BSA = Bovine serum albumin
CLL = Chronic lymphocytic leukaemia
CML = chronic myeloid leukaemia
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GVHD = Graft versus host disease
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NK = Natural killer
NMDP = National marrow donor program
ORF = Open Reading Frame
PBMC = Peripheral blood mononuclear cells
PB SC = Peripheral blood stem cells
PCR = Polymerase Chain Reaction
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PerCP = Peridinin chlorophyll protein
PMA = Phorbol 12-myri state 13-acetate
PMN = Polymorphonuclear leukocytes
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Definitions and Conventions
The following terms with reference to HCMV are defined for the purpose of the 
thesis
Infection = the detection of HCMV by PCR, and may occur in the presence or 
absence of HCMV disease.
Primary infection = infection in a patient not previously infected with HCMV.
Reactivation = the detection of HCMV viraemia by PCR in a patient with 
proven previous HCMV infection as evidenced by HCMV positive serology.
Latency = “the persistence of viral genome in the absence of production of 
infectious virions, but with the ability of the viral genome to reactivate after 
specific stimuli” (Sinclair and Sissons, 2006).
HCMV Disease = the presence of end organ damage due to HCMV infection.
HCMV Serostatus = The serostatus of recipient and donor pairs are expressed 
with recipient serostatus first and donor serostatus second. It is acknowledged 
that this differs from the convention used in solid organ transplantation but has 
been used due to the greater importance of the recipients serostatus on the risk of 
HCMV infection or reactivation in allogeneic stem cell transplantation. A + sign 
is used to indicate a positive serology and a -  sign is used to indicate a negative 
serology. Thus:
R+D+ = Recipient HCMV seropositive/Donor HCMV seropositive 
R+D- = Recipient HCMV seropositive/Donor HCMV seronegative 
R-D+ = Recipienet HCMV seronegative/Donor HCMV seropositive 
R-D- = Recipient HCMV seronegative/Donor HCMV seronegative
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Introduction
1.1 Allogeneic Stem Cell Transplantation
1.1.1 A Historical Perspective
Although the first recorded  organ transplant w as perform ed in 1906 by 
Alexis Carrel, a  British surgeon and pioneer in vascular surgery who 
described the xenotransp lan t of a  hum an kidney (Jaboulay, 1906), the 
ground work for transplantation w as laid by the Australian virologist,
Frank Burnet, a  Noble laureate, with his hypothesis of the  immunological 
recognition of self. M edawar, who was also aw arded the 1960 Noble 
Prize for Medicine or Physiology, first described acquired immune 
tolerance, showing th a t the  infusion of allogeneic bone marrow before 
immune com petence  in mice would result in to lerance of skin grafts from 
the bone m arrow donor but not from a third animal (Billingham et al., 
1953). However, solid organ transplantation in hum ans did not becom e 
routine until th e  pioneering work of Hume and co lleagues at Harvard 
Medical School, Boston, who elegantly described  the  clinical and 
pathological fea tu res  of graft rejection in a  series of 9 renal transplants 
(Hume et al., 1955). Murray, who w as aw arded  the Nobel Prize for 
M edicine in 1990, reported the first successful hum an allograft of a  kidney 
in an identical twin (Guild et al., 1955). Renal transplantation h as  now 
b eco m e com m onplace clinical practice. However, the field of bone 
m arrow  transplantation proved to be m ore problematic.
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1.1.2 Early Scientific Experiments
Early attem pts at infusion of hum an bone marrow to treat aplastic 
anaem ia  w ere unsuccessfu l (Osgood et al., 1939). However, the 
developm ent of the  atom ic bomb and its devastating effects in the 
S econd World W ar stim ulated research into radiation and its effect on the 
bone marrow. Jaco b so n  laid the groundwork for the concept of bone 
marrow transplantation when he dem onstrated that shielding the  sp leen  
protected mice from otherw ise lethal doses of ionizing radiation (Johnson 
et al., 1949). Lorenz then  show ed that intra peritoneal infusion of bone 
m arrow from a second  m ouse resulted in recovery of bone marrow 
function in lethally irradiated mice (Lorenz et al., 1951). It w as 
subsequently  show n that when irradiated mice are  infused with allogeneic 
bone marrow, they no longer reject skin grafts from the donor animal 
(Main and Prehn, 1955). As im m unosuppressive drugs w ere not available 
at this time, one of the  main stimuli to develop marrow transplantation 
cam e  from the desire to allow a recipient to tolerate kidney allografts.
1.1.3 Bone Marrow Transplant Pioneers
In 1957, E. Donnell Thom as, arguably the  father of bone marrow 
transplantation and later a  Noble laureate, using large quantities of 
m arrow reported transient engraftm ent in one patient (Thom as et al., 
1957). Two years later T hom as reported successfully transplanting two 
leukaem ia patients with bone marrow from their identical twins (Thom as 
e t al., 1959), although both patients relapsed a  few m onths later. Mathé, 
ano ther early pioneer in the  field of marrow transplantation.
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unsuccessfully transp lan ted  six victims of a radiation accident in 
Yugoslavia in 1959 (M athe et al., 1959). He later reported the first bone 
marrow transplant in a  patient with acute leukaem ia to survive longer then 
one year, although the patient died after 20 m onths from infection a s  a  
complication of chronic graft versus host d isea se  (M athe et al., 1963). 
Further clinical experience with bone marrow transplants in the 1950's 
and  60 s  were largely unsuccessful, thwarted either by failure of 
engraftm ent or overwhelming graft versus host d isea se  (GVHD).
During this time, extensive experim ents were being undertaken on dogs 
at the  Fred Hutchinson C ancer C entre in Seattle under the direction of 
Thom as. It was shown that following supra-lethal d o ses  of radiotherapy, 
dogs could recover if infused with autologous marrow harvested  prior to 
irradiation (Mannick et al,, 1960). Furthermore, the harvested  marrow 
could be frozen in dimethylsulfoxide (DMSO) and successfully re-infused 
into an irradiated dog at a  later date  (Thom as and Ferrebee, 1962;
C avins et al., 1962). However, allogeneic transplantation in dogs 
rem ained largely unsuccessful due to either GVHD or failure of 
engraftm ent, with the exception of the occasional transplant betw een 
litter-m ates (Thom as and Ferrebee, 1962).
1.1.4 Tissue Typing and Graft Versus Host Disease
A ccording to Billingham, there  are  th ree  requirem ents for the 
developm ent of GVHD; the graft m ust contain immunologically com petent 
cells, the  recipient m ust be unable to m ount an effective immune 
resp o n se  and the recipient m ust ex p ress  antigens not p resen t in the 
donor (Billingham, 1966). Acute GVHD occurs in the first hundred days
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following transplant and  is characterised by derm atitis, enteritis, and 
hepatitis. It is g raded  according to the criteria published by Glucksberg 
(Glucksberg et al., 1974). Chronic GVHD by definition occurs after one 
hundred days, either a s  continuation of acu te  GVHD or a s  a  de  novo 
presentation. Historically, chronic GVHD w as graded a s  limited or 
extensive according to criteria described by Shulm an (Shulm an et al., 
1980), although a  new grading system  based  on the extent of skin 
involvement (greater than 50%  of body surface area), p resen ce  of 
throm bocytopeania and  a progressive-type onset h as  been  proposed 
(Akpek, 2002).
In the early 1960’s, a s  a  result of the pioneering work of D ausset 
(D ausset, 1958), van Rood (van Rood and van Leeuwen, 1963), Payne 
and  Bodmer (Payne et al., 1964), polymorphisms within the  hum an 
lymphocyte antigen (HLA) com plex w ere identified, allowing 
histocompatibility testing to be performed betw een potential bone marrow 
donors and recipients. Using histocompatibility testing, the first HLA 
m atched sibling bone marrow transplant w as perform ed for a  child with 
immunodeficiency (Gatti et al., 1968). In the late 1970’s  T hom as reported 
his experience of 100 bone marrow transplants, perform ed for patients 
with acu te  leukaem ia, from HLA identical siblings, conditioned with 
cyclophospham ide 120mg/kg over two days and total body irradiation 
(TBI) 10 Gy, with only one graft rejection (Thom as et al., 1977). However, 
desp ite  matching by HLA, half the patients developed m oderate to severe  
GVHD, many requiring treatm ent with anti-thymocyte globulin (ATG). In 
addition, interstitial pneum onitis developed in 54 patients with a  fatal
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outcom e in 34 patients, and  the most common etiologic agen t w as hum an 
cytom egalovirus (HCMV), often in association with GVHD. This is one of 
the first stud ies to docum ent the severity of the impact of HCMV infection 
on stem  cell transplantation. An important observation at this time w as 
that the  p resen ce  of GVHD reduced the likelihood of leukaem ic relapse, 
the first description of graft-versus-leukaem ia effect (W eiden et al., 1979).
1.1.5 Post Transplant Immunosuppression and Refinements of 
the Conditioning Regimen
M ethotrexate adm inistered post bone marrow transplantation had 
previously been  show n to am eliorate GVHD in dogs (Storb et al., 1970). 
B ased  on this knowledge, the  Seattle team  introduced a regimen of 
m ethotrexate lOmg/m^on days 1, 3, 6 and 11 following infusion of the 
donor bone marrow (Storb et al., 1977; Storb et al., 1983; T hom as et al., 
1975a; Thom as et al., 1975b), later also  incorporating ciclosporin in 
com bination with m ethotrexate. More recently, the combination of 
ciclosporin and m ycophenolate h as  been  evaluated for the  prevention of 
graft v ersu s  host d isease  following stem  cell transplantation (B ornhauser 
et al., 1999).
A nother important early developm ent in reducing the long term  toxicity of 
bone marrow transplantation h as  been  fractionation of TBI (D eeg et al., 
1986; T hom as et al., 1982), later incorporated into a  protocol of 
cyclophospham ide 60mg/kg for 2 days and  12 Gy fractionated TBI. At the 
sam e  time, S an tos at the John Hopkins Medical School developed a  non- 
TBI regimen using busulfan 16mg/kg over 4 days and cyclophospham ide 
120mg/kg over two days (Santos et al., 1983).
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1.1.6 T-cell Depletion
Another approach to reducing the  risk of GVHD h as  been  to deplete the 
donor graft of T-cells, referred to a s  T-cell depletion (TCD). Early 
attem pts to deplete the  graft of T-cells involved the in-vitro addition of 
murine anti-thym ocyte globulin (ATG) and rabbit com plem ent to the graft 
(Martin et al., 1985). Although this significantly d ec rease d  the incidence 
of acu te  GVHD, graft failure occurred in eight out of the 20 NLA-matched 
patients transplanted in this way, and to overcom e this it w as n ecessary  
to increase the intensity of the conditioning regimen. A further downside 
of T-cell depletion is that it results in a  significantly increased  risk of 
leukaem ia relapse (Goldman et al., 1988). The u se  of monoclonal 
antibodies for T-cell depletion w as pioneered by Prentice and colleagues 
in 1982 (Prentice e t al., 1982), who show ed that the incidence of acute 
GVHD w as reduced from 79%  (based on an earlier cohort of 14 patients) 
to 18% in 17 patients T-cell depleted with the murine monoclonal 
antibody to CD3, 0KT3. It should be noted that in this cohort two patients 
died of dissem inated HGMV infection, another recognized complication of 
T-cell depletion. Using a  cocktail of two potent monoclonal T-cell 
antibodies, resulting in the removal of greater than 99%  donor 
lym phocytes from the graft, the sam e team  reported successfu l 
engraftm ent in 13 patients with no acu te  GVHD score g reater than 1 
desp ite  the ab sen ce  of post-transplant im m unosuppression (Prentice et 
al., 1984). In 1984, W aldm ann introduced the rat derived anti-CD52 
m onoclonal antibody, Cam path-1 to the transplant community, when he 
described  its use for T-cell depletion in 11 HLA-matched transplant
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patients (W aldmann et al., 1984), although two of the patients 
experienced late graft failure. Physical m ethods to deplete the graft of 
lym phocytes while retaining sufficient stem  cells for engraftm ent have 
also  been  em ployed, such  a s  counter flow centrifugation (W agner et al., 
1988; de Witte et al., 1986) and immuno-absorption colum ns (Dreger et 
al., 1995). D espite im provem ents in T-cell depletion, graft failure and 
increased  relapse ra tes continue to be a  significant problem, with the risk 
of graft rejection for HLA-matched sibling transplants with T-cell depleted  
grafts being 9 tim es that for non T-cell depleted grafts (Marmont et al., 
1991).
1.1.7 Unrelated Stem Cell Transplants
A m ajor limiting factor in bone marrow transplantation h a s  been  the 
availability of suitable donors. The ABO blood group barrier w as 
overcom e by G raw in 1974, when he transplanted a blood group A donor 
into a  blood group O recipient, using p lasm apheresis  and  W itensky’s  A 
su b stan ce  to reduce the anti-A titre (Graw, Jr. et al., 1974), although 
grafts from donors with m ajor ABO m ism atch are  now red cell depleted 
using autom ated  cell separato rs. However, for potential stem  cell 
transplant recipients, a  sibling h as  only a  25 percent chance  of being 
HLA-identical. As the average family size in the w estern world continues 
to fall, this limits the num ber of patients for whom sibling donors are  
available. T issue typing of ex tended  family m em bers m ay identify an  HLA 
identical non-sibling related donor in 10 percent of patients, with 
com parable results to HLA-matched sibling donor transplants (Beatty et 
al., 1985), but this still leaves 70 percent of patients without a m atched
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related donor. Using serological matching at the HLA-A, B and DR1 loci 
to identify m atched unrelated donors (so called 6 out of 6 match), 
successfu l outcom es following bone marrow transplant have been  
reported (H ansen et al., 1998), although the incidence of graft failure and 
sev ere  GVHD is g rea te r than HLA-identical siblings (Kernan et al., 1993; 
McGlave et al., 1990) . Further improvements in transplant results have 
been obtained using m olecular HLA typing techniques for both C lass I A, 
B and 0  loci (Sasazuki e t al., 1998), and class II DRB1 loci (Devergie et 
al., 1997; Petersdorf et al., 1995). In order to facilitate the availability of 
m atched unrelated bone marrow donors, large national registries have 
been  established, the  first being the Anthony Nolan Trust in the United 
Kingdom, with over 360,000 donors (www.anthonvnolan.orq.uk). The 
largest registry internationally is the National Marrow Donor Program  
(NMDP) in the United S ta tes  with over six million donors 
(w w w .nm dpresearch.ora). and through the International Bone Marrow 
Transplant Registry (IBMTR), patients have a c c e ss  to over 10 million 
potential donors. For C aucasian  patients, using sophisticated search  
algorithm s the ch ance  of finding at least a  six out of six HLA m atched 
unrelated  donor through the IBMTR is 83 percent although for other 
ethnic groups this is much lower.
1.1.8 Alternative Donor Sources
For patients without a  m atched related or unrelated donor, the Perugia 
group pioneered the technique of haplo-identical transplants (Aversa et 
al., 2005; Aversa et al., 1998). Intensive conditioning regim ens and T-cell 
depletion by CD34 selection w ere used to overcom e the problem of graft
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rejection and  sev e re  graft versus host d isease . The J a p a n e se  on the 
other hand have successfully  used the concept of feto-m aternal 
chimerism (Burlingham et al., 1998) to perform non T-cell depleted  haplo- 
identical transplants (Ichinohe et al., 2004; Narimatsu et al., 2004; O bam a 
et al., 2004; Y oshihara e t al., 2004). Another alternative to unrelated 
donor marrows is the use  of umbilical cord blood transplants, which allow 
a  greater deg ree  of HLA m ism atch with reduced ra tes of GVHD 
(Schoem ans et al., 2006). Although umbilical cord blood transp lan ts are  
asso c ia ted  with high ra tes of graft failure, this can be  overcom e by the 
u se  of double umbilical cord transplants (Barker et al., 2005; Majhail et 
al., 2006).
1.1.9 Peripheral Blood Stem Cell Transplants
Sufficient peripheral blood stem  cells (PBSC) to permit bone marrow 
recovery following m yeloablative chem otherapy can  be harvested  by 
ap h eresis  from patients with malignant d isea se  after stimulation with 
granulocyte colony stimulating factor (G-GSF) (Bensinger et al., 1993). 
This prom pted the harvesting of G-CSF stim ulated PB SC s from healthy 
donors for the  purpose of allogeneic transplantation (Dreger et al., 1993; 
Russell e t al., 1993). Using PBSC s for allogeneic stem  cell transplants 
results in earlier platelet and granulocyte engraftm ent, but is asso cia ted  
with a  higher risk of acute (Schmitz e t al., 2002) and  chronic GVHD 
(Blaise e t al., 2000) in som e but not all studies (Bensinger et al., 2001; 
Pow les et al., 2000). The CD34 cell dose  of the graft influences outcom e, 
a s  the u se  of peripheral blood stem  cells with a high GD34 d ose  (greater 
then  8.3X10®/Kg) for HLA identical sibling transplants have been  shown
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to increase mortality due to chronic GVHD when com pared to low d o se  
grafts (Mohty et al., 2003a). Both cell d ose  and stem  cell source influence 
outcom e. In HLA identical sibling stem  cell transp lan ts for s tandard  risk 
leukaem ia, the  b est outcom e is for patients receiving bone marrow with a  
high (greater then 2.7X10®) cell dose  (Gorin e t al., 2003), although in high 
risk leukaem ia patients, the  best outcom e is se en  with the u se  of PBSC 
(Bensinger et al., 2001).
1.1.10 Reduced Intensity Conditioning Transplants
Due to the toxicity asso c ia ted  with fully myeloablative conditioning 
regim ens, advanced  ag e  and  significant comorbidity have excluded many 
patients from being cand idates  for allogeneic stem  cell transplantation. In 
order to reduce toxicity and  offer allogeneic transplants to a  g reater 
num ber of patients, so  called non-myeloablative or reduced intensity 
conditioning (RIG) transplant regim ens have been  developed. The first 
RIG conditioning regimen w as in fact used in Seattle  for the treatm ent of 
aplastic anaem ia, consisting of cyclophospham ide 50mg/kg for four days 
(Storb et al., 1974). Modern reduced intensity conditioning regim ens use 
one of three approaches; low d o se  TBI with or without fludarabine 
(M cSw eeney et al., 2001), fludarabine and  an alkylating agen t (Girait et 
al., 1997), or T-cell antibodies such  a s  ATG (Slavin et al., 1998) or 
G am path-1H (alem tuzumab) (Kottaridis et al., 2000) in com bination with a 
purine analogue and alkylating agent. O ne third of allogeneic stem  cell 
transp lan ts now incorporate a  reduced intensity conditioning regimen 
(Gratwohl et al., 2006a).
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1.1.11 Donor Lymphocyte Infusion
Donor lymphocyte infusions (DLi) were first successfully em ployed to 
augm ent the donor derived anti-leukaem ia effect for patients relapsing 
following allogeneic transplantation for chronic myeloid leukaem ia (CIVIL). 
DLls have also been  used  to treat relapsed acu te  myeloid leukaem ia 
(AML), m yelodysplastic syndrom e (MDS) and myelofibrosis following 
myeloablative allogeneic transplants (Kolb et al., 1990), although this 
carries a  high risk of also  inducing graft-versus host d isease . In the 
setting of CML, the best results are obtained if DLI is perform ed at the 
time of m olecular or cytogenetic relapse and before full haem atological 
re lapse  (van R hee et al., 1998). Mixed donor chimerism is predictive of 
an increased  risk of relapse of CML (Mackinnon et al., 1994), and  acute 
leukaem ia (Bader et al., 2000; M attsson et al., 2001). With the advent of 
reduced  intensity conditioning regim ens, DLls have also  been  used  to 
convert patients to full donor chimerism, although with variable results 
(Bethge et al., 2004; Marks et al., 2002). A graft-versus tum our effect 
following DLI in patients transplanted  with a  reduced intensity 
conditioning regimen for Hodgkin’s d isease , Non-Hodgkin’s  Lymphoma 
and  multiple myeloma h as  been  dem onstrated (Peggs et al., 2003a; 
P eg g s e t al., 2005; Morris et al., 2004).
1.2 Indications for Aliogeneic Transplantation
Since the  late 1970s, the  num ber of allogeneic transplant procedures h as  
been  increasing steadily. In 2004 the num ber of first allogeneic transplant 
procedures reported to the  European Group for Blood and  Bone Marrow
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Transplantation (EBMT) w as 7,407 (Gratwohl et al., 2006a), with the 
majority perform ed for lymphoid and myeloid m alignancies. With 
continued im provem ents in supportive care and new technologies, the 
indications for allogeneic stem  cell transplantation continue to widen.
1.2.1 Acute Myeloid Leukaemia and Myelodysplasia
Notwithstanding im provem ents in chem otherapy the majority of patients 
with acu te  myeloid leukaem ia (AML) and m yelodysplastic syndrom e 
(MDS) succum b to resistant or relapsed d isease  (Burnett et al., 2002). In 
patients with poor or interm ediate risk AML b ased  on cytogenetic profiles, 
allogeneic stem  cell transplant when used  a s  first line therapy results in 
significantly better d isea se  free survival (DFS) in a  donor versus no donor 
analysis in three large prospective collaborative stud ies (Burnett et al., 
2002; Suciu et al., 2003; C ornelissen et al., 2007). A m eta analysis of all 
th ree  studies dem onstrates a  12 percent overall survival benefit by donor 
availability for patients without a  favourable cytogenetic profile 
(Cornelissen e t al., 2007). In good risk patients, such  a s  those  with 
t(8:21), inv(16) and t(15;17), the treatm ent related mortality (TRM) of 
transplantation outweighs the benefit. Transplantation offers the best 
ch an ce  of cure in patients with relapsed AML (Breem s e t al., 2005). 
P atien ts with primary refractory d isease  generally have a  dismal outlook, 
although Kolb’s  group have reported promising results using sequential 
therapy with fludarabine, high dose  cytarabine and  am sacrine 
chem otherapy followed three days later by a  RIG transplant (Schmid et 
al., 2005). The role of RIG transplant for AML patients unsuitable for 
conventional intensity conditioned transplants h as  also been  evaluated,
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and a  recent EBMT working party retrospective analysis com paring 
autografting with RIC transp lan ts in patients over 50 years of ag e  show ed 
for patients in first com plete remission, RIC is associa ted  with a  better 
DFS at the cost of a  g reater TRM. For patients in second  com plete 
remission, the TRM w as lower for RIC with a  DFS at one year of 76 
percent com pared to 31 percent for autografts (Herr et al., 2007).
1.2.2 Acute Lymphoblastic Leukaemia
Prior to the adaptation of combination therapy used  for paediatric ALL, 
adult ALL w as invariably fatal. However, only about 30 percent of adults 
a re  long term d isease-free  survivors following intensive chem otherapy 
and  this is even lower for relapsed ALL (Pui and Evans, 2006). A French 
study com paring chem otherapy, autologous transplantation and 
allogeneic transplantation for patients in first com plete rem ission found 
that allogeneic stem  cell transplantation show ed a  superior outcom e for 
high risk but not s tandard  risk ALL patients (Thiebaut et al., 2000). The 
J a p a n e se  found no difference in 6 year survival betw een patients 
allocated an HLA identical sibling allogeneic transplant or chem otherapy, 
although Ph+ ALL patients did show  superior survival with allogeneic 
transplantation (Takeuchi et al., 2002). The EORTC ALL-3 trial com paring 
an autologous transplant and m aintenance chem otherapy with an 
allogeneic transplant in patients in first com plete rem ission under 50 
years  of ag e  also failed to show  a  survival advan tage for allogeneic 
transplantation (Labar et al., 2004). A current evidence b ased  review of 
the  published literature supports the view that allogeneic stem  cell 
transplantation in first com plete remission should be reserved  for high risk
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ALL patients (Hahn et al., 2006), Age is one of the  m ost important 
prognostic risk factors for ALL but advancing ag e  is also associa ted  with 
an increasing TRM. In an attem pt to reduce the TRM, RIC transplants 
have been  evaluated  for ALL but are  assoc ia ted  with a high relapse risk 
(Hamaki et al., 2005).
1.2.3 Chronic Myeloid Leukaemia
Since the first description of allogeneic stem  cell transplantation for 
chronic myeloid leukaem ia (Fefer et al., 1979), allogeneic stem  cell 
transplantation has been recognized a s  the only therapy with curative 
potential in chronic myeloid leukaem ia. Long term d isea se  free survival 
ra tes  vary betw een 30 to 80 percent, depending on the s tag e  of d isea se  
at transplantation (Clift et al., 1993; Craddock et al., 2000; Goldman et al., 
1988; Thom as et al., 1986). A graft versus leukaem ia effect is well 
described (Weiden et al., 1979), and the risk of re lapse is increased  with 
T cell depletion (Goldman et al., 1988). This graft versus leukaem ia effect 
can  be utilised to treat re lapse following allogeneic stem  cell 
transplantation by the u se  of DLls (Barrett et al., 1998; Collins, Jr. et al., 
1997; Dazzi et al., 2000; Guglielmi et al., 2002; Kolb et al., 1990; Porter et 
al., 2000). RIC regim ens are increasingly being em ployed b ecau se  of the 
reduced  transplant related mortality (Crawley et al., 2005). However, 
s ince the introduction of targeted  molecular therapy for CML with the 
BCR:ABL tyrosine kinase inhibitor imatinib, the num ber of allogeneic 
transplant procedures perform ed for CML has fallen (Gratwohl et al., 
2006b), a s  most patients a re  now offered imatinib and proceed to 
transplant only if imatinib fails.
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1.2.4 Aplastic Anaemia
The m ost com m only em ployed conditioning regim en for aplastic anaem ia 
is cyclophospham ide 200 mg/kg and ATG 30mg/kg for th ree days with 
m ethotrexate and ciciosporin for GVHD prophylaxis, and  w as pioneered 
in Seattle (Storb et al., 1994). The outcom e for HLA identical sibling 
transplants is good, with long term survival ra tes of g reater than 80 
percent (Bacigalupo et al., 2000; Kahl et al., 2005), although graft 
rejection rem ains a  significant problem in betw een 5-15 percent of 
patients. This com pares favourably with an overall survival of 70 percent 
at 3-4 years for im m unosuppressive therapy with ATG and ciciosporin 
(Frickhofen et al., 2003). Recipients of m atched unrelated bone marrow 
transplants for sev ere  aplastic anaem ia fare significantly w orse with 
higher rates of acu te  and  chronic GHVD, and a  five year overall survival 
rate of betw een 39 and 61 percent (Bacigalupo et al., 2005; D eeg et al., 
2006; Kojima et al., 2001; P assw eg  et al., 2006). The role of allogeneic 
stem  cell transplantation in the inherited bone marrow failure syndrom es 
such  a s  Fanconi anaem ia is also well estab lished  (Dokal, 2003).
1.2.5 Thalassaemia and Sickle Cell Anaemia
T h a lassaem ia  major results in lifelong transfusion depen d en ce  with the 
incum bent co n seq u en ces  of iron overload and shortened  life expectancy. 
Lucarelli p ioneered stem  cell transplantation a s  a  curative procedure for 
th a lassaem ia  (Lucarelli e t al., 1984), and show ed that if patients were 
transplanted  before they developed hepatom egaly, portal fibrosis or 
significant iron overload, excellent results could be  achieved (Lucarelli et
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al., 1990). The first allogeneic transplant in a  patient with sickle cell 
d isea se  w as reported in 1984 for a patient also suffering from acu te  
myeloid leukaem ia (Johnson et al., 1984). The best results have been 
obtained in paediatric sickle cell patients with HLA identical sibling 
transplants (Vermylen et al., 1998; W alters et al,, 2000). Umbilical cord 
blood transplantation h as  also  been evaluated for both tha lassaem ia  and 
sickle cell d isea se  (Locatelli et al., 2003).
1.2.6 Other Haematological Conditions
T he treatm ent of choice for relapsed high grade lymphoma after salvage 
chem otherapy is high d o se  chem otherapy followed by an autologous 
transplant (Philip et al., 1987). Limited treatm ent options are  available to 
patients who relapse following autologous transplantation. A graft versus 
lymphoma effect has been  dem onstrated  following myeloablative 
allogeneic stem  cell transplantation (Jones et al., 1991). However the 
TRM following allogeneic stem  cell transplantation for lymphoma is high 
at up to 40 percent, and following a  failed autografting rises to betw een 
50 and 80 percent (Chopra et al., 1992; de  Lima M. et al., 1997; Jo n es  et 
al., 1991; Tsai et al., 1997; Verdonck et al., 1997). R educed intensity 
conditioning regim ens have generally failed to show  any im provem ent in 
outcom es for high grade lym phom as (Morris et al., 2004; Robinson et al., 
2002). Low grade lymphoma which is incurable by conventional 
chem otherapy and autologous transplantation, has shown promising 
results following reduced intensity conditioning transplantation (Escalon 
et al., 2004; Khouri et al., 2001; Robinson et al., 2002), especially when 
com bined with DLI (Faulkner et al., 2004; Morris et al., 2004).
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Transplantation of relapsed  Hodgkin’s d isea se  using a  RIC regimen h as  
also shown encouraging results (Peggs et al., 2005).
Chronic Lymphocytic Leukaem ia (CLL) is a d ise a se  with a  variable 
prognosis, but fludarabine refractory d isease  h as  a  very poor prognosis 
with a  m edian survival of eight m onths (Keating et al., 2002). Although 
allogeneic transplantation can result in lasting rem ission (Khouri et al., 
1997; Khouri et al., 2002), mortality with conventional conditioning 
regim ens is high with a  TRM of betw een 31 and 60 percent (Doney et al., 
2002; Michallet et al., 1996; Pavletic et al., 2000). R educed intensity 
conditioning regim ens have also  been used  for CLL (Delgado et al., 2006; 
Khouri e t al., 2004; Schetelig et al., 2003), and a  retrospective EBMT 
study h a s  dem onstrated  a reduced TRM (Dreger et al., 2005).
Idiopathic myelofibrosis (IM) h as  also been  successfully treated  with 
allogeneic stem  cell transplantation, with overall survival ra tes of betw een 
39 and 77 percent when conventional intensity conditioning regim ens are  
u sed  (Daly et al., 2003; Deeg et al., 2003; A nderson et al., 1997). R ecent 
reports using RIC regim ens for IM have shown extrem ely good overall 
survival rates of betw een 84 and 100 percent (Devine et al., 2002; Kroger 
et al., 2005; Merup et al., 2006; Rondelli e t al., 2005).
1.2.7 Congenital immunodeficiency Syndromes and Other 
Non-Malignant Conditions
Since the first report of a  successfu l bone marrow transplant for sev ere  
com bined immunodeficiency (Gatti et al., 1968), stem  cell transplantation 
is now perform ed for a  wide range of immune deficiency syndrom es 
including sev ere  com bined immunodeficiency, Wiskott Aldrich syndrom e,
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chronic granulom atous d isease , and leukocyte adhesion deficiency. 
Allogeneic transplants a re  also performed to treat inherited m etabolic 
disorders such a s  Hurlers syndrom e, adrenoleukodystrophy and 
osteopetrosis although they are  generally m ost effective before the 
patient is sym ptom atic (Yeager, 2002).
1.3 Complications of Transplantation
Since the developm ent of allogeneic stem  cell transplantation, treatm ent 
related mortality h as  steadily improved (Gratwohl et al., 2006b). This h as  
largely been b ecau se  of im provem ents in supportive care, such a s  better 
control of GVHD and  the prevention and treatm ent of infectious 
complications.
1.3.1 Infectious Complications
Due to the im m unosuppressed nature of allogeneic stem  cell transplant 
recipients, patients are  at a  greatly increased risk of opportunistic 
bacterial, fungal, and viral infections. D eaths from infections account for 
11% of all d ea th s  following transplantation for early leukaem ia, with 36% 
due to bacteria, 31%  due to viruses and  28% due to fungi (Gratwohl et 
al., 2005). The u se  of empiric antibiotics for the m anagem ent of 
neutropaenic fever h as  reduced the death  rate from bacterial infections, 
but the em ergence  of bacterial resistance such a s  vancom ycin-resistant 
en terococcus represen ts an increasing hazard (Avery e t al., 2005). While 
C andida albicans is effectively prevented by the use  of prophylactic 
azoles, invasive asperglllus infections remain a  major c a u se  of mortality
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following allogeneic transplant, although newer ag en ts  are becom ing 
available (Marr et al., 2002).
The m ost com m on viral infection complicating stem  cell transplantation is 
HCMV and is d iscussed  in further detail in the following sections. 
Reactivations of other latent herpes viruses are also responsible for 
significant morbidity and mortality. Prophylaxis with aciclovir is highly 
effective at preventing reactivation of H erpes simplex (HSV) infections. 
Ebstein Barr Virus (EBV) reactivation can result in EBV associa ted  Post 
Transplant Lymphoproliferative D isease (EBV-PTLD). Established EBV- 
PTLD carries a high mortality even when treated  by DLI and the 
monoclonal anti-CD20 antibody, Rituximab (Loren et al., 2003). Risk 
factors for EBV reactivation include T-cell depletion, reduced intensity 
conditioning and recently umbilical cord transplants (Brunstein et al.,
2006). Polym erase chain reaction (PCR) monitoring to guide pre-em ptive 
therapy either by modulation of im m unosuppression or u se  of Rituximab 
h as  been  shown to be effective in preventing the developm ent of EBV- 
PTLD (C esaro  et al., 2005; Kinch e t al., 2007). Im m unotherapy with donor 
derived EBV specific cytotoxic T cells h as  also been  shown to be 
effective (Liu et al., 2002). Reactivation of Human H erpes Virus 6 (HHV6) 
h as  been  associa ted  with delayed platelet engraftm ent and  can  cau se  
encephalitis and  hepatitis (Ljungman et al., 2000). Reactivation of 
varicella zoster virus (VZV) ten d s  to occur late after transplantation, and 
usually p resen ts  as  a  limited herp es  zoster (shingles) infection but may 
c a u se  a dissem inated varicella infection.
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Among the  non-herpes viruses complicating allogeneic stem  cell 
transplantation, one of the m ost important is adenovirus, reported to 
occur in betw een 5 to 21 percent of patients following stem  cell 
transplantation, with a  mortality of up to 50 percent (Chakrabarti et al., 
2002b). Paediatric transplant patients are at a  particularly high risk, and 
viral monitoring of blood and stool, with pre-em ptive cidofovir is 
recom m ended, white adoptive im m unotherapy is under evaluation 
(Feuchtinger et al., 2006). Respiratory viruses are  also important 
pathogens in allogeneic stem  cell transplant recipients. A prospective 
multicentre EBMT study docum ented an incidence of lower respiratory 
tract infection due to respiratory viruses of 2.1 percent, with respiratory 
syncytial virus and  influenzae A being the m ost com m on (Ljungman et al., 
2001b). BK virus is assoc ia ted  with painful hem orrhagic cystitis, and 
related donors a re  at g rea test risk, while RIC transplants ap p ear to be 
protective (Erard et al., 2005; Giraud et al., 2006).
The hepatitis viruses, particularly hepatitis B can also be a  major problem 
following transplantation. Hepatitis B viral loads can  increase markedly 
following allogeneic stem  cell transplantation in chronically infected 
patients, and  there  is a  high risk of fulminant hepatitis at the time of 
im m une recovery, although the  risk can be reduced by the  u se  of antiviral 
ag en ts  such lamivudine (Francisci et al., 2006).
1.3.2 Non-infectious Complications
Non-infectious complications are  generally the result of GVHD, 
com plications of the conditioning regimen or im m unosuppressive agen ts, 
or a  complication of drugs u sed  to treatm ent infection. All organ system s
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of the body m ay be affected following transplantation. Although by no 
m eans an exhaustive list, som e of the m ore com m on complications are  
listed in Table 1-1.
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Table 1-1 Major non-infectious complications of allogeneic stem cell transplantation.
Organ System Complication Cause
Pulmonary Idiopathic Pneumonitis
Diffuse Alveolar Haemorrhage Thromboc ytopaeni a
Bronchiolitis Obliteraans GVHD
Cardiac Cardiomyopathy
Arrhythmias
Cyclophosphamide, prior Anthracyclines
Cardiac Tamponade Thalassaemia
Renal Drug Nephrotoxicity Ciciosporin, Aminoglycoside, Amphotericin
BMT-related Thrombotic Microangiopathy HLA mismatched transplants
Hepatic Veno-occlusive Disease High dose busulfan
Liver GVHD HLA mismatched transplants
Gastrointestinal Gut GVHD HLA mismatched transplants
Mucositis TBI, methotrexate
Neurological Metabolic Encephalopathy Ciciosporin
Seizures Busulfan, Ciciosporin
Leukoencephalopathy Intrathecal methotrexate, cranial irradiation
Haematologic Immune Thrombocytopaenia 
Autoimmune Hemolytic Anaemia
Alloimmune Hemolytic Anaemia ABO incompatibility
Endocrine Hypothyroidism
Hyperthyroidism
TBI
Gynaecologic Infertility Radiation, high dose chemotherapy
Ocular Cataracts TBI
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1.4 Discovery of Human Cytomegalovirus
The first description of the  histopathological ch an g es  characteristic of 
HCMV infection w as m ade in 1904 by Jesionek  from an autopsy study of 
a prem ature infant thought to have died of syphilis (Jessionek, 1904). He 
described enlarged cells, 20-30 pm in diam eter, with intra-nuclear 
inclusions but attributed the ch an g es  to a  protozoa infection. The term 
‘cytomegali’ w as applied to th e se  histological features by G oodpasture 
and Talbot in 1921 (G oodpasture and Talbot, 1921). In 1926 Cole 
dem onstrated that th e se  histological ch an g es could be induced in guinea 
pigs by a  transm issible agent, and speculated that it w as m ost likely a  
virus (Cole and Kuttner, 1926). In 1956 the HCMV virus w as 
independently isolated by th ree groups (Rowe et al., 1956; Smith, 1956; 
Craig et al., 1957), with the nam e cytomegalovirus being applied by 
Weller’s group b ecau se  of the  effect of viral infection in cell culture. An 
electron micrograph im age of the HCMV virion, illustrating the capsid, 
tegum ent and envelope with surface glycoproteins is shown in Figure 1.1.
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Figure 1-1 Electron micrograph image of the HCMV virion (Courtesy of Vincent Emery).
1.5 Classification of Human Cytomegalovirus
HCMV is a member of the family Herpesviridae, subfamily 
Betaherpesviridae, genus Cytomegalovirus, and species Human 
herpesvirus 5. The family herpesviridae is characterised by a  linear 
double stranded DMA, an icosadeltahedral capsid, a  tegum ent and an 
envelope em bedded with glycoprotein spikes. Based on biological 
properties, the herpesviridae family is subdivided into three groups, the 
alphaherpesviridae, the betaherpeseviridae and the gam m aherpesviridae 
(Roizman, 1995). HCMV, along with Human herpesvirus 6 and human 
herpesvirus 7, belong to the betaherpesviridae subfamily, which is 
characterised by a slow replication in culture, cytomegalia formation, and 
latency in secretary glands, lymphoreticular cells, kidneys and other 
tissues.
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HCMV displays m any sites of genetic variability and  can  be subdivided 
into identifiable strains b ased  on genotyping. However, infection with one 
strain of HCMV d o es  result in a  level of immunity to other strains 
(Chandler and McDougall, 1986). The sequ en ce  for the gen e  encoding 
the  gB protein has been used  to subdivide HCMV into 4 genotypes (Chou 
and  Dennison, 1991), Although useful for epidemiological studies, the 
evidence that different genotypes have an influence on virulence and 
clinical outcom e is contradictory and inconclusive (Pignatelli et al., 2004).
1.6 Epidemiology of Human Cytomegalovirus
The overall prevalence of prior infection with HCMV in the general 
population is 70 percent for countries with good socio-econom ic status, 
and  90 percent for those  countries with a poor socio-econom ic sta tus 
(P ass , 1985). The virus is m ost commonly acquired during childhood, 
frequently from other children a s  dem onstrated by the increased 
frequency of infection am ong children attending day care  cen tres (P ass  et 
al., 1984). Infection a s  an adult may occur through sexual contact 
(Handsfield et al., 1985) or acquired from infected children a s  evidenced 
by the increased rate of infection am ong adult workers In childcare 
facilities (P ass  et al., 1990). HCMV can be found in saliva, sem en  and 
cervicovaginal secretions, and  in children the virus m ay be excreted  in 
the urine for many m onths following primary infection (Gehrz et al., 1982). 
Vertical transm ission occurs via the  transplacental route or intrapartum 
from cervical secretions p resen t at birth, a s  well a s  via hum an b reast milk 
postpartum . The HCMV transm ission rate to n eonates  of seropositive 
m others is 2.2 percent, and  in m others experiencing primary infection
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during gestation is a s  high a s  20 to 40 percent (Griffiths and Baboonian, 
1984). Nosocomial transm ission may occur a s  a result of receiving an 
HGMV infected solid organ or stem  cell graft or by a  blood transfusion, 
although the later risk is much reduced since the  adoption of universal 
leukodepletion (de Witte et al., 1990).
1.7 Human Cytomegalovirus Structure and Organisation
1.7.1 Structure
At 300 nm in diam eter, HCMV is the largest of the herpes viruses. It 
consists of a lipid envelope spiked by immunogenic glycoproteins and an 
icosadeltahedral capsid m ade up of 162 capsom eres enclosing the  DNA. 
By electron cryomicroscopy at a resolution of 18 Angstrom it has  been 
shown that the capsid  proteins form an icosahedral structure consisting of 
12 pentons, 150 hexons and  320 triplexes (Chen et al., 1999). Betw een 
the envelope and the  capsid  is the tegum ent, an electron d en se  layer 
containing proteins important for controlling host cell function following 
viral entry into the cell (S paete  et al., 1994; Britt and Mach, 1996; 
McGavran and Smith, 1965). As well a s  the com plete virus, two non- 
infectious forms can be identified on electron microscopy: the  d en se  body 
which is an am orphous structure without a capsid or DNA, and  the non- 
infectious enveloped particle, consisting of an em pty capsid (Roby and 
Gibson, 1986).
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1.7.2 Genomic Organisation
The HCMV genom e is organised into two linked segm en ts  (L and S). 
Each segm ent is m ade up of a  unique seq u en ce  (U l and Us) flanked on 
either side by an inverted repetitive segm ent (TR l, IR l, TRs, IRs), and the 
segm ents can be arranged into four concatam eric forms (Bankier et al., 
1991).
The first com plete genom e seq u en ce  for HCMV w as described for the 
highly p assag ed  ADI 69 strain, a  laboratory strain of HCMV initially 
developed a s  a  vaccine candidate (Elek and Stern, 1974). The genom e 
length is reported a s  235 kilobase pairs, and w as originally reported to 
encode 208 non overlapping O pen Reading Fram e's (ORF), with 14 
duplications (Chee et al., 1990). Recent work using sophisticated gene  
finding algorithms has attributed only 192 ORFs to the ADI 69 strain 
(Murphy et al., 2003a). C om pared to low p assag ed  (less then 4) strains 
such a s  Merlin and Toledo, 22 open reading fram es are  missing from the 
ADI 69 sequence  (Dolan et al., 2004; C ha et al., 1996). T hom as S henk’s  
team  at Princeton University has recently com pared the seq u en ce s  of 
ADI 69 and Towne HCMV strains to the Toledo and clinical HCMV strains 
(isolated from a  bone marrow transplant patient, a  pregnant wom an with 
primary HCMV infection and an HIV patient with retinitis) (Murphy et al., 
2003b). By using bacterial artificial chrom osom es and  extensive 
sequencing, they have shown that clinical HCMV strains contain 252 
O RFs, including an additional seq u en ce  betw een UL133 to UL151 and an 
additional IR l sequence. A m ap of the organisation of the HCMV genom e 
from a  clinical HCMV isolate is shown in Figure 1-2. Many of the missing
46
gen es  from laboratory strains of HCMV encode im m uno-evasion g en es  
and  are d ispensable for growth in cell culture (Kollert-Jons et al., 1991), 
such a s  the chem okine analogues UL146 and UL147 (Prichard et al., 
2001).
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Figure 1-2 Map of the HCMV genome, reproduced with permission from Thomas Shenk 
(Murphy et al., 2003a)
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1.7.3 Important Structural Proteins
The ORFs of AD 169 plus additional missing seq u en ces  found in the 
Toledo and Towne strains are  predicted to encode a t least 213 proteins 
(Novotny et al., 2001). Using ‘in silico' or autom ated pattern b ased  
com puter algorithms to elucidate protein function, the HCMV genom e 
encodes a large num ber of glycoproteins, including 125 O R Fs with 
glycosylation sites (Rigoutsos et al., 2003), much greater then the 53 
originally identified by G hee (Chee et al., 1990). In addition, 144 integral 
m em brane proteins (half of which are glycoproteins), nine 
phosphorylation sites, and 15 ORFs with G-protein se q u e n ce s  have been 
identified (Rigoutsos et al., 2003). Although not all the g en es  encoded  by 
HCMV have had functions attributed, the following is a brief description of 
the more important structural proteins. G enes regulating transcription and 
viral DNA replication are  d iscussed  in section 1.8.2 (Viral Replication), 
and the gen es  involved in im muno-evasion are  d iscussed  in section 1.10 
(Immune Manipulation by HCMV).
C apsid Proteins
The major capsid protein (MCP, UL86) is the m ost abundant capsid 
protein. Five copies form the  capsid penton, and six copies in association 
with six copies of the sm allest capsid protein (SCP, UL48.5) form the 
capsid  hexon (Chen et al., 1999). Two copies of the minor capsid protein 
(mCP, UL85) and one copy of the m CP binding protein (mCP-BP, UL46) 
form the triplex. In addition fragm ents of the two scaffolding proteins, the
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maturational p ro tease  precursor, pUL80a, and the assem bly protein 
precursor, pUL80.5 are  also  contained within the  capsid (Loveland et al.,
2007).
Tegument proteins
The viral tegum ent contains at least 25 proteins, and many of th ese  
proteins have a role in HCMV replication by regulating viral gene  
expression or modulating the host cell. The tegum ent proteins are mainly 
phosphoproteins, (denoted by the  suffix ‘pp’), are  highly immunogenic, 
and  are important for the early s tag e s  of gene transactivation and the 
taking over of the host’s  cellular m achinery following penetration.
Included am ong this group is pp65 (encoded by UL83 and also known a s  
lower matrix protein), the m ost abundant tegum ent phosphoprotein. It is a  
major target for both the humoral (Jahn et al., 1987) and cellular immune 
response (Bitmansour et al., 2001 ; Kern et al., 2002; Laughlin-Taylor et 
al., 1994). Following cell penetration by HCMV, pp65 rapidly translocates 
to the cell nucleus (Schmolke et al., 1995a), and plays a role in immune 
modulation (see  section 1.10). The tegum ent phosphoprotein pp71 
(encoded by UL82 and also  known a s  the upper matrix protein), 
transactivates im m ediate early viral prom oters and is a  cell cycle 
regulator, targeting the  cellular Retinoblastom a family of tum our 
su ppresso r proteins for degradation, inducing DMA synthesis in otherwise 
quiescent cells (Kalejta et al., 2003). Acting together with pp71 is pUL69, 
another immediate-early viral transactivator, which h as  also  been  shown 
to arrest cell cycle progression in G1 phase  (Lu and Shenk, 1999). PP150 
(encoded by UL32, and also  known a s  basic phosphoprotein) is the
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second most abundant phosphoprotein in the capsid and  is also  highly 
immunogenic (Jahn et al., 1987; Gyulai et al., 2000; La R osa et al.,
2005). The UL84 gene  product, pp86 (1E2) is a  transactivator of both viral 
and cellular gen es  (G ebert et al., 1997), while UL26 is another important 
transcriptional activator (Stam m inger et al., 2002).
Envelope proteins
Envelope proteins are  important for viral binding to the cell surface and 
are a  major target for neutralizing antibodies in immune hum an serum . To 
da te  glycoprotein B (gB), glycoprotein H (gH), glycoprotein L (gL) and 
glycoprotein M (gM) have been shown to be essential for production of 
infectious virus (Hobom et al., 2000). The m ost abundant envelope 
protein is gB (encoded by UL55), with 906 amino acid residues and 
constitutes the disulfide-linked glycoprotein complex I (gCI) (Kari et al., 
1990). Transcribed in the  early and late phase  of viral replication, this 
large immunogenic protein protrudes from the envelope and is important 
for adsorption, cell fusion and the cell-to-cell sp read  of HCMV (Tuglzov et 
al., 1994). The second  disulfide linked glycoprotein complex is gCII, and 
is com prised of gM (encoded by UL100) and gN (encoded by UL73)
(Mach et al., 2000), while the third glycoprotein complex, gClli, is form ed 
from gH, gL a s  well a s  glycoprotein O (Huber and Compton, 1998; Li et 
al., 1997).
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1,8 Human Cytomegalovirus Infection
1.8.1 Tissue tropism
In vivo, HCMV infects fibroblasts, epithelial cells, m acrophage, 
m onocytes, sm ooth m uscles cells, and endothelial cells. In culture, the 
ADI 69 strain of HCMV displays tropism for hum an fibroblast cell lines, 
although clinical HCMV isolates have been  shown to infect endothelial 
cells (Sinzger et al., 1999b; M acCormac and Grundy, 1999), hepatocytes 
(Sinzger et al., 1999a) and  cells of the m onocyte/m acrophage lineage 
(Fish et al., 1996; Taylor-W iedeman et al., 1994). Following p a ssa g e  in 
cell culture, the HCMV genom e undergoes loss of som e of the genetic 
content important for virulence and  immuno-evasion, but d ispensab le  for 
viral replication (Mocarski, Jr., 2002).
1.8.2 Viral Replication 
Cell Entry
Substantial progress has recently been m ade into the m eans by which 
HCMV gains entry into the cell. Glycoprotein B in concert with a  complex 
of the glycoproteins gH, gL and gO, binds to epidermal growth factor 
receptor (EGFR) and the integrins, alpha2beta1, alphaO betal and  
alphavbetaS act a s  coreceptors, to stim ulate viral entry (Boyle and  
Compton, 1998; Feire et al., 2004; W ang et al., 2005; W ang et al., 2003). 
This triggers a cell signalling ca sc a d e  similar to the effect of cell 
stimulation with interferon gam m a (Simmen et al., 2001). By fusion of the 
virus envelope with the cell m em brane, the virus penetra tes  the cell
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m em brane, gaining entry into the cytoplasm and the nucleocapsid then 
m akes its way to the nucleus.
Immediate Early, Early and Late Gene Expression
There is a clearly defined seq u en ce  of protein expression in cells infected 
by HCMV (Stinski, 1978). Immediate early exp ressed  g en es  are  those  
g en es  expressed  on viral entry and do not require the expression of other 
viral genes (Spector, 1996). Many are transactivators for DMA replication. 
The most important are  IE1 (also known a s  IE72) and IE2 (also known as  
IE86), generated  through differential splicing and polyadenylation of a  
primary transcript of the major im m ediate early (MIE) region, consisting of 
the ORFs UL122 and UL123. They play a  central role in controlling viral 
and  cellular gene transactivation in order to facilitate viral DMA production 
(Stenberg, 1996). Both IE1 and IE2 further enhance  major immediate 
early (MIE) gene transcription through NF-kappaB m ediated binding of 
the enhancer region of MIE and IE2 autoregulates its own prom oter by 
binding to the cis repression sequence. O ther im m ediate early g en es  are 
also known to play a  role (Colberg-Poley, 1996). Early gene expression is 
dependent on the expression of immediate early gene  products, and 
includes mainly viral DMA replication g en es  such a s  UL54. Late gene 
expression includes many of the structural proteins gB and gH. The total 
transition from immediate early to late phase  takes 24 to 36 hours, with 
maximal virus production at 72 to 96 hours.
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Taking Over of Cell Machinery and Arresting Cell Division 
In S Phase
HCMV is not capab le  of producing its own RNA, and therefore m ust take 
over the machinery of the cell and subvert it for its own purpose. Three 
g en es  have been identified a s  being responsible for manipulating the cell 
cycle. The ppUL69 blocks the  cell at the G1 ph ase  (Hayashi et al., 2000; 
Lu and Shenk, 1999). The UL82 gene product, pp71, stim ulates the cell 
cycle through G1 p h ase  (Kalejta and Shenk, 2003). IE1 inhibits cell cycle 
progression from G1 to S ph ase  by activation of a  p53 response  (Castillo 
et al., 2005).
In addition, HCMV h as  also  evolved a num ber of m echanism s to inhibit 
apoptosis. UL122 and UL123 block apoptosis by an a s  yet unknown 
m echanism  (Zhu et al., 1995). The protein pUL36 (viral inhibitor of 
casp ase -8  induced apoptosis, vCIA) inhibits FAS m ediated apoptosis by 
blocking the cleavage of p rocaspase-8  (Skaletskaya et al., 2001 ; Zhu et 
al., 1995). The protein pUL37 (viral mitochondrial-localized inhibitor of 
apoptosis, vMIA) acts  a s  a  mitochondrial inhibitor of apoptosis by 
interfering with the aden ine nucleotide translocase Bax, which controls 
cytochrom e C release during apoptosis (Poncet et al., 2004).
A ssem bly  of New Infectious Units
Replication and assem bly of the new virion occurs in the host cell 
nucleus. Six HCMV proteins constitute the replication fork responsible for 
viral genom ic replication, a  two sub-unit DMA polym erase consisting of 
pUL54 and its associa ted  protein ppUL44, a  three sub-unit helicase-
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prim ase complex m ade up of pUL70, pUL102, and pUL105, and a  single 
stranded DNA binding protein, ppUL57 (Anders and McCue, 1996). The 
viral genom e is produced by rolling circle replication, with initial 
circularization of the parental genom e followed by the production of 
concatem ers of viral DNA, with the addition of the genom ic termini at the 
c leavage and packaging s tag e  (McVoy and Adler, 1994). The constituent 
capsid  proteins form an icosahedral procapsid structure through protein 
interaction and self-assem bly, with the proteins UL80a and UL80.5 
providing a  scaffolding function (Loveland et al., 2007). The viral DNA 
probably enters the capsid through a  single portal in a m echanism  similar 
to that dem onstrated using time lapse cryo-electron microscopy for 
h erpes simplex virus capsid assem bly  (Cardone et al., 2006; Heym ann et 
al., 2003). The putative HCMV portal protein is pUL104, a protein which 
CO localizes both in the nucleus and cytoplasm with the HCMV term inase 
protein pUL56, which is responsible for cleaving the  viral DNA into 
genom e length units (Dittmer et al., 2005). In common with other herpes 
viruses, it is likely that following initial capsid formation within the nucleus, 
the nucleocapsid enters the  cytoplasm  by envelopm ent at the inner 
nuclear m em brane, and then de-envelopm ent occurs at the outer nuclear 
m em brane. Final envelopm ent prior to re lease  of the virus occurs at the 
trans-Golgi network, w here the major glycoproteins are  assem bled  
(Crump et al., 2003). Evidence for the  so called re-envelopm ent model 
(Smith, 1980) has been supported by recent im m unoflorescence and cell 
tracking studies (Turcotte et al., 2005).
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HCMV can sp read  from cell to cell by direct contact and fusion with 
neighbouring infected cells, a s  dem onstrated by the transfer of green 
fluorescent labelled HCMV protein from infected to uninfected cells (Digel 
et al., 2 006). W hen endothelial cells are  infected with wild type but not 
laboratory HCMV strains, culturing with polym orphonuclear cells results in 
transitory micro fusion even ts (G erna et al., 2000), resulting in the 
transfer of infectious virus to leucocytes which can then dissem inate to 
sites distant to the primary infection. Supporting evidence for 
dissem ination by infected leukocytes is provided by the fact that the 
quantity of HCMV present in the leukocyte fraction is higher than plasm a 
or cell free com ponent (G erna et al., 1994), and infectious virus can only 
be cultured from the cellular com partm ent (Lipson et al., 2001).
1.8.3 Latency and Reactivation
Viral latency has been  defined a s  “the  persistence of viral genom e in the 
ab sen ce  of production of infectious virions, but with the ability of the viral 
genom e to reactivate after specific stimuli” (Sinclair and  S issons, 2006).
In healthy HCMV seropositive individuals, using sensitive PCR 
techniques, peripheral blood m onocytes are the major site for HCMV 
DNA (Larsson et al., 1998). It is likely that this is the site of HCMV 
latency, a s  even highly sensitive reverse transcrip tase PCR (RT-PCR) 
fails to detect productive viral IE gene  products in m onocytes and 
m onocyte precursors of seropositive HCMV carriers (Taylor-W iedeman et 
al., 1994). HCMV DNA has also  been  dem onstrated in bone marrow 
derived CD344- myeloid progenitors (M endelson et al., 1996). The exact 
m echanism  by which HCMV m aintains latency is not clear, but latency
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associated  transcripts have been identified in granulocyte m acrophage 
precursors arising from alternative expression of the MIE g en e  locus, 
including a  se n se  transcript with two novel start sites and  an unspliced 
anti-sense transcript com plem entary to IE1 exons 2-4 (Kondo et al., 
1996).
Reactivation from latency can occur a s  a  result of im m unosuppression 
(Reinke et al., 1999), and  a s  a  result of the cytokines re leased  a s  part of 
the alloreactive p rocess occurring during GVHD reactions (Soderberg- 
Naucler et al., 1997). Certain pro-inflammatory cytokines such as  
interferon gam m a, tum our necrosis factor, interleukin four and 
granulocyte m acrophage colony stimulating factor (GM-CSF) can 
stimulate reactivation of latently infected CD33+ cells into active viral 
replication in vitro (Hahn e t al., 1998).
1,9 Role of the Immune Response in Controlling Human
Cytomegalovirus Infection
Both the innate and adaptive immunity are  important for controlling 
HCMV infection. Following initial inoculation, the virus infects epithelial 
cells of the m ucosal linings. This results in an inflammatory response, 
with recruitment of neutrophils, which then d issem inate the infection. At 
this time, the infected individual becom es viraemic. In otherwise healthy 
individuals, the innate immune, humoral and cellular immune response  
acts to contain the infection and  maintain the virus in a  latent state.
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1.9.1 Innate Immune Response 
T o l l  L i k e  R e c e p t o r s
Through the interaction of gB and gH on the viral envelope with the Toll 
like receptors TLR1 and TLR2 on the host cell surface, activation of the 
cells innate immune system  occurs, with the induction and secretion of 
inflammatory cytokines via the NF-kappaB pathway (Boehm e et al., 2006; 
Compton et al., 2003). Toll like receptors are  a  family of receptors that 
recognize microbial pathogens, and stimulate the innate immune system  
when they recognize pathogen associa ted  m olecular patterns (PAMP’s).
It is conceivable that HCMV may utilize inflammatory cytokine release 
and subsequent recruitment of neutrophils and m acrophages to 
d issem inate infection and facilitate viral replication.
N a t u r a l  K i l l e r  C e l l s
M ouse strains deficient in natural killer (NK) cells are  a t increased  
susceptibility to murine CMV infection and d isease  (Shellam et al., 1981). 
In hum ans, NK cells are  capab le  of killing HCMV infected cells in an 
interferon gam m a independent m anner (Borysiewicz et al., 1985), and 
congenital deficiency of NK cells results in susceptibility to HCMV 
infection (Biron et al., 1989). The fact that HCMV h as  evolved a  large 
num ber of m echanism s to evade NK cell killing (see  section 1.10) further 
also testifies to the im portance of the NK cell response. Following 
allogeneic stem  cell transplants, NK cell counts tend to be higher in 
HCMV seropositive than HCMV seronegative recipients (Hokland et al., 
1988; Kook et al., 1996). Recently it has  been shown that in allogeneic
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stem  cell transplants w here both the donor and the recipient are HCMV 
seropositive, a donor with m ore than one activating killer immunoglobulin­
like receptor (KIR) w as associa ted  with a 65 percent reduction in HCMV 
infection (Cook et al., 2006).
1.9.2 Humoral immune Response
Following initial infection with HCMV, a  primary IgM response  occurs, 
which gradually m atures over 6 w eeks until an HCMV specific IgG 
response develops. The major HCMV targets of hum an serum  are  the 
surface glycoproteins gB, gH, gM, gN, and the phosphoproteins pp150 
and pp52 (Schoppel et al., 1997; Schoenberger et al., 1998). Between 40 
and 70 percent of the humoral response  to HCMV is directed to the 
glycoprotein gB (Britt et al., 1990). There is evidence that although the 
humoral response is not essential for resolution of primary HCMV 
infection, it limits dissem ination of recurrent virus (Schoppel et al., 1997). 
The humoral response  to HCMV ap p ears  to provide protection from 
HCMV d isease  in the neonate  (Yeager et al., 1981) and the solid organ 
setting (Snydman and Falagas, 1996).
1.9.3 Cytotoxic T Cell Response
CD8+ T cell recognise peptides p resen ted  by C lass I HLA m olecules 
p resent on all cells in the body. Antigens p resen ted  by C lass I m olecules 
are derived from the proteosom ic degradation of the proteins of 
intracellular pathogens including HCMV. The resultant peptides are  then 
transported to the lumen of the  endoplasm ic reticulum by TAP 
(transporter associa ted  protein), and loaded onto C lass I m olecules by
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tapasin. HLA C lass I m olecules bind peptides of 8-10 amino acids at both 
ends, while interaction betw een anchoring residues of the peptide and the 
binding groove of the HLA molecule determ ine specificity (R am m ensee,
1995). For instance the pp65 peptide, NLVPMVATV has been  identified 
a s  an HLA A*0201 restricted HCMV specific epitope (Diamond et a!.,
1997; Solache et al., 1999). The C lass I heavy chain, P2 microglobulin, 
and the antigenic peptide form a  stab le complex which is then transported 
to the cell surface, ready for antigenic recognition by CD8+ T cells. 
Following an acu te  infection, there  is an initial expansion of antigen 
specific CD8+ cytotoxic T-cells (CTLs), which acquire effector functions 
including: the ability to sec re te  tum our necrosis factor alpha (TNFa) and 
interferon gam m a (IFGy), ex p ress  cytotoxic granules such a s  perforin and 
granzyme, and the ability to en ter non-lymphoid tissue. Two to three 
w eeks after maximal expansion, 90 to 95 percent of th ese  cells undergo 
apoptosis. A su b se t of th e se  cells acquire a  memory phenotype, 
characterised by the  ability to be maintained in the ab sen ce  of an antigen, 
and with stimulation reacquire the  ability to produce TNFa and  IFGy a s  
well a s  cytotoxic function, and with maturation increased capability to 
secre te  interleukin 2 (IL 2). Two types of memory cells can  be identified: 
effector memory (T em ) cells characterised  by CCR7'°'" and  CD62L‘°'^  
expression and an inability to en ter lymph nodes via high endothelial 
venules, and central m em ory (Tcm) cells characterised  by CCR7'^'^^ and 
GD62L^'^'^ expression and the ability to en ter lymph nodes and  lymphoid 
organs such a s  the  spleen (Sallusto et al., 1999). Both cell types produce 
TNFa and IFGy but only T cm  cells produce high levels of IL2. Over time.
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there is a  transition from T em  to Tcm - With antigenic restimulation, T cm  
cells revert to T em  cells. In the p resence  chronic viral infections, such as  
HCMV, a  num ber of ch an g es  in the immune response  occur (G am adia et 
al., 2001). O vertim e, the CTL memory response becom es dom inated by 
a  small num ber of greatly expanded clones responding to a few peptides, 
and characterised by a  CD57+ CD28- CD8+ phenotype (W eekes et al., 
1999). There is also  a reversion from CD45RO^'^'^ to CD45RA'^'^'^ in vivo. 
The main targets of the CTL response  are IE1 and pp65 (Kern et al.,
1999; Khan et al., 2002a), with pp65 dominating (Wills et al., 1996; 
Laughlin-Taylor et al., 1994), although responses to pp150 are  also 
significant (Gyulai et al., 2000; La R osa et al., 2005). C lass I tetram er 
technology (Altman et al., 1996) has greatly facilitated the study of 
antigen specific T-cells. The CD8 response  to HCMV has one of the 
highest CD8+ T cell antigen specific frequencies recorded, ranging from 1 
percent in healthy individuals up to 10 percent of the total CD8 T cell 
population in BMT and organ transplant recipients (Emery, 2000; 
Engstrand et al., 2000; Gillespie et al., 2000; Singhal et al., 2000). With 
increasing ag e  the frequency of HCMV specific CD8+ T cell frequency 
continues to increase, although there is evidence that this is also 
associated  with impaired function, suggesting immune burn-out due to 
chronic stimulation (Ouyang et al., 2003).
1.9.4 Helper T Cell Response
Following primary infection, activation of naïve CD4 T cells occurs 
through recognition of foreign peptides on HLA class II m olecules on the 
surface of professional antigen presenting cells (APCs), such  a s  dendritic
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cells, m acrophages and  B cells. Degradation of endocytosed proteins 
within endosom es or lysosom es g enera tes  the peptides p resen ted  by 
C lass II HLA m olecules. The C lass It a  and (3 heavy chains are  stabilised 
in the endoplasm ic reticulum by the invariant chain, which blocks the 
binding groove, and the com plex is then transported to endocytic 
vesicles, where the invariant chain is broken down and peptide loading 
occurs. Although anchoring residues are also important in determining 
peptide affinity for C lass II m olecules, peptide binding conditions are 
m ore relaxed than C lass I, with a  minimum of 12 amino acids, but not 
constrained by a  maximum length, with the ends of the binding groove 
being open. After being transported to the cell surface, the peptide loaded 
c lass II molecule, in conjunction with the costimulatory CD28 ligand B7, 
interacts with the T-cell receptor and its co-receptor CD4, to activate the 
T cell. After activation, naïve CD4-h T cells differentiate into either ThI 
cells, characterised by IFy secretion and protection against intracellular 
infection, and Th2 cells, characterised  by IL4 secretion and protection 
against extracellular infections (S eder and Ahmed, 2003). Like CD8+ T 
cells, the majority of the  initial expansion of CD4-n activated cells 
undergoes apoptosis. Som e of the T-cells stim ulated in the ThI direction 
develop into long-term memory cells. Naïve CD4+ T-cells exp ress  
CD45RA, CD62L'^‘ and  are  CCR7 . Tcm cells are characterized by a 
CD45RA', CD62L"', and  CCR7^ phenotype, while Tem cells have a  
CD 6 2 L^‘^ '-o, QQR7 - and  CD45RA+^ phenotype.
CD4 T helper cells play a  num ber of crucial roles in the immune resp o n se  
to viral infections:
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i) Mediate the re lease  of inflammatory cytokines such a s  IL2 (Su et 
al., 1998).
il) Condition the antigen presenting cells (Bennett et al., 1998; Ridge 
et al., 1998; S choenberger et al., 1998).
iii) Have direct cytotoxic activity on virally infected cells (Appay et al., 
2002).
iv) Provide help for virus specific antibody production (Jonjic et al., 
1994).
Animal m odels have dem onstrated  that the function of m em ory CD8 T 
cells is impaired in the  ab sen ce  of GD4 help (Jan ssen  et a!., 2003; 
Shedlock and Shen, 2003; Sun and Sevan, 2003), In hum ans infected 
with chronic viral infections, CD4+ T cells play a  crucial role in sustaining 
CTL responses (Matloubian et al., 1994), a s  well a s  the secondary  
expansion and developm ent of memory CD8+ T cells, (Schoenberger et 
al., 1998). It has been  suggested  that CD4+ T cells, through CD40L, may 
imprint a unique molecular signature on effecter CD8+ T cells, giving 
them  the ability to improve memory function (Bourgeois et al., 2002), 
perhaps by conditioning the ARC via interaction of CD40L with CD40 
(Jan ssen  et al., 2003).
Proliferative HCMV specific CD4+ T cells resp o n ses  have been 
dem onstrated to pp65, gB, gH, IE1, IE2, UL69, pp71, and gpUL18 with 
the dominant resp o n ses  to pp65 (Beninga et al., 1995; He et al., 1995). 
B ased  on antigen specific cytokine production, 63 percent of healthy 
donors have a  detectable  CD4 response  to IE1 (Kern et al., 2002).
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In addition, a subse t of cytotoxic CD4 T cells express perforin and 
granzym e B, are characterised  by the ab sen ce  of the costimulatory 
m olecules CD28 and CD27 (Appay et al., 2002), and are  described in 
chronic viral infection. T hese  cells have been described following primary 
HCMV infection with proliferative response  specifically to HCMV (van 
Leeuwen et al., 2004; van Leeuwen et al., 2006). Further evidence for the  
im portance of CD4 helper function in controlling HCMV infection is that 
HCMV d isease  in HIV patients normally only occurs when the CD4 count 
falls below 50 X 10®/L (M acGregor et al., 1995). Recovery of HCMV 
specific immunity with HAART therapy is correlated with a fall in the 
incidence of HCMV infection and HCMV d isease  (Komanduri et al.,
1998).
1.10 Immune Manipulation by HCMV
Human CMV has probably evolved m ore ways to evade and modify the 
immune system  then any other hum an viral pathogen, perhaps reflecting 
the fact that beta-herpes viruses have been  co-evolving with their hosts 
for at least 180 million years (McGeoch et al., 1995). T hese  m echanism s 
are likely to be responsible for the enorm ous su ccess  of this pathogen in 
achieving such a  high prevalence and maintaining lifelong latency without 
apparently harming the host. Much of the initial investigation into the 
stra teg ies by which CMV ev ad es  the immune system  w as perform ed in 
the m ouse , a s  murine CMV u ses  many of the sam e im m unoevasion 
m echanism s as  HCMV, and this is well reviewed by R eddahase  
(R eddehase, 2002; R ed d eh ase  et al., 2004). Table 1-2 sum m arises the 
m echanism s by which CMV ev ad es  the immune system  in the hum an
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host, although this list is not com prehensive and undoubtedly, further 
strategies will continue to be uncovered.
Down regulation of MHC c la ss  I and  II
HCMV is capable of modification of the HLA pathw ays through the 
expression of im m unoevasion genes, which result in the  down regulation, 
decreased  expression and increased degradation of both HLA c lass  I and 
class II molecules. The expression of th ese  g en es  is also dependen t on 
the s tage  of viral replication with different gen es  being active at different 
s tages. The US2 to U S11 region encodes four glycoproteins involved in 
the down regulation of HLA c lass I expression. The gene product of US3, 
gpUS3, expressed  during the immediate early p h ase  of replication, 
inhibits tapasin m ediated peptide loading in the endoplasm ic reticulum by 
impairing HLA C lass I heavy chain eg ress  from the endoplasm ic 
reticulum (Jones et al., 1996). US2 and U S11, which are  both ex p ressed  
in the early phase, down regulate HLA class I by redirecting the n ascen t 
HLA class I protein from the endoplasm ic reticulum to the cytosol (Story 
et al., 1999). US6, which is ex p ressed  in the early and  late p h ase , blocks 
TAP in the endoplasm ic reticulum (Ahn et al., 1997). In vitro stud ies have 
dem onstrated that all four g en e  products are  individually capab le  of down 
regulating HLA c lass I expression. In addition to their effect on levels of 
HLA class I expression, US3 can down regulate HLA class II expression 
by disrupting the invariant chain interaction (Hegde et al., 2002), and US2 
by inhibiting HLA class  II translocation (Tomazin et al., 1999). Infection 
by HCMV of the professional antigen presenting cell, the dendritic cell
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has been shown to down regulate HLA class II antigen presentation 
(Jahn et al., 1999).
Avoidance of NK cell killing
The reduction of HLA class I surface expression would normally render a  
cell vulnerable to NK cell killing, due to the absen ce  of an inhibitory 
signal. However, HCMV has also evolved a  rem arkable array of 
strategies to bypass NK cell lysis. UL141 blocks the surface expression of 
GDI 55, the ligand for NK cell activating receptors CD226 and CD96 
(Tom asec et al., 2005), and UL142 encodes an HLA class I like molecule 
that down regulates the  NKG2D ligand, MICA (Chalupny et al., 2006;
Wills et al., 2005). UL16 is responsible for the down regulation of the 
NKG2D ligands MICB and UL binding proteins (V ales-Gom ez et al.,
2006). HLA-E normally p resen ts  the leader sequ en ce  of other C lass I 
HLA proteins at the cell surface, and inhibits NK cell activation by binding 
to the CD94/NKG2A receptor. The leader seq u en ce  of gpUL40 can up 
regulate HLA-E independent of TAP, a s  dem onstrated by up regulation of 
HLA-E expression in HCMV infected TAP deficient cells, thereby 
inhibiting NK cell m ediated cell lysis (Ulbrecht et al., 2000; T om asec et 
al., 2000). UL18 com plexes with hum an p2-microglobulin and is 
expressed  on the surface a s  a  HLA C lass I homologue. Paradoxically, it 
has been  shown to increase NK killing, but it is also binds to the 
leukocyte immunoglobulin like receptor (LIR1) on m acrophages, acting a s  
a decoy (Chapm an et al., 1999).
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Cytokine and cytokine recep tor ana logues
HCMV encodes a  viral hom ologue of interleukin 10 (IL10), cmvlLIO, 
encoded on UL111a (Kotenko et al., 2000). This chem okine hom ologue 
has affinity for both IL10R1 and IL10R2 receptors. It h as  a  num ber of 
Im m unosuppressive properties, including: inhibition of mitogen stim ulated 
monocyte proliferation, inhibition of cytokine secretion, down regulation of 
HLA class I and II m olecules, blocking of cytokine Induced differentiation 
of m onocytes into functionally active phagocytic m acrophages and 
inhibition of dendritic cell maturation and function (Chang et al., 2004; 
Gredmark et al., 2004; S pencer e t al., 2002). UL146 and UL147 encode  
CXC chem okines. The UL146 gene product is a  viral CXC chem okine 
that can bind to the CXCR2 IL8 receptor, and show s equal potency to 
hum an IL8 a s  a  neutrophil chem oattractant (Penfold et al., 1999; 
Saederup  and Mocarski, Jr., 2002). There is considerable seq u en ce  
variation in UL146 and UL147, and based  on studies of congenitally 
infected infants there is som e early evidence that this m ay contribute to 
differences in d isea se  m anifestations (He et al., 2006; Lurain et al., 2006; 
rav-Boger et al., 2006). US28 encodes an HCMV CC chem okine receptor 
which seq u este rs  and internalizes the chem okines monocyte chem otactic 
protein 1 (MCP1) and  RANTES surrounding an infected cell, preventing 
leukocyte chem otaxis and  activation of effecter function, a s  well a s  
initiating cell signalling pathw ays in infected cells (Billstrom et al., 1998; 
Bodaghi et al., 1998).
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Subversion  of Innate Cellular Immunity
The tegum ent phosphoprotein UL71 subverts a  cellular innate immune 
defence m echanism , promyelocytic leukaem ia nuclear body (PML-NB) 
protein Daxx, which would otherwise block immediate early gene  
expression through histone deacety lase  activity, by mediating its 
proteosom al degradation (Saffert and Kalejta, 2006). The phosphoprotein 
pp65, by interfering with NF-kappaB and interferon response  factor I and 
3 (Abate et al., 2004), inhibits the ability of cells to respond to exogenous 
interferon (Browne and Shenk, 2003). pp65 also has the ability to 
phosphorylate IE1, thereby preventing its breakdown in the proteosom e, 
and subsequent presentation by HLA class I m olecules (Gilbert et al.,
1996). Despite th e se  roles, pp65 is in fact dispensible for cell growth in 
culture (Schmolke et al., 1995b).
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Table 1-2 Mechanisms by which HCMV evades host immune system
Mechanism Reference
Down Regulation of M HC Class I and II
US2 Redirects MHC Class I proteins from ER to cytosol (Story et al., 1999)
Inhibit M HC Class II by degrading HLA DR-alpha and (Tomazin et al., 1999)
DM-alpha
US3 Impairs MHC Class I heavy chain egress from ER (Jones et al., 1996)
Down regulates M HC Class II by disrupting invariant chain (Hegde et al., 2002)
interaction
US6 Down regulates MHC Class I by blocking TAP in ER (Story et al., 1999)
U S ll Redirects MHC Class I proteins from ER to cytosol (Ahn et al., 1997)
Avoidance of NK Celi Killing
UL16 Down regulates the NKG2D ligands MICB and UL binding (Vales-Gomez et al..
protein 2006)
UL40 Up regulates cell surface HLA-E expression (Ulbrecht et al., 2000) 
(Tomasec et al., 2000)
UL141 Blocks surface expression of CD 155, ligand for CD226 and 
CD96
(Tomasec et al., 2005)
UL142 Encodes MHC Class I like molecule that down regulates 
the NKGSD ligand MICA
(Wills et al., 2005)
Cytokine and cytokine receptor analogues
U L l l l a cmvILlO, a viral analogue of ILIO (Kotenko et al., 2000)
UL146 viral CXC chemokine 1, a ligand for the CXCR2 IL8 
receptor
(Penfold et al., 1999)
U LI47 viral CXC chemokine (Penfold et al., 1999)
US28 cmv CC chemokine receptor, neutralizes M CPl and (Billstrom et al., 1998)
RANTES (Bodaghi et al., 1998)
Subversion of innate cellular immunity
UL71 Proteosomal degradation of Daxx (Saffert and Kalejta, 
2006)
UL83 Inhibition of interferon response via NFkapppaB and (Abate et al., 2004)
(pp65) Interferon Response Factor 1
Phosphorylation of lE l ,  preventing proteosomal (Gilbert et al., 1996)
degradation and MHC Class I presentation
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1.11 Immune Recovery Following Allogeneic Stem Cell 
Transplantation
Recovery of the immune system  following stem  cell transplantation 
includes recovery of the innate immune system , B cell immune function, 
and T-cell immune function.
The innate immune system  is the first com ponent to recover. Injury 
sustained to the m ucosal barrier due to the conditioning regimen takes 
betw een one and three m onths to heal, and during this time is a 
significant portal of entry for infections, particularly bacterial pathogens. 
Neutrophil counts normally recover within a  month following 
transplantation, but the recovery of neutrophil functional deficits such a s  
chem otaxis, superoxide production and phagocytic activity takes 
significantly longer (Zimmerli et al., 1991). NK cell recovery, which is 
important for the control of HCMV infection, is detectable a s  early a s  one 
week following peripheral blood stem  cell transplantation, with similar 
frequencies to normal donors at 3 months, although absolute levels 
remain less then normal donors even at 12 m onths following transplant 
(Chklovskaia et al., 2004).
B cells recovery is important for reconstitution of the humoral immune 
system . B cell levels remain undetectable for one to two m onths post 
transplantation, but by 1-2 years, they rise to greater then normal levels, 
with non-myeloablative transplants being associa ted  with slow er recovery 
(Petersen  et al., 2003). B cell recovery probably occurs due to 
regeneration of naïve B cells from the donor stem  cell, rather then
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infusion of the m ature B cells from the graft. Serum  levels of immune 
globulins fall immediately post transp lan t Apart from responses to 
antigens encountered early post transplant, such a s  the HCMV proteins 
glycoprotein gB, other com m on antigen specific antibody levels gradually 
fall post transplant (Engelhard et al., 1991; Lutz et al., 1996). The non­
specific antibody levels of IgM, IgGI and lgG3 recover to normal or 
greater then normal levels within months, but IgA and lgG4 can take 
several years, while the lgG2 subclass is the last to recover (Sullivan et 
al., 1996). Antibody specificity post transplant is of a limited spectrum  but 
may include significant num bers of auto antibodies, particularly in the 
p resence of chronic GVHD (Patriarca et al., 2006).
The cellular immune system  consists of both CD4 T-helper cells and  CD8 
cytotoxic cells, and both play a  pivotal role in the control of HCMV 
infection. Initial T-cell recovery following allogeneic transplantation is of 
phenotypically m ature antigen primed memory CD45RA-1- T cells, with a  
limited diversity based  on analysis of the T-cell receptor repertoire, 
particularly following T-cell depleted transplants (Roux et al., 1996). By 
m easuring T-cell receptor rearrangem ent excision circles (TRECs) it can  
be shown that early thymic dependen t naïve T cell recovery becom es 
active betw een 6 and 12 m onths post transplant, while increasing age, 
chronic GVHD and T-cell depletion predicted delayed thymic recovery 
(Fallen et al., 2003). This recovery of thymic function is characterised  by 
the  appearan ce  of GD4+ CD45RA-I- RO- T cells which are of donor origin 
(Roux et al., 2000). The abso lu te  CD4 levels rem ains very low for the first 
few m onths post transplant, gradually rising to a  m ean of 300 cells/pL at
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one year, but even five years post transplant does not achieve normal 
levels (Storek et al., 1995).
Absolute CD8+ T cell counts also remain low in the first three m onths 
following allogeneic transplantion, usually less than 200 cells/pL, but 
achieve normal or supranorm al levels by one year (Storek et al., 1995). 
Similar to CD4+ T cells, the phenotype is that of an antigen primed cell 
with high expression of GDI la ,  C D IIb , CD29, CD57, and  HLA-DR but 
low expression of CD28, CD45RA, and CD62L com pared to normal 
individuals. The increased  expression of CD57, C D IIb , a s  well a s  the 
ab sen ce  of CD28 expression sug g ests  much of the numerical increase is 
functionally anergic (Dolstra et al., 1996). Early studies of antigen specific 
responses including to HCMV as  well a s  HLA specific cytotoxicity a ssa y s  
suggest a  defect early post allogeneic stem  cell transplant, but a s  th ese  
experim ents were done on total m ononuclear preps, they w ere not 
quantitative (Quinnan, Jr. et al., 1981; R eusser et al., 1991; Riddell et al., 
1992; W alter et al., 1995). Later studies using limiting dilution a ssay s  
suggested  the defect in fact to be quantitative (Lucas et al., 1996). It is 
noteworthy that HCMV seropositive recipients with a  seropositive donor 
have a  greater HLA C lass 1 restricted HCMV specific response  than 
patients with seronegative donors (Li et al., 1994). W alter show ed that in 
allogeneic transplant recipients the HCMV specific CD8 response  is 
impaired in the ab sen ce  of a  CD4 response (Walter et al., 1995) .
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1,12 Clinical Features of Human Cytomegalovirus 
Infection
1.12.1 Infection in the Immunocompetent
HCMV infection in the normal healthy individual is usually asym ptom atic 
but may present a s  an ‘infectious m ononucleosis’ like syndrom e although 
heterophile antibody negative (Zanghellini et ai., 1999). Clinical features 
of HCMV infection include fever in the majority of cases , a s  well as  
lym phadenopathy, pharyngitis and splenom egaly, while a  rash is presen t 
in 30 percent of infected individuals. Over 90 percent have a mild 
elevation of liver transam inases, and an elevation of the lymphocyte 
count with atypical lymphocytes on blood film occuring in the majority of 
individuals.
In 1960 the so  called ‘post perfusion syndrom e’ w as described, consisting 
of fever, splenom egaly, atypical lymphocytosis and raised HCMV 
antibody titres 3 to 4 w eeks following open heart surgery, and w as 
attributed to the receipt of blood products infected with HCMV (Lang et 
al., 1968). This syndrom e is now prevented by the leukodepletion of 
blood products (Pamphilon et al., 1999).
D espite the very high prevalence of latent HCMV infection in the  general 
population, relatively few HCMV d isea se  associations in otherw ise 
healthy individuals have been m ade, HCMV DNA as  well a s  latent HCMV 
virus can  be found in the arterial walls of patients with severe  
atherosclerosis (Hendrix et al., 1990; Melnick et al., 1993). Furthermore, 
coronary restenosis h as  been  associa ted  with HCMV infection (Speir et
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al., 1994). A therosclerosis is an  inflammatory p rocess  (Ross, 1999) and  it 
has  been suggested  that HCMV infection plays a  crucial role in 
mediating atherosclerosis through the induction of adhesion m olecules 
and growth factors (W estphal et al., 2006). There is also som e evidence 
that early onset pre-eclam psia, a  d isease  caused  by arteriole 
insufficiency may also  be associa ted  with HCMV infection (Carreiras et 
al., 2002; von D adelszen et al., 2003).
Recently it has becom e recognized that HCMV contributes to ag e  related 
im m unosenescence. Among the elderly, the immune response  to HCMV 
becom es increasingly focused tow ards single dom inant epitopes (Khan et 
al., 2002b). An HCMV specific im m unophenotype of CD8+ CD57+ I  cells 
with loss of CD45RA and CD28 expression occurs (Ouyang e t al., 2003). 
Reversal of the CD4/CD8 ratio and expansion of CD8+ T cell population 
w as associated  with HCMV seropositivity and predictive of an increased 
risk of death over the sub seq u en t one to two years (Olsson et al., 2000; 
Wikby et al., 2002). Furtherm ore, the ability to respond to new antigenic 
challenges is impaired, a s  dem onstrated by the reduced immune 
response to influenza vaccination in HCMV seropositive elderly people 
(Trzonkowski et al., 2003).
1.12.2 Infection in the Immunosuppressed Host
In contrast to the situation in healthy individuals, HCMV infection in 
patients with impaired immune function, particularly T-cell immunity, can 
result in significant morbidity and mortality. Immunodeficiency a s  a  result 
of immaturity (such a s  the fetus or very prem ature neonate), acquired 
immunodeficiency due to infection with the hum an immunodeficiency
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virus (HIV), congenital immunodeficiency s ta te s  (R aeiszadeh et al.,
2006), iatrogenic im m unosuppression in the context of solid organ 
transplantation and bone marrow transplantation, and monoclonal 
antibody therapy for the treatm ent of lymphoproliferative disorders 
(Bowen et al,, 1997) are all conditions that render patients susceptib le to 
HCMV d isease . Infection may occur b ecau se  of primary infection (such 
a s  transplant of an  HCMV seropositive graft into an HCMV seronegative 
recipient), reactivation of primary infection, or reinfection with a  new 
strain in an HCMV seropositive patients with primary infection in the past. 
The d isease  manifestation of HCMV differs according to the underlying 
condition, and this m ay reflects differences in the nature of the 
immunodeficiency in th ese  patients.
Congenital infection
Congenital HCMV infection occurs in 1 percent of all live births, and 18 
percent of congenitally infected infants have clinical manifestation of 
HCMV d isease  such a s  microcephaly, mental retardation, blindness, 
deafness  a s  well a s  non-central nervous system  m anifestations such a s  
throm bocytopaenia, hepatitis, pneumonitis and myocarditis (Fowler et al., 
1992). However betw een 7 and 25 percent of congenitally infected 
asym ptom atic infants at birth p resen t with sensorineural hearing loss at 
up to four years of ag e  (Iwasaki et al., 2007; Fowler et al., 1997), and 
congenital HCMV infection is the m ost common cau se  of childhood 
deafness. The greatest risk of congenital HCMV infection is in the infants 
of seronegative m others experiencing primary infection during pregnancy 
(Fowler et al., 1992), although there is evidence that re-infection with a
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new strain in a seropositive m other also confers an  increased risk 
(Boppana et al., 2001). HCMV is the  m ost common cau se  of congenital 
infection of the newborn, and for this reason, there is a  strong argum ent 
for the developm ent of an effective vaccination.
S o l i d  o r g a n  t r a n s p l a n t a t i o n
HCMV infection following a  kidney transplantation typically p resen ts  1 to 
4 months post allografting (Rubin, 1990), and may m anifest a s  anything 
from a  mild viral illness with fever, rash and  leukopaenia to m ore severe  
organ dysfunction including pneumonitis, hepatitis and gastro-enteritis. 
Kidney transplantation betw een an HCMV seropositivity donor and  a 
seronegative recipient (D+/R+) carries the highest incidence (40-73 
percent) of HCMV d isea se  (Lowance et al., 1999), and is due to primary 
infection from the graft. HCMV infection following liver transplant is 
associated  with hepatitis (Rubin, 1997). HCMV following cardiac 
transplantation has been  associa ted  with accelerated  atherosclerosis and  
transplant vasculopathy (Fateh-M oghadam  et al., 2003), while HCMV 
infection significantly increases the risk of obliterative bronchiolitis in lung 
or heart-lung transplants (Cerrina et al., 1992). As well a s  the direct 
effects of HCMV infection, there are indirect co n seq u en ces  on solid organ 
transplantation, including an increased  risk of graft rejection and 
secondary  infections. HCMV d isea se  (Toupance et al., 2000) and 
according to som e authors also HCMV infection (S ageda et al., 2002) is 
an independent risk factors for acu te  rejection, as  well a s  being 
implicated as  a  cau se  of chronic allograft nephropathy (Yates and 
Nicholson, 2006).
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HIV
Prior to the advent of HAART therapy for HIV patients, betw een 10 and 
30 percent of patients with advanced HIV infection developed HCMV 
d isease  per year (Shepp et al., 1996). The main risk factor predicting 
HCMV infection is the  CD4 count, with patients with a  CD4 count less 
then 100/pL being at the g reatest risk. Unlike solid organ transplant 
recipients, the major d isea se  manifestation of HCMV infection in HIV 
patients is retinitis, while encephalopathy, polyradiculopathy, 
gastroenteritis, and hepatitis are  also common. Since the introduction of 
HAART, the incidence of HCMV retinitis has d ecreased  dramatically 
(Deayton et al., 2000), although even in the e ra  of HAART, detection of 
HCMV viraemia rem ains an independent risk factor for death (Deayton et 
al., 2004).
1.13 HCMV Infection in Aiiogeneio Stem Celi 
Transplantation
Prior to the advent of sensitive surveillance m ethods and effective 
antiviral therapy for hum an cytomegalovirus (HCMV), interstitial 
pneumonitis due to HCMV occurred in 10-20 percent of stem  cell 
transplant recipients and  untreated has a mortality of greater then 80 
percent (Meyers et al., 1986). Despite therapy with ganciclovir and 
intravenous immunoglobulin, mortality of established HCMV d isea se  
rem ains high (Emanuel et al., 1988; Ljungman et al., 1992; R eed e t al., 
1988). The main source of infection is reactivation of latent infection in the 
recipient (Winston et al., 1985), although in HCMV seronegative
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recipients, unfiltered blood products or unm anipulated marrow from 
HCMV seropositive donors can also give rise to a primary infection 
(Meyers et al., 1986). By contrast HCMV infection is infrequent following 
autologous stem  cell transplant, with HCMV pneum onia being a  rare 
occurrence (Konoplev et al., 2001).
1.13.1 Disease Manifestations
The m ost common d isea se  manifestation of HCMV d isea se  following 
stem  cell transplantation is HCMV pneumonitis, and is initially 
characterised by fever, cough, and  hypoxia with diffuse interstitial 
ch an g es on X-ray before progressing to respiratory failure (Ljungman, 
1995; Salom on and Perlm an, 1999). Figure 1.3 is an exam ple of the 
chest X-ray changes of HCMV pneumonitis. It is likely that the 
pathogenesis of HCMV pneumonitis in the im m unocom prom ised host has 
an immunological basis (Riddell, 1995; Grundy et al., 1987). HCMV 
hepatitis is characterised  by hepatic dysfunction while liver biopsy may 
show  typical viral intranuclear inclusions. Gut involvement by HCMV 
includes colitis, which typically p resen ts with diarrhoea and abdom inal 
pain but may also cau se  life-threatening haem orrhage, a s  well a s  gastritis 
and oesophagitis. HCMV retinitis is a  late complication of HCMV infection 
in allogeneic transplant recipients but appears  to be increasing In 
frequency (Crippa et al., 2001 ; Larsson et al., 2002; Xhaard et al., 2007). 
Formal definitions of HCMV d isea se  were first defined by the First 
International CMV W orkshop in 1993 and have subsequently  been  
updated. (Ljungman et al., 2002b).
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Figure 1-3 Chest X-ray changes of HCMV pneumonitis in an allogeneic stem cell transplant 
recipient.
1.13.2 Risk Factors
Previously identified risk factors for HCMV d isease include HCMV 
seropositivity, GVHD, total body irradiation, and asymptomatic HCMV 
infection (Goodrich et al., 1991; Meyers et al., 1986; Meyers et al., 1990; 
Wingard et al., 1988), while positive donor HCMV serology may be 
protective (Grob et al., 1987). Acute GVHD is associated with HCMV 
infection post BMT (Miller et al,, 1986), and there is good evidence that 
the alloimmune response can stimulate HCMV reactivation from the latent 
state (Soderberg-Naucler et al., 1997; Winston et al., 1985). T-cell 
depletion has also been identified as  a  significant risk factor for HCMV 
infection and d isease  (Couriel et al., 1996; Hertenstein et al., 1995), as 
has the use of unrelated donors (Takenaka et al., 1997). Following 
reduced intensity conditioning regimens incorporating ATG or 
alemtuzumab, HCMV infection rates are increased (Chakrabarti et al.,
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2002a; Mohty et al., 2000), although the Seattle group using a  low d o se  
TBI based  reduced intensity conditioning regimen have reported no 
differences in the  rate of HCMV infection at 12 m onths (Junghanss et al., 
2002).
Blood based  dissem ination of the virus is an important precursor of later 
disease, with nearly all allogeneic stem  cell transplant recipients with 
HCMV d isease  experiencing a  preceding viraemia (Schmidt et al., 1991 ; 
Enright et al., 1993; M eyers et al., 1990). HCMV antigeneam ia has been 
correlated with transplant related mortality due to HCMV d isease  
(Bacigalupo et al., 1995). Einsele h as  shown that patients requiring 
greater than 4 w eeks of therapy to eliminate HCMV infection during pre­
emptive therapy are  at an  increased risk of late HCMV d isease , while the 
p resence of HCMV viraem ia prior to transplant is associa ted  with a  very 
high risk of d isease  (Einsele et al., 2000).
Using a quantitative competitive PCR technique, it h as  been 
dem onstrated that the major risk factor predicting HCMV d isea se  is the 
peak viral load at the time of HCMV infection (Gor et al., 1998). The 
p resence of HCMV d isea se  prior to transplantation is associa ted  with a 
very high risk of early HCMV d isea se  and death  after transplantation 
(Fries et al., 2005),
1.13.3 Indirect Effects
HCMV infection is a  recognized risk factor for aspergillus infection in lung 
transplant recipients (Husni et al., 1998), and the high risk of death  due to 
bacterial and fungal infection am ong HCMV seronegative recipients of 
stem  cell transplants from seropositive donors provides further evidence
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for indirect effects of primary HCMV infection (Nichols et al., 2002). In 
vitro, HCMV infection is m yelosuppressive, both by directly infecting 
myeloid progenitors and  indirectly through a  cytokine m ediated 
m echanism  (Torok-Storb et al., 1992), and it is likely that a  similar 
m echanism  occurs in vivo.
1,13.4 Impact of HCMV Serology on Transplant Mortality
A Dutch study reported that in m atched unrelated donor transplants but 
not related donor transplants, recipient HCMV seropositivity adversely 
affected overall survival and transplant related mortality (Meijer et al., 
2002).
A large EBMT metafile analysis show ed that for HLA identical sibling 
allografts, HCMV sero sta tu s of the donor had no influence on survival of 
HCMV seropositive recipients, but for unrelated donors there  w as a  
reduced transplant related mortality and  a significant survival advan tage if 
HCMV seropositive donors were used  (Ljungman et al., 2003a). Another 
recent study in reduced intensity conditioned transplants su g g ested  that 
HCMV donor seropositivity reduced the incidence of leukaem ia relapse 
but this did not translate into improved survival due to increased  
treatm ent related mortality (N achbaur et al., 2006). In the setting of T-cell 
depleted transplants for CML, Craddock has reported that HCMV donor 
seropositivity is associa ted  with adverse  transplant outcom es (Craddock 
et al., 2001).
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1.14 Laboratory Diagnosis and Monitoring
1.14.1 Serology
HCMV IgG seropositivity is indicative of past infection, and it is essential 
to establish the se ro sta tu s  of both the donor and recipient prior to 
transplant. HCMV IgM positivity in the non-transplant setting is indicative 
of recent infection. The urea dénaturation test rem oves low avidity 
antibodies formed early following infection, and can be used  to docum ent 
recent infection in IgG seropositive patients, such a s  pregnant woman 
who may be at risk of congenital HCMV infection (Blackburn et al., 1991). 
Following allogeneic stem  cell transplant, patients with an HCMV 
seropositive donor typically show a  secondary antibody response  with 
rising levels of high avidity antibodies, while patients with seronegative 
donors show a primary pattern of antibody response, ch a rac te rised  by 
low avidity maturing to high avidity antibodies, at approximately 250 days 
post transplant (Lutz e t al., 1996). HCMV serology cannot be used  to 
d iagnose active infection in the allogeneic transplant recipeint.
1.14.2 Tissue Diagnosis
The characteristic histopathological feature of HCMV d isea se  is the 
intranuclear ‘owl eye inclusion body', which is highly specific and 
correlates with the HCMV viral load, although significantly less sensitive 
then molecular techniques to detect the virus in the sam e organ (Mattes 
et al., 2000). Figure 1-4 show s a  haematoxylin & eosin (H&E) stained 
slide of a colonic biopsy from a patient developing HCMV colitis 64 days 
following a reduced intensity unrelated donor allogeneic transplant.
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Immunochemical and DNA hybridisation techniques may also be used for 
histological diagnosis of HCMV disease.
Figure 1-4 H&E stained slide of a colon biopsy of an allogeneic stem cell 
with HCMV colitis showing typical viral inclusion bodies (personal colle
l transplant patient 
ction).
1.14,3 Cell Culture Techniques 
Cell culture
Conventional cell culture techniques to detect HCMV rely on the detection 
of a cytopathic effect (CPE) in human foreskin fibroblast cultures, but 
although cell culture has 100% specificity, the test requires up to six 
weeks incubation. Detection of early antigen fluorescent foci (DEAFF) 
using monoclonal antibodies, combined with the shell vial culture system  
which uses centrifugation to inoculate a monolayer of fibroblasts, can 
shorten the procedure to 24 hours (Griffiths et al., 1984). However culture 
techniques are limited by low sensitivity and rapid loss of viability of 
stored sam ples (Boeckh and Boivin, 1998), Viral quantification can be 
calculated from serial dilutions of the sample. There are three methods of
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quantifying HCMV by culture. The plaque a ssay  u ses  serial dilutions of 
sam ple onto fibroblast m onolayers, and looks for plaque formation (virus 
sp reads from cell to cell). The infective dose  to cau se  50% infection of 
tissue culture (TCID5 0 ) is determ ined by serial dilutions of a  sam ple, 
which are cultured onto hum an foreskin fibroblasts and observed  for six 
weeks. The third technique is direct m easurem ent of the num ber of 
infective foci using the shell vial technique.
1.14.4 pp65 Antigenaemia
The antigenaem ia te st is based  on the direct staining of polymorpho­
nuclear leukocytes (PMN) by monoclonal antibodies to pp65 conjugated 
to an im m unofluorescence marker, with the results being exp ressed  a s  
the num ber of antigen positive cells relative to the num ber of cells used  to 
prepare the slide. The original description of the m ethod used  150000 
cells per slide (van der Bij et al., 1988), but to reduce error when low level 
viraemia is present it is recom m ended to perform the test on 2 to 3 slides 
(Boeckh and Boivin, 1998). Com pared to cell culture, antigenaem ia h as  
the sam e specificity but greater sensitivity and can be perform ed in less 
than three hours (Erice et al., 1995; Ho et al., 1998). The major limitation 
of the antigenaem ia a ssa y  is the requirem ent for sufficient num ber of 
PMNs, a criteria that may not be fulfilled early post stem  cell 
transplantation, a  time when the risk of HCMV infection is g reatest 
(Boeckh e t al., 1992).
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1,14.5 Polymerase Chain Techniques 
Qualitative PCR
Qualitative HCMV DNA can  be used  to detect HCMV viraemia transplant 
recipients (Jiwa et al., 1989). Symptomatic HCMV infection in allogeneic 
transplant recipients a s  well as  resolution of infection following ganciclovir 
therapy correlates with the detection of HCMV by PCR in blood and urine 
(Einsele et al., 1991). PCR is significantly more sensitive then cell culture, 
and HCMV can be detected  in blood by PCR a  m ean of five days prior to 
onset of d isease, com pared to 13 days after the onset of d isea se  for 
conventional cell culture techniques (Kidd et al., 1993). Although HCMV 
is a  cellular virus, it can  also  be detected  in the cell free com ponent of 
blood (Gerna et al., 1992; Grefte et al., 1994; Revello et al,, 1992). In 
allogeneic transplant patients, PCR of whole blood w as shown to be more 
sensitive in one study (Nolte et al., 1995) while m ost studies find either no 
difference (Hebart e t al., 1996) or whole blood to be less sensitive 
(Boeckh et al., 1997). A recent UK based  study of renal and stem  cell 
transplant patients dem onstrated that HCMV monitoring by PCR is m ore 
sensitive and specific than the pp65 antigenaem ia test, and significantly 
less expensive (Szczepura et al., 2006).
Quantitative
Quantitation of DNA by competitive PCR can be perform ed by adding a 
PCR competitor with identical primer sites but a  restriction enzym e 
digestion site engineered  into it, so the amplification of the differentiation 
products can be run out on a  gel. This h as  been developed for HCMV
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using a hom ologous gB competitor with the exception of a  unique 
restriction site (Fox et al., 1992). Although viral load monitoring can also 
be used for monitoring response  to therapy (G erna et al., 1995), the 
technique is cum bersom e, labour and time intensive and is not suitable 
for routine use, batch processing.
1.15Antiviral Therapy
The first drugs to show significant antiviral activity against the 
herpesviruses with tolerable side effect profiles were the nucleoside 
analogues first syn thesised  in the 1970s, although ganciclovir w as not 
developed until 1982 (Verheyden, 1988). O ther drugs with activity against 
HCMV include foscarnet, cidofovir and the an tisense  nucleotide, 
formivirsen. The biochemical structure of drugs with activity against 
HCMV is shown in Figure 1-5.
1.15.1 Aciclovir
Aciclovir or 9-(2-hydroxethoxymethyl) guanine is a  guanosine nucleoside 
analogue, which com petes with dOTP for the viral DNA polym erase, and  
c au ses  termination of DNA synthesis by preventing the formation of 
phosphodiester bonds. Before the drug is active, it m ust undergo 
phosphorylation to the m onophosphate form by the viral enzym e, 
thymidine kinase, followed by further phosphorylation by cellular 
enzym es, which convert it to the active aciclovir triphosphate form.
Toxicity to non-infected cells is minimal a s  the enzym e for the first 
phosphorylation is not p resen t in uninfected cells, although aciclovir can 
cau se  renal impairment and  rarely neurological dysfunction. Its spectrum
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of activity includes HSV 1 and 2, and VZV. It w as initially thought that 
aciclovir w as not active against HCMV, but the HCMV 
phosphotransferase encoded  by UL97 is capable of phosphorylating 
aciclovir (Talarico et al., 1999), and aciclovir has partial activity against 
HCMV (Tyms et al., 1981).
As the oral bioavailability of aciclovir is poor, the 1-valyl e s te r  of aciclovir, 
valaciclovir has been  formulated. Hydrolysis by a valine e s te ra se  occurs 
in the small intestine and results in a  substantially higher oral 
bioavailability of approximately 60 percent, and hence higher serum  
levels. Valaciclovir h as  been  evaluated as  prophylaxis for HCMV infection 
in both solid organ (Lowance et al., 1999; Fiddian et al., 2002) and stem  
cell transplant patients (Ljungman et al., 2002a) and shown to be 
effective. In the high risk setting of alem tuzum ab conditioned stem  cell 
transplant, the combination of pre-transplant ganciclovir and post­
transplant oral valaciclovir reduced the incidence of HCMV infection from 
53 percent to 29 percent (Kline et al., 2006). The higher d o se  of serum  
levels of aciclovir may result in formation of urine crystals, so  good urine 
output needs to be maintained.
1.15.2 Ganciclovir
Ganciclovir or 9-(1,3-dihydroxy-2-propoxy) m ethylguanine is also a  
guanosine analogue, differing from aciclovir by the p resen ce  of a  
hydroxymethyl group. Its spectrum  of activity includes HSV and HCMV, 
and is licensed for u se  in HCMV. Initial phosphorylation by the HCMV 
specific phophotransferase UL97 (Littler et al., 1992) followed by further 
phosphorylation to ganciclovir triphosphate by cellular k inases is required
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for activity.The oral bioavailability of ganciclovir is poor, estim ated at 
approximately 7 percent in stem  cell transplant patients (Boeckh et al., 
1998b). The plasm a half-life is 3-4 hours, and c learance is by renal 
excretion, although in the p resence of renal impairment, the half-life is 
significantly prolonged. Major side effects include neutropaenia, which is 
more severe in stem  cell transplant recipients (Reed et al., 1990), 
throm bocytopaenia and nephrotoxicity.
Low level resistance to ganciclovir may occur due to substitution or 
deletion mutation of the  catalytic domain of UL97 (Baldanti et al., 1995; 
Chou et al., 1995b; Chou et al., 1995a; Sullivan et al., 1993). High level 
resistance occurs a s  a  result of mutation in the DNA polym erase, UL54 
(Smith et al., 1997), which also results in cross resistance to foscarnet. 
Ganciclovir resistance is uncommon in the allogeneic stem  cell transplant 
setting (R eusser et al., 1996), and generally only occurs following 
prolonged therapy (Erice et al., 1998).
Valganciclovir, the L-valyl e s te r  of ganciclovir, like valaciclovir, undergoes 
hydrolysis by a valine e s te ra se  in the intestine, with a  markedly improved 
bioavailability. A num ber of small trials have evaluated valganciclovir in 
allogeneic transplant patients (Ayala et al., 2006; van der Heiden et al., 
2006). Valganciclovir at a  dose  of 900mg twice daily has an equivalent 
efficacy and safety profile to intravenous ganciclvoir at a  dose  of 5mg/kg 
twice daily in patients with gut GVHD and HCMV infection, although oral 
valganciclovir results in higher blood levels of ganciclovir, and oral 
bioavailability is estim ated to be 75 percent (Einsele et al., 2006).
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1.15.3 Foscarnet
Foscarnet or trisodium phophonoform ate is not a  nucleoside analogue 
but a  pyrophosphate analog. It has activity against all herpesv iruses a s  
well a s  Hepatitis B and  HIV. It is a  non-competitive inhibitor of viral DNA 
polym erase. R esistance can occur b ecau se  of mutations in the viral DNA 
polym erase UL54, which also result in cross-resistance to ganciclovir a s  
discussed above. It is renally excreted, and the major toxicity is 
nephrotoxicity, which can be limited by saline prehydration (Deray et al., 
1989). Metabolic disturbances are common, including hypo or 
hyperkalaemia, hypom agnesaem ia, hypo or hyperphosphataem ia, and 
calcium abnormalities. O ther side effects include n au sea  and  vomiting a s  
well a s  neurologic toxicities including tremor, altered sensation , and 
seizures. Foscarnet at a  dose  of 60mg/kg twice daily is effective a s  
m onotherapy for HCMV infection in bone marrow transplantation 
(Ljungman et al., 1996b), and has equal efficacy to ganciclovir 5 mg/kg 
twice daily with a  lower incidence of neutropaenia (R eusser et al., 2002).
1.15.4 Cidofovir
Cidofovir or (S)-1-(3-hydroxy-2-phosphoryl methoxypropyl) cytosine, is a  
m onophosphate that is converted intracellularly to the diphosphorylated 
form by the  actions of cellular kinases. It acts a s  an analogue of the 
nucleoside dCTP, to inhibit viral DNA polym erase, causing prem ature 
DNA chain termination. The main indication for cidofovir is the treatm ent 
of HCMV infection but it h a s  also been used  to treat adenovirus infections 
following allogeneic transplants (Feuchtinger et al., 2007; Ljungman et al..
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2003b). Although the serum  half-life is only 2.6 hours, the intracellular 
half-life is g reater then 48 hours, allowing intermittent dosing (Cundy et 
al., 1996). Its u se  is com plicated by a high incidence of nephrotoxicity due 
to tubular d am age (Polls et al., 1995), with other com m on side effects 
including fever, n au sea  and rash. Probenecid administration pre and post 
infusion reduces renal clearance and allows weekly or biweekly dosing, 
while saline prehydration reduces renal toxicity. Viral resistance  can 
occur due to m utations in the HCMV DNA polym erase gene, with cross
resistance to ganciclovir but not foscarnet (Emery, 1998). Cidofovir is
currently used a s  second  line therapy for HCMV infection in allogeneic 
stem  cell transplant recipients (Ljungman et al., 2001a),
1.15.5 Formivirsen
Formivirsen is an  an tisense  oligonucleotide, which binds to the mRNA of 
IE2. It is licensed for intra- vitreal administration for the  treatm ent of 
HCMV retinitis (de Clercq E., 2003).
1.15.6 Combination Therapy
While the main toxicity of ganciclovir is marrow suppression  and for 
foscarnet is renal and  metabolic, combining both drugs at 50 percent of 
the dose  used  for m onotherapy results in reduced toxicity. This regimen 
has been  studied in both solid and allogeneic stem  cell transplant 
recipients and has similar efficacy to ganciclovir therapy (M attes et al.,
2004), although there is no evidence to suggest a  synergistic effect.
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Figure 1-5 Chemical structure o f commonly used drugs for the treatment o f human 
cytomegalovirus infections.
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1.16 Strategies for the Prevention and Treatment of HCMV 
Disease in Allogeneic Stem Cell Transplantation
1.16.1 Prevention
HCMV seronegative allotransplant recipients receiving HCMV unseiected  
blood products have a  risk of transfusion-associated infection of betw een 
28 and 57 percent (Bowden et al., 1986; Miller et al., 1991). In HCMV 
seronegative recipients, HCMV infection can be prevented by the u se  of a 
negative donor if available, and by the use of HCMV seronegative blood 
products or leukocyte depleted blood products (Bowden et al., 1991 ; 
Verdonck et al., 1987). A study com paring the u se  of filters that reduce 
leukocytes in blood by three logs with seronegative blood products show  
that both approaches are equally efficacious in preventing HCMV 
infection, although a  small but statistically significant greater num ber of 
patients receiving filtered blood experienced HCMV d isea se  (Bowden et 
al., 1995).
1.16.2 Treatment of established disease
O nce HCMV d isease  is established, mortality is very high. Although 
outcom es have improved with the administration of ganciclovir and 
intravenous immunoglobulin, survival rates rem ains poor with only 31 
percent of patients with HCMV pneumonitis surviving (Em anuel et al., 
1988; Ljungman et al., 1992; R eed et al., 1988; Schmidt et al., 1988). Use 
of intravenous ganciclovir for two w eeks for the treatm ent of 
cytomegalovirus gastroenteritis w as not associated  with clinical 
improvement (Reed et al., 1990). B ecause of the very high mortality of
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HCMV infection in the stem  cell patient, prevention of clinical d isease  
should be the goal of any treatm ent strategies.
1.16.3 Intravenous Immunoglobulin
Although early reports support the use of intravenous immunoglobulin in 
combination with ganciclovir for the treatm ent of HCMV d isease , there  is 
little evidence for a beneficial effect in the prevention of HCMV infection in 
allogeneic stem  cell transplantation (Sokos et al., 2002). There is som e 
evidence for a  role for both intravenous immunoglobulin or hyperimm une 
HCMV immunoglobulin in combination with ganciclovir, but not alone in 
preventing HCMV d isea se  in the solid organ setting, particularly following 
heart and lung transplant (Bonaros et al., 2004; Garcia-Gallo et al., 2005; 
Kocher et al., 2003; Kruger et al., 2003; Weill et al., 2003). High titre 
HCMV immune globulin can  am eliorate HCMV d isea se  in solid organ 
transplant (Snydman et al., 1987). However, a  large trial using HCMV 
hyperimmune immunoglobulin in allogeneic stem  cell transplant recipients 
provided no benefit (Ringden et al., 1987).
1.16.4 Prophylactic Aciclovir
Aciclovir has been  show  to reduce HCMV infection and improve survival 
in som e (Meyers et al., 1988; Prentice et al., 1994) but not all clinical 
trials (Boeckh et al., 1998a). The initial study by Prentice show ed that use 
of high dose  intravenous followed by oral aciclovir in stem  cell recipients 
at risk of infection reduced the frequency and time to infection, but could 
not show a  reduction in frequency of d isease , although a  follow-up study 
show ed a  significant survival advantage for high dose  aciclovir (Prentice
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et al., 1997). A recent study incorporating a strategy of pre-transplant 
prophylactic ganciclovir, post-transplant acyclovir and pre-em ptive 
ganciclovir for HCMV infection has proved to be  very effective at 
preventing HCMV d isea se  (Verma et al., 2003). The aciclovir prodrug, 
valaciclovir, with its higher oral bioavailability, has been  used  to achieve 
higher serum  levels of aciclovir, and has been evaluated in a  large trial in 
the renal transplant setting (Lowance et al., 1999). S tudies have also  
been performed in the stem  cell setting (Mori et al., 2006; W inston et al., 
2003; Ljungman et al., 2002a; Vusirikala et al., 2001), and show  a 
reduced incidence of HCMV infection when com pared to aciclovir, 
although there w as no difference in HCMV disease .
1.16.5 Prophylactic Ganciclovir
Universal prophylactic administration of ganciclovir for all patients at risk 
of HCMV infection by virtue of a  positive donor and or recipient serology 
reduces the incidence of HCMV infection and d isease  in both solid organ 
transplant and allogeneic stem  cell transplantation. In the stem  cell 
transplant setting, the d o se  of ganciclovir used is lower (5mg/kg daily) 
then the therapeutic dose, although a  lower dose of 5mg/kg th ree tim es 
per week has also used. Although effective at reducing HCMV d isea se  
am ong stem  cell patients, there is no d ec rease  in overall mortality 
(Goodrich et al., 1993; Boeckh et al., 1996; W inston et al., 1993), m ost 
likely due to an increased frequency of bacterial and fungal infection 
secondary  to neutropaenia (Salzberger et al., 1997). Thus, m any patients 
receive ganciclovir unnecessarily  and are exposed  to the 
m yeolosuppressive side effects. The recovery of HCMV specific immunity
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is also delayed when prophylactic ganciclovir is used  (Li et al., 1994), and 
this increases the risk of late HCMV infection.
1.16.6 Surveillance and Pre-emptive Therapy
Pre-emptive therapy utilises highly sensitive m ethods to identify patients 
at risk for d isease  from HCMV prior to the onset of d isease , targeting 
antiviral therapy only to those  patients requiring it. Initial attem pts at p re­
emptive therapy w ere based  on surveillance cultures taken at se t tim es 
following transplantation (Goodrich et al., 1991) or surveillance by BAL 
(Forman and Zaia, 1994; Schmidt et al., 1991). Schmidt undertook a  trial 
of prophylactic ganciclovir, initiated when a  surveillance BAL w as culture 
positive for HCMV, and show ed a  significant reduction in HCMV d isease , 
and no deaths due to HCMV interstitial pneumonitis when com pared to 
patients with a  positive BAL not given ganciclovir. This w as an effective 
approach at identifying patients at risk of d isease , but often d isease  was 
already present by the time cultures results were available. This lead to 
the developm ent of m ore rapid and sensitive techniques to detect 
viraemia. The antigenaem ia test h as  been used extensively for 
surveillance a s  part of a  pre-emptive therapy program (Bacigalupo et al., 
1995; Boeckh et al., 1992), and com pares favourably with HCMV culture 
techniques (Nicholson et al., 1997). Although rapid, with a  potential 
turnaround time of two hours, it is limited by being dependen t on a 
sufficient neutrophil count. This has lead to many transplant units 
adopting qualitative PCR of peripheral blood for surveillance strateg ies 
(Einsele et al., 1995; Ljungman et al., 1996a). In com parison with 
antigenaem ia, the PCR technique is more sensitive and not dependent
95
on the leukocyte count (Boeckh et ai., 1997; Hebart et al., 1996; Vlieger 
et al., 1992). Few stud ies have directly com pared a  pre-em ptive strategy 
with a  prophylactic strategy a s  part of a  random ized trial. Boeckh found a  
greater frequency of HCMV d isease  with a  pre-emptive approach, but 
greater fungal infection and late d isease  with universal ganciclovir 
prophylaxis, and no difference in survival, although in this trial, ganciclovir 
w as only initiated at high level antigenaem ia, and not on the basis of a 
positive PCR (Boeckh et al., 1996). In the United S tates, the majority of 
allogeneic stem  cell transplant program s operate an exclusively p re­
emptive program (Avery et al., 2000). Ganciclovir d o ses  used for pre­
emptive therapy have generally been 5mg/kg twice daily, but a  trial 
evaluating low dose pre-em ptive ganciclovir at 5mg/kg per day in patients 
receiving peripheral blood stem  cell transplants has also been evaluated 
(Vij et al., 2003). Although the authors argue that this dose  is effective, 
they do report a  9 percent incidence of HCMV d isease  in patients treated  
in this way. Pre-em ptive therapy can safely be discontinued once a  
patient becom es PCR negative (Einsele et al., 1995).
1.17New Approaches for the Prevention or Treatment of 
HCMV Infections in Allogeneic Stem Ceil Transplant 
Recipients
1.17.1 Immunotherapy
The infusion of HCMV specific donor cells enh an ces  the HCMV specific 
immunity of the recipient and provides protection against recurrence of 
infection and HCMV d isease . W alter et al described a  study of the
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infusion of HCMV specific CD8+ cytotoxic T cell clones, generated  by 
stimulating donor PBMCs with HCMV infected donor derived fibroblasts 
(Walter et al., 1995). They dem onstrated  by T-cell receptor 
rearrangem ent studies that th ese  clones were not present in the recipient 
prior to infusion and persisted for at least 12 weeks. A major shortcoming 
in this study is that a  live virus is required to generate  the HCMV specific 
cell lines. Peggs et al described an approach of generating both CD8+ 
and CD4+ HCMV specific T-cell lines by stimulating peripheral blood 
lymphocytes from HCMV seropositive donors with autologus monocyte 
derived dendritic cells pulsed with HCMV viral lysate (Peggs et al., 2001). 
E insele's group used donor derived PBM Cs, stimulated directly with 
HCMV viral lysate to generate  HCMV specific cell lines (Einsele et al., 
2002). However, the generation of HCMV specific cell lines is time 
consuming. Furthermore, although th ese  studies were effective in 
controlling HCMV infection, the use  of viral lysate carries a risk of viral 
contamination of the  therapeutic product. Thus, this approach cannot 
confirm to good m anufacturing practices. An alternative strategy is to 
select HCMV specific CD8+ T cells using C lass I restricted HCMV 
specific tetram ers com bined with immunomagnetic beads (Cobbold et al.,
2005). The p rocess is rapid, and despite the relatively low cell dose  
infused ap p ears  to be effective. This technique is limited to known C lass I 
HCMV epitopes for which tetram ers are available, and does not provide a 
source of HCMV specific CD4+ T-cells. An im m unom agnetic interferon 
gam m a capture system  can also be used to isolate HCMV specific T-cells 
following stimulation of donor blood with HCMV specific C lass I and  II
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peptides (R auser et al., 2004). T hese cells can then be expanded, 
generating large num bers of HCMV reactive but allodepleted cells in a 
technique that conform s to good manufacturing practice. More recently, 
workers at the Sloan-Kettering C ancer Centre evaluated the u se  of 
overlapping peptides for the immunodominant HCMV protein, pp65, to 
generate  T-cell lines, an approach which is not restricted to known HCMV 
specific c lass I and II epitopes (Trivedi et al., 2005).
1.17.2 HCMV vaccine
Although significant progress in immunotherapy for HCMV has been 
m ade, it is still a  requirem ent for the donor to be seropositive for HCMV. 
S trategies for HCMV vaccination include protein subunit vaccines, live 
attenuated vaccines, viral vector vaccines, peptide vaccines and DNA 
vaccines, but no licensed vaccine for HCMV is available yet (Schleiss and 
Heineman, 2005). The Towne vaccine, a live attenuated  virus (a highly 
p a ssag e  strain of HCMV) h as  been used for vaccination in renal 
transplant recipients (Quinnan, Jr. et al., 1984; Plotkin et al., 1976). 
Although it did not reduce the frequency of HCMV infection in 
seronegative recipients of seropositive grafts, the incidence of HCMV 
d isease , in paticularly severe  d isease  w as reduced, similar to a  level 
se en  in seropositive renal recipients (Plotkin et al., 1984; Plotkin et al.,
1991). The canary pox-CMV gB recom binant virus has been successfully 
used  to generate  a  humoral gB specific response to HCMV (Adler et al., 
1999). In order to generate  a CTL response, a canary pox CMV pp65 
recom binant virus w as used  successfully (Berencsi et al., 2001).
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A subunit vaccine using gB and a  novel adjuvant, MF59, has also had 
som e su ccess  in generating humoral response (P ass  et al., 1999). Novel 
approaches to HCMV vaccination includes the u se  of DNA vaccines and 
peptide vaccines, which have been evaluated in animal m odels (Gallez- 
Hawkins et al., 2004; Gopal et al., 2005; Schleiss et al., 2006). Universal 
HCMV vaccination to prevent congenital HCMV infection has been 
assigned the highest priority by the United S ta tes of Ameirica Institute of 
Medicine (Arvin et al., 2004), and would also have the additional benefit 
of eventually eliminating the problem of HCMV infection in solid organ 
and stem  cell transplants.
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y. 18 Aims of the Thesis
1. To identify the risk factors for HCMV infection in allogeneic stem  
cell transplant recipients receiving high dose  aciclovir prophylaxis, 
HCMV surveillance by qualitative PGR, and pre-em ptive therapy 
for infection.
2. To evaluate the technology of the TaqM an m ethod for real time 
PGR viral load monitoring, to a s s e s s  the predictive value of the 
viral load when using a strategy of pre-emptive therapy to prevent 
HGMV d isease , and to a s s e s s  the utility of real time PGR in 
predicting the likely response  to HGMV antiviral therapy in 
allogeneic stem  cell transplant recipients.
3. To evaluate the role of HGMV specific immunity in controlling 
HGMV infection in allogeneic stem  cell transplant patients by
prespectively monitoring HGMV specific GD4+ and GD8 4 - T cell 
function following transplantation.
4. To characterise the GD4+ T cell response to HGMV and identify 
HGMV specific c lass II epitopes to the HGMV proteins pp65 and 
IE1 in HGMV seropositive healthy controls and stem  cell transplant 
recipients for the purposes of targeted monitoring of HGMV 
specific GD4+ T immune recovery and a s  possible antigens for 
generating T-cell clones for immunotherapy and use  a s  a  peptide 
vaccine.
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Chapter 2 Risk factors for HCMV VIraemia in 
Ailogeneic Stem Ceii Transpiant Recipients in 
the Era of Pre-emptive Therapy
2.1 Introduction
In order to reduce the risk of symptomatic HCMV infection, the goal is to 
either avoid HCMV infection altogether by the use  of prophylaxis, or to 
pre-emptively treat asym ptom atic infection to prevent viraemia reaching 
levels that will c au se  d isease . Although prophylaxis is effective in 
preventing HCMV viraemia and d isease  when used in the first one 
hundred days following transplantation (Boeckh et al., 1996), it does not 
reduce overall mortality, due to increased bacterial and fungal infections 
secondary to ganciclovir induced m yelosuppression negating the 
reduction in HCMV mortality. Furthermore, prophylactic administration of 
ganciclovir delays the recovery of HCMV specific immune reconstitution 
(Li et al., 1994), increasing the risk of late d isease . The alternative 
strategy of pre-emptive therapy based  on viral monitoring either by 
antigenaem ia or PCR m ethods has the advantage of preventing HCMV 
d isease  while minimising exposure to m yelosuppressive and nephrotoxic 
drugs.
Despite the use of HCMV surveillance and pre-emptive therapy, problem s 
with late infection remain (Peggs et al., 2000; Einsele et al., 1995). 
Previously identified risk factors for late HCMV infection include; HCMV 
antigenaem ia before th ree m onths, lymphopaenia (absolute lymphocyte 
count less than 100 X 10^/L), undetectable HCMV specific T cell
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response, and GVHD, with a  frequency of late d isease  am ong 
seropositive patients of up to 17.8 percent and a mortality of 46 percent 
(Boeckh et al., 2003; Boeckh and Nichols, 2004; Peggs et al., 2000). 
GVHD following allogeneic transplantation is also a  significant cau se  of 
mortality and impaired quality of life following allogeneic stem  cell 
transplantation. The risk of GVHD can be reduced by depleting T-cells 
from the graft with C am path-1, a  monoclonal antibody against CD52, an 
antigen found on T cells, B cells, NK cells and dendritic cells (Hale et al.,
1983). The rat IgM form, Campath-1 M, is effective at depleting donor T- 
cells from the graft and reducing the risk of GVHD when used  ex vivo 
with autologous serum  a s  a source of com plem ent (W aldmann et al.,
1984). However, this technique has been associa ted  with an increased 
risk of graft rejection, probably m ediated by host T-cells (Bunjes, 2000). 
To overcom e this, Campath-1 G (IgG rat form) can be used in vivo to 
deplete host T-cells prior to infusion of the graft, relying on an Antibody 
D ependent Cell-m ediated Cytotoxicity (ADCC) in vivo (Hale e t al., 1998), 
and is effective in reducing acu te  but not chronic GVHD (Willemze et al.,
1992). More recently a  recom binant hum anised form of anti-CD52, 
Campath-1 H (Alemtuzumab) has been developed and this h as  
supersed ed  the use  of Campath-1 M and 1G both for ex-vivo and in vivo 
use  (Williams et al., 2000; Phillips et al., 2001). The use of Campath-1 H 
in the setting of non-myeloablative transplant h as  been reported to be 
associa ted  with an increased  frequency of HCMV infection when used  in 
the non-myeloablative transplant setting, while RIC not utilising
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monoclonal antibodies show no differences (Chakrabarti et al., 2002a; 
Junghanss et al., 2002).
At the Royal Free Hospital, a  strategy of prophylactic high d o se  acyclovir 
and pre-emptive therapy for HCMV viraemia detected by PCR h as  been 
used to prevent HCMV d isease . The extensive experience in the use of 
both Campath-1 G and Campath-1 H for in vivo and ex vivo T-cell 
depletion in allogeneic stem  cell transplantation allows an a sse ssm e n t of 
the impact of th ese  agen ts  on HCMV infection in stem  cell transplant 
recipients.
2.2 Methods
2.2.1 Patients
All patients receiving an allogeneic stem  cell transplant betw een 1®^ of 
January  1995 and 31st of D ecem ber 2000 were retrospectively identified. 
Patient characteristics including age, gender, indication for transplant, 
d isease  sta tus at the time of transplant, donor type, stem  cell source, 
degree of HLA match, donor and recipient HCMV serostatus, conditioning 
regimen, form of T-cell depletion a s  well a s  the clinical outcom e were 
collected using the clinical notes and checked against the transplant 
da tabase . Risk stratification w as performed on the basis of underlying 
d isease  according to standard  criteria (Glucksberg et ai, 1974). An 
underlying diagnosis of CLL w as classified a s  high risk. Patients were 
regarded a s  being a com plete HLA match if they were identical at C lass I 
A, B or C lass II DR by the highest resolution tissue typing available at the
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time of transplant. Peripheral blood HCMV PCR results were obtained 
from the laboratory d a tab ase .
2.2.2 Conditioning and GVHD Prophylaxis
Standard conditioning regim ens were used  depending on the indication 
for transplantation, Non-myeloablative transplants were non-TBI based , 
using fludarabine, Cam path and either busulfan, m elphalan, or BEAM 
(carmustine, etoposide, cytosine arabinoside and m elphalan), depending 
on the underlying condition. Second transplants w ere conditioned with a 
fludarabine, cytosine arabinoside and idarubicin based  regimen a s  
described previously (Paw son et al., 2001). Non T-cell depleted 
transplants, with the exception of syngeneic transplants, received short 
course m ethotrexate and ciclosporine for GVHD prophylaxis. In the ca se  
of T-cell depleted transplants, GVHD prophylaxis with ciclosporine w as 
only used for HLA m ism atched or aplastic anaem ia transplants. Ex-vivo 
T-cell depletion w as perform ed by the addition of 20mg of Cam path to the 
stem  cell graft for a  minimum of 30 minutes at room tem perature prior to 
infusion into the recipient. Campath-1 G w as used prior to 15^ *^  O ctober 
1998, and Campath-1 H subsequen t to 15^  ^O ctober 1998. In 7 c a se s  ex- 
vivo T-cell depletion w as performed by positive CD34 selection using the 
Baxter Isolex system  (Dreger et al., 1995). In-vivo T-cell depletion w as 
performed by the administration of Cam path (C am pathIG  prior to 15^ *^  
O ctober 1998 and 1H post 15^ *^  O ctober 1998) to the transplant recipient 
prior to transplantation. The standard  regimen consisted of 20mg 
Cam path 1G or Cam path 1H adm inistered intravenously daily for 5 days 
prior to infusion of the graft, with a  dose  reduction for paediatric patients.
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Radiotherapy when used  in the conditioning regimen (N=152) w as TBI at 
a dose of 750 centlGy target dose, with the exception of two patients who 
received fractioned TBI (six fractions over three days). In addition, eight 
patients received Total Lymphoid Irradiation (TLI), and five patients with 
Fanconi anaem ia received Thoraco Abdominal (TA) irradiation.
2.2.3 Infection Prophylaxis
All patients were nursed in positive p ressure HEPA (High efficiency 
particulate air filter) filtered rooms. Ciprofloxacin, amphotericin 
suspension, and itraconazole or fluconazole were com m enced pre­
transplant. Pneum ocystis pneum onia prophylaxis consisted  of nebulized 
pentam idine until engraftm ent, then oral trimethoprim/sulfamethoxazole 
480 mg twice daily two days per w eek (dose adjusted for paediatric 
patients). All HCMV seropositive transplant recipients and seronegative 
recipients with an HCMV seropositive donor received aciclovir 10mg/kg 
intravenously three tim es daily during their inpatient stay, followed by 
aciclovir SOOmg four tim es daily or valaciclovir 2 g four tim es daily until 
100 days post transplant. D oses were modified in the p resence of renal 
impairment. Otherwise, aciclovir 200m g three tim es daily w as 
adm inistered a s  prophylaxis for H erpes Simplex Virus (HSV) if HSV 
serology w as positive. All HCMV seronegative stem  cell transplant 
recipients received HCMV seronegative and leucodepleted blood 
products, irrespective of donor HCMV serostatus.
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2.2.4 HCMV PCR Monitoring
DNA w as extracted from whole blood using the QiaAMP DNA Blood 
minikit (Qiagen). Qualitative HCMV PCR w as perform ed using an in- 
house PCR a ssay  (Kidd et al., 1993). The lower limit of sensitivity for this 
a ssay  is 200 genom e copies/ml of blood. Stem  cell transplant recipients 
underwent HCMV PCR monitoring twice weekly a s  an inpatient, then 
weekly for the first month following discharge, and fortnightly thereafter. 
Monitoring w as continued for a minimum of three months.
2.2.5 HCMV Pre-emptive Therapy
HCMV pre-emptive therapy w as com m enced after two consecutive 
HCMV PCR positive results. HCMV viraemia w as treated with either 
ganciclovir 5mg/kg intravenously twice daily, or foscarnet 90mg/kg 
intravenously twice daily or a  combination of both at half dose. D oses 
were adjusted in the p resence of renal failure according to the 
m anufacturer's guidelines. G-CSF w as adm inistered to counteract the 
bone marrow suppressive effect of ganciclovir. During pre-em ptive 
therapy, aciclovir prophylaxis w as discontinued. Pre-emptive HCMV 
therapy w as continued until two consecutive negative HCMV PCR results 
were obtained. Aciclovir prophylaxis w as recom m enced when pre­
emptive therapy w as discontinued.
2.2.6 Clinical Outcomes
The major endpoints of this study were first HCMV infection, late HCMV 
infection, and HCMV d isease . Time to HCMV infection w as defined a s  the
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time betw een transplant and the first of two consecutively positive HCMV 
PCR results. Late HCMV infection w as defined a s  any infection occurring 
after day 100, irrespective of w hether an infection had occurred prior to 
100 days. O ther endpoints of the study were overall survival, relapse free 
survival and time to death. Acute GVHD w as graded according to 
standard criteria (Glucksberg et al., 1974).
2.2.7 Statistical Analysis
Statistical analysis w as performed using S P S S  version 12.1. Kaplan 
Meier survival analysis w as used  to calculate HCMV infection rates, acu te  
GVHD rates, overall survival, and relapse free survival. The null 
hypothesis of the influence of prognostic factors was tested  by the log 
rank score, and p values were two tailed. Univariable risk analysis for 
HCMV infection w as performed using Cox proportional hazards 
regression models, and multivariable risk analysis w as perform ed using a 
backwards selection procedure (Cox, 1972). The null hypothesis for 
regression analysis w as tested  by the Wald statistic, and the relative risks 
were estim ated a s  hazard ratios. Median time to HCMV infection w as 
com pared using the Mann W hitney U test.
2,3 Resu/ts
2.3.1 Patients and Disease Characteristics
Two hundred and six transplant recipients were identified a s  having 
received an allogeneic stem  cell transplant betw een the 1®^ of January  
1995 and 31st of D ecem ber 2000. Patient and d isease  characteristics are 
sum m arised in Table 2-1. The median age at transplantation w as 27y
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(range 3 to 60y). The major indications for transplantation were acute 
myeloid leukaem ia (n=61), acu te  lymphoblastic leukaem ia (n=52), chronic 
myeloid leukaem ia (n=30), myelodysplastic syndrom e (n=16) and non- 
Hodgkin's lymphoma (n=12), with a  sm aller num ber of patients being 
transplanted for other malignant (n=12) or non-malignant conditions 
(n=23). O ne hundred and eighty-three transplants were a com plete 6 out 
of 6 HLA match and 21 transplants were less than a  6 out of 6 HLA 
match. One hundred and thirty patients received an HLA identical sibling 
graft, 8 patients received non-sibling related grafts, and 68 patients 
received unrelated grafts. The source of the graft w as bone marrow in 
141 c a se s  and G-CSF mobilised peripheral blood stem  cells in 64 cases.
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Table 2-1 Characteristics of transplant recipients.
No. of transplants, n 206
Median age at transplant, yrs (range)
Proportion of males (%)
Indication for transplant
Acute Myeioblastic Leukaemia 
Acute Lymphoblastic Leukaemia 
Chronic Myeloid Leukaemia 
Myelodysplastic Syndrome 
Non-Hodgkin’s Lymphoma 
Other Malignant Disorder®
Other Non-malignant Disorder*’
Risk Group
Standard risk 
High risk 
Donor Type 
Sibling
Non-sibling related donor 
Unrelated donor 
HLA Match”
6 Antigen match 
Less than 6 antigen match 
Source of Graft
Bone marrow 
Peripheral blood stem cell 
Median CD34 dose XtoVkg recipient weight^ (range) 
Type of transplant
Reduced intensity conditioning 
Myeloablative 
Pre-transplant conditioning
Non radiotherapy based conditioning 
Radiotherapy based conditioning 
Campath In Vivo Use®
No Campath in vivo 
Campath-1 G in vivo 
Campath-1 H in vivo 
Form of Ex vivo T-Ceil Depletion 
No ex vivo T-Cell Depletion 
Campath-1 G 
Campath-1 H 
CD34 selection 
HCMV serology (recipient/donor)'
Neg/Neg
Neg/Pos
Pos/Neg
27 (3-60) 
138 (67%)
61 (30%) 
52 (25%) 
30 (15%) 
16(8%)
12 (6 %)
12 (6%) 
23(11%)
86 (42%) 
120 (58%)
130 (63%)
8 (4%)
68 (33%)
183 (89%) 
21 (10%)
141 (68%) 
64(31%) 
2.6 (0.2-18.4)
1 2 (6%) 
194 (94%)
41 (20%) 
165 (80%)
105 (51%) 
44 (21%) 
52 (25%)
116(56%) 
43 (21%) 
40(19%)
7 (3%)
56 (27%) 
20 (10%)
36 (17%)
Idiopathic myelofibrosis, multiple myeloma, sarcoma,
*’ Aplastic anaemia, Fanconi anaemia, thalassaemia major, metachromic leucodystrophy 
” HLA tissue typing data unavailable in 2 recipient/donor pairs 
‘*CD34 dose unavailable in 17 patients 
® In-vivo Campath use data unavailable in 5 patients
* HCMV serology unavailable in 3 recipient/donor pairs
109
2.3.2 Transplant Related Outcomes
Forty-one patients experienced acute GVHD of grade II or greater, with 
an actuarial incidence of 24±3.3% when analysed with death  a s  a 
competing variable. The incidence of grade II, III and IV acu te  GVHD was 
16.2±2.9% (n = 27), 4.3+1.6%  (n = 5) and 4.1 ±1.5% (n = 5) respectively. 
After a  median follow-up of 528 days, overall survival w as 79+2.9%  at 
day 100, 57.1 ±3.6% at 1 year, and 38.2+4.1% at 3 years. By univariable 
Cox regression analysis, neither HCMV serosta tu s of the recipient and/or 
donor, nor the p resence  of HCMV infection had a  statistically significant 
effect on the overall survival when the entire cohort w as analysed, and by 
subgroup analysis for HLA-identical sibling transplants and m atched 
unrelated transplants, Table 2.2. Overall survival for patients transplanted 
for malignant conditions (n=183) w as 77.5±3.1%  at day 100, 52.8±3.8%  
at one year and 32.3±4.2%  at 3 years, with a progression free survival of 
70.9±3.4% at day 100, 40.8±3.7%  at one year and 26.1 ±3.7% at 3 years. 
Neither HCMV serosta tu s of the recipient and/or donor or HCMV infection 
had a statistically significant impact on overall survival or progression free 
survival in this subgroup.
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Table 2-2 Univariable Cox Regression analysis of the impact of HCMV serology and infection on overall survival.
Relative Hazard 95% Cl p value
All patients (n = 203)
Positive recipient HCMV serology 1.20 0.74-1.95 0.47
Positive donor HCMV serology 1.01 0.66-1.55 0.98
HCMV infection 1.15 0.71-1.85 0.57
HLA identical sibling transplants (n = 128)
Positive recipient HCMV serology 1.05 0.53-2.08 0.9
Positive donor HCMV serology 0.73 0.38-1.41 0.35
HCMV infection 1.23 0.67-2.25 0.51
Matched unrelated transplants (n=68)
Positive recipient HCMV serology 1.31 0.60-2.85 0.50
Positive donor HCMV serology 0.93 0.50-1.74 0.82
HCMV infection 1.01 0.43-2.39 0.98
I l l
2.3.3 HCMV Infection
Median follow-up for HCMV PCR monitoring w as 129 days. Sixty-six 
patients experienced HCMV infection, with a m edian time to HCMV 
infection of 39 days post transplant (range 0 to 206 days).
Kaplan Meier survival analysis w as performed with respect to time to first 
HCMV infection post transplant on all 147 patients at risk of HCMV 
infection based  on a positive donor and/or recipient HCMV serology. 
Overall, by Kaplan Meier analysis the cumulative infection rate w as 
15.3±3.0% by 1 month (30 days), 40.1 ±4.2% by 2 m onths (60 days), 
42.4±4.2%  by 3 m onths (100 days), 48.7±4.4%  by 6 months (180 days) 
and 50.7±4.4% by 1 year (365 days) after transplant. Figure 2-1. Kaplan 
Meier analysis of the incidence of HCMV infection stratified by donor (D) 
and recipient (R) HCMV serosta tus is sum m arised in Figure 2-2. The 
cumulative infection rate at 6 m onths for the R+D- group w as 56.3±9.1%, 
for R+D+ w as 55.5+5.5%  and for the R-D+ group w as 16.9±9%. The 
difference in the cumulative HCMV infection rates betw een the R-D-i- 
group, and the R+D- and R+ D+ groups w as statistically significant 
(p=0.009 for R+D- group and p=0.007 for R+D+ group when com pared 
with the R-D+ group, Log Rank Score). There was no statistically 
significant difference in infection rates betw een the R+D- group and the 
R+D+ group.
No HCMV viraemia w as detected  in the R-D- group, although one patient 
in this group did develop HCMV colitis with a  positive DEAFF test despite 
an absen ce  of HCMV viraemia.
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Figure 2-1 Kaplan Meier estimate of the cumulative incidence of HCMV infection in 
intermediate or high risk patients.
The Kaplan Meier estimate of the cumulative incidence of HCMV infection is plotted for 
recipient and/or donor HCMV seropositive patients (n=147). The cumulative incidence of 
infection is 15.3+3.0% at 30 days, 40.1+4.2% at 60 days, 42.4+4.2% at 100 days, 48.7±4.4% at 
180 days and 50.7+4.4% at 360 days. The cross bars indicate censored events.
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Figure 2-2 Kaplan M eier estim ate of the cumulative incidence of HCMV infection 
according to HCMV serology.
The Kaplan Meier estimates of the cumulative incidence of HCMV infection according to 
HCMV serology of the recipient and the donor is plotted. The R-D- group (n=56, green line) did 
not experience any episodes of viraemia. The cumulative incidence of viraemia of the R-D+ 
group (n=20, black line) was 16.9±9%, the R+D- group (n=36, red line) was 56.3±9.1% and the 
R+D+ group (n=91, blue line) was 55.5±5.5%. %. The difference in the incidence of HCMV 
infection between the R-D+ group, and the R+D- and R+ D+ groups was statistically significant 
(p=0.009 for R+D- group and p=0.007 for R+D+ group when compared with the R-D+ group. 
Log Rank Score). There was no statistically significant difference in infection rates between the 
R+D- group and the R+D+ group (p=0.71, Log Rank Score). The cross bars indicate censored 
events.
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2.3.4 Analysis of the Risk Factors for HCMV Infection
The results of univariable Cox regression analysis for the risk factors for 
HCMV infection in patients at risk of HCMV viraemia are  sum m arised in 
Table 2-3. Consistent with the results of the cumulative incidence of 
HCMV infection by Kaplan Meier analysis, univariable Cox regression 
analysis shows that R+D+ serosta tus (RH 4.28, p = 0.02) and R+D- 
serostatus (RH 4.73, p=0.02) are associated  with the g reatest relative 
hazards for HCMV infection. Among the other factors exam ined, the use 
of Campath-1 H both in vivo (RH 2.15, p = 0.006) and ex vivo (RH 2.11, p 
= 0.009) are identified a s  significant risk factors for HCMV viraemia. 
Following multivariable Cox regression analysis using a proportional 
hazards model (Table 2-4), R+D+ (adjusted RH 8.1, p = 0.004) and R-t-D- 
(adjusted RH 5.91, p = 0.02) serosta tus remain the highest risk factors for 
HCMV infection. The use  of Campath-1 H in vivo (adjusted RH 3.68, p < 
0.001) but not Campath-1 G in vivo (adjusted RH 1.76, p = 0.15) also 
rem ains independently associa ted  with a significantly increased  risk of 
HCMV infection. Ex-vivo T-cell depletion by any m ethod was no longer 
identified a s  increasing the relative hazard of HCMV infection. The only 
other factors identified to independently increase the relative hazard of 
HCMV infection w as use  of radiotherapy based  conditioning (adjusted RH 
2.3, p = 0.03) and the CD34 stem  cell dose  (adjusted RH 0.87 per 
1X10®/kg CD34 cells, p = 0.04), while age  w as no longer significant.
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Table 2-3 Univariable Cox Regression analysis of the risk factors for HCMV infection.
Relative Hazard 95% Cl p value
Age per year 1.02 1.00-1.03 0.08
Gender Female 1.12 0.68-1.83 0.66
Risk High Risk 0.87 0.54-1.41 0.58
Campath In Vivo No Campath 1.00 0.024
Campath-1 G 1.36 0.69-2.68 0.38
Campath-1 H 2.15 1.24-3.73 0.006
Campath Ex Vivo No Campath 1.00 0.06
Campath-1 G 1.04 0.54-1.99 0.91
Campath-1 H 1.97 1.06-3.66 0.009
CD34 Selection 0.00 0.90
Acute GVHD GVHD grade II or higher 1.25 0.70-2.22 0.45
Pre-transplant conditioning Radiotherapy based conditioning 1.97 0.97-3.97 0.06
Donor Type Sibling 1.00 0.44
Unrelated 1.34 0.79-2.29 0.28
Non Sibling Related Donor 0.67 0.16-2.77 0.58
Donor Match Fewer than 6 antigen match 1.10 0.44-2.75 0.83
BMT Type Reduced intensity 0.83 0.25-2.56 0.71
Graft Source PBSC 0.90 0.54-1.52 0.70
CD34 dose per 10^/kg recipient weight 0.90 0.80-1.01 0.08
HCMV serology NegPos 1.00 0.04
(Recipient/Donor) PosNeg 4.73 1.39-16.1 0.02
PosPos 4.28 1.33-13.74 0.02
Disease ALL 1.00 0.94
AML 0.90 0.46-1.75 0.75
CML 1.22 0.58-2.61 0.59
MDS 1.07 0.45-2.95 0.77
Other Malignant 0.81 0.35-1.90 0.64
Other Non-Malignant 0.90 0.37-2.20 0.82
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Table 2-4 Multivariable Cox Regression analysis of the risk factors for HCMV infection.
Relative
Hazard
95% Cl p value
Campath In Vivo Use No Campath 1.00 <0.001
Campath-1 G 1.76 0.81-3.84 0.15
Campath-1 H 3.68 2.02-6.72 <0.001
Pre-transplant Conditioning Radiotherapy based conditioning 2.30 1.07-4.91 0.03
CD34 dose per 10®/kg recipient weight 0.87 0.77-0.99 0.04
HCMV serology NegPos 1.00 0.02
(Recipient/Donor) PosNeg 5.91 1.34-26.06 0.02
PosPos 8.10 1.93-33.91 0.004
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2.3.5 Effect of In Vivo Campath Use on Time to HCMV Infection
Kaplan Meier survival curves for HCMV infection stratified by u se  of 
Cam path in vivo were plotted for all patients at risk of HCMV viraemia, 
(Figure 2-3). The cumulative HCMV infection rate for patients receiving 
Campath-1 H in vivo w as 64.7±8.6%, for patients receiving Campath-1 G 
in vivo w as 41.6+10.4%  and for patients receiving no Campath-1 in vivo 
w as 42.8±5.8%. The difference in the cumulative incidence of HCMV 
infection between the Campath-1 H group and the non-Cam path group 
w as highly significant (p=0.0024, Log Rank Score), but the difference 
betw een the Campath-1 G group and the Campath-1 H group did not 
reach statistical significance. Although the group receiving no Cam path in 
vivo had a lower incidence of infection prior to day 100 (cumulative 
incidence of 52.2+5.3%), the overall cumulative incidence was 
com parable to the Campath-1 G group.
To a s se s s  the interaction betw een HCMV serostatus and the  effects of 
Cam path in vivo, sep a ra te  Kaplan Meier survival curves according to in 
vivo Cam path use were plotted for R-hD-i- patients, (Figure 2-4) and R+D- 
patients, (Figure 2-5). In the R+D+ group, although HCMV infection 
occurs earlier in the groups receiving either Campath-1 H in vivo 
(cumulative incidence 63.9±12.9% ) or Campath-1 G in vivo (cumulative 
incidence 58.4±15.6%) com pared to patients receiving no C am path in 
vivo (cumulative incidence 49.7±6.7%), there is no significant difference 
in the overall cumulative incidence of HCMV infection (p = 0.15, Log Rank 
Score). In the R+D- group, the cumulative incidence of HCMV infection is 
100% for Campath-1 H in vivo, 46+17.3%  for Campath-1 G in vivo and
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25±12.7% for no Cam path. This difference is statistically significant (p < 
0.001, Log Rank Score). In the R-D+ group, the cumulative incidence of 
HCMV infection am ong patients receiving Campath-1 H in vivo w as 
16.7±15.2%, and am ong patients not receiving Cam path in vivo w as 
14.3±13.2%, while none of the  patients that received Campath-1 G in vivo 
experienced infection. The difference was not significant (p=0.72, Log 
Rank Score).
W hen the cumulative incidence of infection betw een R-i-D- and R-i-D-f- 
patients was com pared in a  subgroup analysis according to Cam path in 
vivo use, none of the groups show ed a statistically significant difference 
(p=0.13 for no Cam path group, p=0.61 for Campath-1 G in vivo group 
and p=0.24 for Campath-1 H in vivo group, Log Rank Score).
HCMV infection occurred significantly earlier in patients receiving either 
Campath-1 G in vivo, with a m edian time to infection of 27 days, or 
Campath-1 H in vivo with a m edian time to infection of 33 days, when 
com pared to patients receiving no Cam path in vivo, m edian time to 
infection of 51 days (p=0.007 for Campath-1 G vs. no Cam path and 
p=0.006 for Campath-1 H vs. no Cam path, Mann W hitney U Test), Figure 
2.6. The difference in the time to HCMV infection betw een the C am path­
IG  and the Campath-1 H group w as not statistically significant (p=0.97, 
Mann Whitney U Test).
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Figure 2-3 Kaplan Meier estimate of the cumulative incidence of HCMV infection 
according to Campath in vivo use.
The Kaplan Meier estimate of the cumulative incidence of HCMV infection in recipient and/or 
donor HCMV seropositive patients, according to in vivo Campath use is plotted. The cumulative 
incidence of HCMV infection in the group receiving no Campath in vivo (red line, n=85) was 
42.8±5.8%, for the group receiving Campath-1 G in vivo (blue line, n=28) was 41.6+10.4%, and 
for the group receiving Campath-IH (green line, n=32) was 64.7 ±8.6%. The difference in the 
cumulative incidence of infection between the Campath-IH group and the no Campath group was 
significant (p=0.002. Log Rank Score), while the difference between the group receiving 
Campath-1 G and no Campath group (p=0.71. Log Rank Score), and Campath-1 G and Campath- 
IH (p=0.13. Log Rank Score) was not significant. The cross bars indicate censored data.
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Figure 2-4 Kaplan Meier estimate of the cumulative incidence of HCMV infection in R+D+ 
patients according to Campath in vivo use.
The Kaplan Meier estimate of the cumulative incidence of HCMV infection in R+D+ allogeneic 
transplant patients according to the in vivo use of Campath. The cumulative incidence of HCMV 
infection for the group not receiving Campath in vivo (n=63, red line) is 49.7±6.7%, for the 
group receiving Campath-1 G in vivo (n = ll)  is 58.4±I5.6%, and for the group receiving 
Campath-IH is 63.9+12.9%. There was no statistically significant difference between the curves 
(p=0.15, Log Rank Score). The cross bars indicate censored data.
C 100-
80-
63.9±12.9%
60-
58.4±15.6%
49.7±6.7%40-
20 -
2000 100 300
Campath In Vivo 
Use
—  Campath-1 G
—  Campath-1 H
—  No campath
Days Post Transplant
121
Figure 2-5 Kaplan Meier estimate of the cumulative incidence of HCMV infection in R+D- 
patients according to Campath in vivo use.
The Kaplan Meier estimate of the cumulative incidence of HCMV infection in the R+D- group is 
plotted according to in vivo Campath use. The cumulative incidence of HCMV infection in the 
no Campath group (red line, n=15) was 25±12.7% and the Campath-1 G group (blue line, n=10) 
was 46+17.3%. All the non-censored patients in the Campath-1H group (green line, n=10) 
experienced HCMV infection. The difference between the curves was statistically significant 
(p=().(X)05, Log Rank Score). The cross bars indicate censored data.
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Figure 2-6 Time to first HCMV infection according to Campath in vivo use.
The time to first HCMV infection following transplantation is plotted for allogeneic recipients 
according to Campath in vivo use. The horizontal bar indicates the median value and the 
interquartile range. The median time to HCMV infection in the group not receiving Campath in 
vivo (n=33) was 51 days (range 0 to 206 days), for the group receiving Campath-1G (n=l 1) was 
27 days (range 3 to 56 days), and for the group receiving Cam path-IH  (n=20) was 33 days (range 
4 to 106 days). There was a significant difference in time to first HCMV infection between the 
Campath-1 G group and the non Campath group (p=0.007, Mann Whitney U Test), and between 
the Cam path-1H group and the non Campath group (p=0.006, Mann Whitney U Test). The 
difference between the Cam path-IG  and Cam path-IH  group was not significant (p=0.97, Mann 
Whitney U Test).
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2.3.6 Late HCMV Infection
O ne hundred and seven teen  patients with follow-up beyond 100 days 
were identified and included in the analysis of risk factors for late HCMV 
infection. Twenty patients experienced HCMV infection beyond 100 days. 
The Kaplan Meier estim ate of the incidence of late HCMV viraemia is 
19.5±5.4%, Figure 2-7. There w as no statistically significant difference in 
the incidence of late HCMV infection according to HCMV serosta tus, 
Figure 2-8.
Univariable Cox regression analysis of the risk factors for late HCMV 
infection is shown in Table 2-5. Infection before day 100 (RH 2.5, p=0.05) 
w as the only significant factor predictive of the risk of late infection. 
However, following multivariable Cox regression analysis, increasing ag e  
(adjusted RH 1.04 per year p = 0.04) and an acute GVHD score of II or 
greater (adjusted RH 4.0, p = 0.01) were both statistically significant 
predictors of an increased risk of late HCMV infection, while a  higher 
CD34 stem  cell dose  w as associa ted  with a reduced risk of late infection 
(RH 0.8 per 1X10® CD34 cells/kg recipient weight, p = 0.05). T hese data  
are sum m arised in Table 2-6.
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Table 2-5 Univariable Cox regression analysis of the risk factors for late (>100 days) HCMV infection.
Relative Hazard 95% Cl Significance (p value)
Age per year 1.03 1.00-1.06 0.07
Gender Female 1.10 0.44-2.76 0.84
Risk High Risk 0.91 0.38-2.19 0.84
Campath In Vivo use Campath-1G 1.11 0.31-3.94 0.87
(Reference group is No Campath) Cam path-1H 1.06 0.36-3.02 0.91
Campath Ex Vivo Use Campath-1G 2.05 0.70-6.02 0.19
(Reference group is No Campath) Cam path-1H 1.46 0.50-4.26 0.49
CD34 Selection 0 O-oo 0.98
Acute GVHD GVHD grade II or higher 2.27 0.87-5.93 0.09
Pre-transplant Conditioning Radiotherapy based conditioning 5.68 0.76-42.43 0.09
Donor Type Unrelated 1.47 0.57-3.83 0.43
Non Sibling Related Donor 0 O-oo 0.98
Donor Match Fewer than 6 antigen match 1.21 0.16-9.06 0.85
BMT Type Reduced intensity 1.50 0.20-11.23 0.69
Graft Source PBSC 0.97 0.37-2.53 0.95
CD34 dose per 10®/kg recipient weight 0.81 0.62-1.04 0.1
HCMV serology (Recipient/Donor) PosNeg 1.93 0.39-9.54 0.42
(Reference group is Neg/Pos) PosPos 1.27 0.29-5.69 0.75
Disease ALL 1 0.53
AML 1.41 0.41-4.83 0.58
CML 1.03 0.19-5.59 0.98
MDS 2.96 0.66-13.24 0.16
Other Malignant Disorder 0.70 0.08-6.23 0.75
Other Non-Maiignant Disorder 0.42 0.05-3.75 0.44
HCMV Infection Before Day 100 Yes 2.47 1.01-6.05 0.05
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Table 2-6 Multivariable Cox Regression analysis of the risk factors for late (>100 days) HCMV Infection.
Relative
Hazard
95% Cl Significance 
(p value)
Age per year 1.04 1.00-1.09 0.04
Acute GVHD GVHD grade II or higher 3.96 1.39-11.30 0.01
Radiotherapy Radiotherapy based conditioning 6.06 0.60-61.71 0.13
BMT Type Reduced intensity 10.11 0.87-117.54 0.07
CD34 dose per 10^/kg recipient weight 0.78 0.61-0.99 0.05
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Figure 2-7 Kaplan Meier estimate of the cumulative incidence of late HCMV infection.
The Kaplan Meier estimate of the cumulative incidence of HCMV infection after day 100 post 
transplant is plotted for patients at risk of HCMV infection and with follow-up beyond 100 days 
(n=l 17). The cumulative incidence of infection was 19.5±4%. The cross bars indicate censored 
data.
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Figure 2-8 Kaplan Meier incidence of late HCMV infection according to HCMV serology.
The Kaplan Meier estimate of the cumulative incidence of HCMV infection occurring after one 
hundred days is plotted for patients at risk of HCMV infection and follow-up beyond 100 days. 
The cumulative incidence for R+D- patients (n=27, blue line) is 25.8+9.6%, for R+D+ patients 
(n=75, red line) is 18.9±5%, and for R-D+ patients (n=15, green line) is 13.3+8.9%. The cross 
bars indicate censored data. There was no statistically significant difference in the curves by the 
Log Rank Test.
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2.3.7 HCMV Disease
In this cohort of patients, there were five confirmed c a se s  of HCMV 
d isease, including three c a se s  of HCMV colitis, one ca se  of HCMV 
hepatitis, and one ca se  of HCMV pneumonitis. There were an additional 
three c a se s  of probable HCMV d isease  that did not fulfil the current 
working group definitions of HCMV d isease . There was one confirmed 
death due to HCMV d isease , in a patient with m yelodysplastic syndrom e 
and primary graft failure who developed fatal HCMV pneumonitis. The 
actuarial incidence of confirmed HCMV d isease  for the entire cohort of 
patients a s  determ ined by Kaplan Meier survival analysis is 2.6±1.2%. 
Due to the small num ber of patients experiencing HCMV d isease , no 
single risk factor by Cox regression analysis w as identified a s  significantly 
increasing the risk of HCMV disease .
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2A Conclusions
The efficacy of aciclovir prophylaxis, combined with HCMV PGR 
surveillance and pre-em ptive therapy is confirmed by the fact that there 
w as a very low incidence of HCMV d isease. The ab sen ce  of HCMV 
viraemia in the R-D- group confirms the effectiveness of using HCMV 
seronegative blood products to prevent HCMV infection in th ese  patients. 
The small num ber of HCMV infections in the R-D+ group m ost probably 
represents primary infections acquired from the donor. This observation 
and the absen ce  of a significant difference in infection rates betw een the 
R+D+ and R+D- groups suggests  that the majority of infections in 
seropositive recipients are  due to reactivation of latent virus. A positive 
donor serology w as not found to be protective for HCMV infection in this 
study, contrary to what has been shown previously (Grob etal., 1987). In 
the ca se  of patients not receiving Cam path in vivo, the incidence of 
HCMV infection w as in fact higher for R+D+ patients (49.7±6.7%) than 
R+D- patients (25±15.2%), and while the incidence in R+D- patients 
receiving Campath-1 H (100%) w as higher than R+D+ patients receiving 
Campath-1H (63.9±12.9%), neither of th ese  differences w as found to be 
significant.
In this study, HCMV seropositive donor and/or recipient HCMV had no 
impact on overall survival for the whole group or subgroup analysis for 
sibling and m atched unrelated transplants. This contrasts with the 
findings of Craddock et al who reported that HCMV recipient 
seropositivity had an adverse  influence on outcom e for T-cell depleted 
m atched unrelated transplants for CML using Cam path (Craddock et al.,
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2001). In addition, Kroger show ed a  substantially reduced overall survival 
in HCMV seropositive m atched unrelated transplant recipients T-cell 
depleted with ATG com pared to HCMV seronegative patients (Kroger et 
al., 2001). HCMV seropositivity has also been  reported to d ec rease  5 
year overall survival by up to 24% following partially T-cell depleted HLA 
identical sibling transplants (Broers et al., 2000) due to an increase in 
treatm ent related mortality, probably a s  a  result of the m yelosuppressive 
effect of ganciclovir. However, in a  large EBMT study, Ljungman show ed 
a  beneficial effect of positive donor HCMV serosta tus on overall survival 
and treatm ent related mortality for m atched unrelated donor transplants, 
although the benefit w as not seen  with T-cell depletion (Ljungman et al., 
2003a). HCMV infection detected  by antigenaem ia when m anaged in the 
context of pre-emptive therapy has been associated  with a  w orse 
outcom e (Yanada et al., 2003), but there was no impact of HCMV PCR 
positivity on overall survival in this study.
Consistent with previous studies, HCMV seropositivity is confirmed as  the 
most significant risk factor for HCMV infection. In this study, the next m ost 
important predictor for HCMV infection was the use  of Campath-1 H in 
vivo, which is consistent with the findings of Chakrabarti (Chakrabarti et 
al., 2002a) who show ed that Campath-1 H in vivo in the setting of non- 
myeloablative conditioned transplants increased HCMV infection rates. 
The finding of an  earlier time to HCMV viraemia in recipients of Cam path- 
1H or Campath-1 G in vivo com pared to patients receiving no Cam path in 
vivo is likely to reflect higher rates of viral replication in the ab sen ce  of an 
immune response, suggesting delayed recovery of HCMV specific
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immunity. The impact of HCMV specific immunity on viral replication 
following liver transplantation show s that HCMV seronegative recipients 
of an HCMV positive organ experience higher rates of HCMV replication 
than seropositive recipients, due to partial suppression of viral replication 
by the pre-existing immune response (Emery etal., 2002). The data  
showing the greater cumulative incidence of infection in R+D- patients 
receiving Campath-1 H in vivo com pared to no Cam path in vivo su g g ests  
that Campath-1 H prevents the generation of an HCMV specific immune 
response, perhaps with a disproportionately greater effect on pre-existing 
recipient HCMV immunity, and this effect is greater with Campath-1 H 
than Campath-1 G.
In contrast to the in vivo use  of Cam path, ex vivo use  of Cam path to T- 
cell deplete the graft did not significantly increase the risk of HCMV 
infection. Com pared to T-cell depletion by positive selection, ex vivo T- 
cell depletion by Cam path results in less removal of T-cells and NK cells 
(Dreger et at., 1995). The use of Cam path “in the bag”, particularly the 
lower dose  of lOmg h as  been shown to effectively d ec rease  the 
incidence of graft versus host d isea se  without compromising immune 
recovery (Chakrabarti et al., 2003; Novitzky et al., 2004).
In this study there w as a trend tow ards a  higher incidence of HCMV 
infection with Campath-1 H com pared to Campath-1 G, and this is 
probably be due to the difference in half lives betw een the two forms of 
Cam path. Following the administration of 20 mg of Campath-1 H for five 
days (-8 to -4), the antibody rem ains detectable 28 days after transplant 
(Morris et al., 2003), and it is likely that this is a  significant factor in
132
delaying HCMV specific T-cell immune reconstitution com pared to 
patients receiving no Cam path in vivo. Campath-1 G has a significantly 
shorter half life, of approximately 24 hours (Rebello et al., 2001), and 
when used in vivo, effectively depletes host dendritic cells without 
delaying donor dendritic cell reconstitution (Klangsinsirikul et al., 2002). 
There w as a steady increase in the cumulative incidence of first ep isode 
of HCMV infection up to day 100, followed by a  further slower increase 
after day 100. It is likely that there are  different factors predisposing 
patients to HCMV infection before and after 100 days. Age, an acute 
GVHD score of II or greater and a  low CD34 dose  were identified a s  the 
m ost significant predictors of late HCMV infection. However, the study of 
risk factors for late HCMV infection are susceptible to selection bias a s  
only patients felt to be  at increased risk of HCMV infection were 
monitored beyond 100 days.
An acute GVHD score of II or g reater w as only found to be a  risk factor 
for HCMV infection beyond the first 100 days am ong those  high risk 
patients selected  for ex tended monitoring, and is is likely to be due to the 
use  of im m unosuppressive therapy, including corticosteroids. A 
Jap a n e se  study by Y anada (Y anada et al., 2003) found that acu te  GVHD 
(grades ll-IV) w as the only significant factor to predict HCMV infection on 
multivariate analysis. Allogeneic reactions are known to stimulate HCMV 
from a  latent s ta te  into the replicative sta te  (Soderberg-N aucler et al., 
1997), and the use  of steroid to treat GVHD, further su p p resses  immune 
function, allowing the viral replication rate to increase. The overall 
frequency of acute GVHD in this study w as low, probably due to the
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extensive use  of T-cell depletion with Cam path, and this may account for 
the finding that an acu te  GVHD score of greater than I did not significantly 
increase the risk of HCMV infection in the first 100 days. 
Non-myeloablative transplant regim ens also show ed a trend tow ards a 
greater frequency of late infection in this study, independent of the effect 
of Campath, but due to the relatively small num ber of such transplants in 
this cohort as  well a s  selection bias, this study is not adequately  powered 
to answ er this question. In m atched RIC sibling allogeneic transplant 
recipients using ATG b ased  conditioning, bone marrow a s  a  source of 
stem  cells is associated  with an increased risk of HCMV infection (Mohty 
et al., 2003b). The Seattle group have shown similar findings in the non-T 
cell depleted setting, (Hakki et al., 2003), a s  well a s  delayed CD4 and 
CD8 recovery. However, the Seattle group found the incidence of HCMV 
infection in RIC transplants using m ycophenolate and low dose  (2Gy) 
radiotherapy at 365 days w as similar to conventional intensity conditioned 
transplants but a later time to infection (Junghanss et al., 2002). Thus, 
prolonged monitoring for HCMV should be performed in selected  patients, 
including RIC transplants, older transplant recipients, patients with 
GHVD, and patients with poor CD34 counts.
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Chapter 3 HCMV Replication Kinetics
3.1 Introduction
O ne of the main risk factors for the developm ent of HCMV d isea se  in the 
im m unosuppressed patient is the peak viral load attained during viraemia. 
This is true in HIV (Specter et al., 1998), renal transplantation (Cope et 
al., 1997; Hassan-W alker et al., 1999), liver transplantation (H um aret al., 
1999; M endez et al., 1998) and stem  cell transplantation (Cope et al., 
1997; Gor et al., 1998). However, th ese  studies were performed by 
retrospectively quantifying HCMV viral loads by quantitative competitive 
PCR and did not utilise pre-emptive therapy for HCMV infection. 
Furthermore, by the time peak viral load is attained, d isease  is already 
present. Thus, in order to prevent HCMV d isease, the goal should be to 
prevent high levels of HCMV viraemia by using a  sensitive surveillance 
technique to initiate pre-em ptive therapy for infection. In addition, the 
identification of patients at risk of high viral loads on the basis of viral 
replication kinetics can be envisaged (Emery et al., 2000). A model of 
viral replication established initially for HIV and applicable to HCMV 
infection show s that the main determ inants of peak viral load are  the rate 
of viral replication, the num ber of target cells present, the rate of infected 
target cell death  and the rate of clearance by either the immune system  
or antiviral therapy, and this can be mathematically predicted, a s  shown 
in Equation 3.1 (Bonhoeffer et al., 1997).
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Equation 3-1 Model for HCMV Replication.
dl/dt = piT — S/l—plE
/ = the number of infected cells, t=  time, p = the rate of new infections occurring in 
uninfected cells, T = target cell number, 5i = death rate of infected cells, p  = proportion of 
infected cells undergoing CTL lysis and E  = number of HCMV-specific effector CTLs.
In contrast to the rate of viral replication in fibroblast culture, replication of 
HCMV in vivo is rapid with a  doubling time of 24 hours in individuals with 
impaired immunity (Emery et al., 1999). W hen viral loads are exam ined in 
solid organ and stem  cell transplant recipients, both the initial viral load at 
the time of a first PGR positive result, and the initial rate of viral 
replication are predictive of the risk of HCMV d isease  (Emery et al.,
2000). Using the initial rate of rise in viral load, it is also possible to 
calculate the Ro or the basic reproductive num ber of HCMV, which is a 
m easure of the num ber of infected cells produced from a  single HCMV 
infected cell before target oells are  depleted. This value can be used  to 
infer the level of HCMV immunity, a s  has been shown in a  com parison of 
HCMV infection in immune and non immune liver transplant recipients 
(Emery et al., 2002), w here the doubling time of HCMV reflects pre­
existing HCMV immunity.
Viral dynam ics can also be used to evaluate the efficacy of antiviral 
therapy. In solid organ transplant recipients, HCMV viral load dynamics, 
specifically the time to viral clearance and the half life of decline in viral 
load are  significantly correlated with the risk of recurrence (Humar et al..
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2002), with viral load kinetics following a  logarithmic decay according to 
the calculation, Equation 3.2.
Equation 3-2 Logarithmic decay curve of viral load following initiation o f antiviral therapy.
y=Voe^''
yo=initial viral load, a=decay constant and x=time from start of treatment.
Since the incidence of HCMV d isease  has fallen considerably with the 
advent of HCMV monitoring and pre-emptive therapy, viral dynam ics can 
also be used a s  a  surrogate m arker for comparing the efficacy of 
treatm ents such a s  ganciclovir and combination ganciclovir/foscarnet.
The feasibility of this approach has already been established in the liver 
and renal transplant setting, with the dem onstration of equivalence in 
efficacy of ganciclovir and valganciclovir in controlling viraemia (Mattes et 
al., 2005).
With the advent of real time PCR techniques such a s  TaqM an and 
LightCycler it is now possible to monitor the viral load with a  very short 
laboratory turnaround time. However, the impact of viral dynam ics using a 
real time PCR monitoring strategy on pre-emptive therapy strateg ies h as  
not been fully a s se s se d .
3.2 Methods
3.2.1 Patients
Allogeneic stem  cell transplant recipients were prospectively monitored 
for HCMV infection by twice weekly blood sam ples whilst an inpatient
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then at each outpatient appointment. All patients at risk of HCMV 
infection received high dose  aciclovir prophylaxis.
Prior to 1/7/02, patients with HCMV infection (based on two consecutive 
HCMV PCR positive results) were treated either with ganciclovir (5mg/kg 
twice daily), valganciclovir 900mg twice daily or combination therapy with 
ganciclovir (5mg/kg per day) and foscarnet (90mg/kg per day) at the 
clinician's discretion. For patients receiving ganciclovir therapy, G-CSF 
300 pg was adm inistered on alternate days to counteract any 
neutropaenia due to bone marrow suppression. Antiviral therapy was 
continued until HCMV PCR w as negative on two consecutive occasions. 
Following the 1®* of July 2002, HCMV specific antiviral therapy w as 
initiated if the patient had a  single positive PCR result g reater than 3000 
copies/ml, or two consecutive positive results irrespective of the viral 
load. A dherence to the protocol w as generally good, with only two 
exceptions identified.
3.2.2 Extraction of DNA from Whole Blood
HCMV PCR w as perform ed on whole blood using citrated blood sam ples 
a s  EDTA and heparinised sam ples may interfere with the PCR 
amplification. DNA w as extracted using the QIAamp DNA blood 
extraction kit (Qiagen, UK). 200 pL of a  citrated whole blood sam ple w as 
added to a  micro centrifuge tube containing 20 pL of QIAGEN P ro tease  
and 200 pL of lyses buffer w as added. After pulse vortexing the sam ple 
w as incubated at 56°C for 10 minutes. 200 pL of 96% ethanol (v/v) w as 
added to the sam ple and after further pulse vortexing; the mixture w as 
added to a QIAamp spin column containing a  silica matrix for adsorption
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of the DNA. The spin column w as spun at 6000 RPM for 1 minute. The 
column w as w ashed twice with 500 pL aliquots of Qiagen buffers. The 
DNA was then eluted by the  addition of 200 pL of Qiagen AE buffer. 
Sam ples were either quantified immediately or stored at -20°C for later 
quantification.
3.2.3 Real Time Quantitative PCR
HCMV viral load w as determ ined by real time PCR using a Taqm an (ABI) 
based  method. The probe and primer seq u en ces  were designed using 
the Primer Express software (Perkin-Elmer, Applied Biosystem s, Foster 
City, Calif.), and produced by MWG-Biotech AG (Germany).
The sequence  for the Glycoprotein B specific CMV primers used  was: 
gB1 5 ’-GAGGACAACGAAATCCTGTTGGGCA-3’ 
gB2 5-TCGACGGTGGAGATACTGCTGAGG-3'
The gB probe used w as a  29-m er Taqm an probe labelled with 6-FAM at 
the 5' end and TAMRA at the 3 ’ end, with the sequence:
5’-CAATCATGCGTTTGAAGAGGTAGTCCACG-3’
The reaction mixture consisted of 2.5 pL of 10x PCR buffer (containing
1.5 mmol/L of M gC y, 0.5 pL of MgCI (25 mmol/L), 0.75 pL of dNTPs 
(containing 6.25 mmol/pL of dATP, dCTP, dGTP and dUTP), 1.2 pL of the 
gB TaqMan probe (5 pmol/pL), 1 pL of gBI and gB2 primers (15 
pmol/pL), 0.25 pL of HotStart Taq DNA polym erase (0.25 lU/pL) and 12.8 
pL of sterile w ater to m ake a  final volume of 20 pL, which w as added  to 
each well of an ABI 96 well plate. For the generation of a control curve, 1, 
5, 10, 50, 1 X 10^, 1 X I 0^ and 1 X 10"^  gB genom e copies per 5 pL were 
prepared by serial dilution of a  plasmid at 1 X 10® genom e copies/ml
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concentration of the entire gB sequence  (courtesy Nigel Temperton) into 
lOmMol TRIS buffer pH 8.5 containing sheared  salm on sperm . 5 pL of 
extracted unknown or control DNA w as added to each  well of a  96 well 
plate (Applied Biosystems), and the optical lid w as closed. The reaction 
w as performed in the ABI Prism 7700 (Applied Biostsystem s). The 
thermal cycling conditions used were 50° C for 2 min, 95° C for 10 
minutes, then 60 cycles of 95° C for 15 seconds and 60° C for 30 
seconds.
DNA amplification w as determ ined by the detection of fluorescent 
em ission between 500 and 660 nm from the FAM (6-carboxy-fluorescein) 
reporter dye from the TaqMan probe a s  it is freed from the quencher, 
TAMRA (6-carboy-tetramethyl-rhodamine), by the action of the 5'-3' 
nuclease activity of the Taq polym erase. The fluorescent intensity versus 
the cycle num ber of a  typical reaction is shown in Figure 3-1. The num ber 
of DNA copies of gB presen t in the sam ple is proportional to the cycle 
num ber at which the fluorescent emission reaches the threshold level.
The standard curve w as derived from the average of each  of the triplicate 
control sam ples, Figure 3-2. The curve w as accep ted  if the slope w as 
within the range -3.0 to -3.8 and the regression coefficient of the  curve (r^) 
was 0.98 or greater. The DNA copy num ber of the unknown sam ples w as 
then interpolated from the standard  curve. In order to determ ine the copy 
num bers per ml of blood, the duplicate results were averaged, and 
multiplied by 200. The lower limit of detection w as 200 copies per ml. 
Sam ples prior to 1/7/02 were quantified retrospectively from frozen DNA 
extracts, and sam ples obtained after 1/7/02 were quantified prospectively.
140
Figure 3-1 Real Time PCR fluorescence emission plot for serially diluted control samples.
The log fluorescence emission versus cycle number plot of serially diluted control samples. Each 
control sample contains a known copy number of gB plasmids, and is analysed in triplicate on the 
ABI Prism 7700, using a TaqMan probe.
Figure 3-2 Standard curve for determination of HCMV viral load.
A plot of the standard curve derived from serially diluted samples with known copy numbers of 
gB. This plot is used to determine the HCMV viral load of DNA extracts of whole blood by 
interpolation. The correlation coefficient in this example is 0.982 and the slope is -3.471.
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3.2.4 Calculation of HCMV Replication Kinetics
The initial viral replication rate (Kmax, day'^) w as calculated a s  the 
difference betw een the natural log of the first positive HCMV PCR result 
and the previous negative result (assigned a  value of 200 copies/ml a s  
this is the lower limit of detection of the assay), or betw een the natural log 
of the first two HCMV PCR positive results, whichever w as the  greater, 
divided by the num ber of days betw een sam ples.
The “m ean” viral replication rate (K m e a n , day'^) w as determ ined from the 
slope of a line fitted by linear regression to the viral load in logio genom e 
copies/ml versus days post transplantation up to the peak viral load and 
prior to initiation of therapy. The result was raised to the power of 10 and 
converted to the natural log.
The decline rate (Kdecwne, day^) w as determ ined from the slope of the 
linear regression line fitted to the viral load on the linear part of the 
downward curve of the viral load in logio genom e copies/ml versus days 
post transplant. The result w as raised to the power of 10 and converted to 
the natural log.
3,3 Results
3.3.1 Patient outcomes
Between 1/1/01 and 31/12/04, 57 allogeneic stem  cell transplant 
recipients with at least one ep isode of HCMV infection based  on two 
consecutive positive PCR results were identified. The characteristics of 
this group of patients are shown in Table 3-1.
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The median time to first HCMV infection following transplant w as 37 days, 
ranging from -7 to 474 days post transplant. Two patients experienced 
HCMV infection during conditioning therapy but prior to the infusion of 
donor stem  cells, and  one patient experienced late HCMV infection post 
transplant, after im m unosuppressive treatm ent for GVHD following a 
donor lymphocyte infusion. The median total duration of viraemia w as 17 
days, with a range of 4 to 59 days, while three patients failed to clear the 
virus prior to death due to HCMV d isease.
Forty-nine patients received HCMV specific antiviral therapy prior to 
clearance of viraemia, with 24 patients initiated on ganciclovir 
monotherapy, 22 patients on a  combination of ganciclovir and  foscarnet, 
one patient on valganciclovir and two patients on foscarnet alone. In 
addition six patients were HCMV PCR negative at the time of initiation of 
antiviral therapy, and two patients successfully cleared the  virus from 
their blood spontaneously and were not initiated on antiviral therapy. 
Among the patients receiving HCMV specific antiviral therapy, 13 patients 
had a change in drug therapy. Ten patients were changed from 
ganciclovir m onotherapy, six to combination therapy with foscarnet and 
ganciclovir, three to foscarnet m onotherapy and one to valganciclovir 
m onotherapy. In six patients this w as b ecause  of persistent viraemia, in 
two becau se  of ganciclovir induced pancytopaenia, and two patients to 
facilitate outpatient therapy. The median time for change from ganciclovir 
therapy was 12 days (range 5 to 21 days). Two patients w ere changed 
from combination ganciclovir and foscarnet therapy to ganciclovir 
m onotherapy due to foscarnet induced side effects, and one patient from
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valganciclovir to foscarnet, because  of persistent viraemia. The m edian 
time to viral c learance following initiation of therapy w as 14 days (mean 
15.3 days, range 2 to 39 days) although an additional three patients failed 
to clear viraemia prior to death.
S eventeen  patients (31%) experienced a  second HCMV infection, with a 
medium time following first infection of 17 days (Range 4 to 119 days). 
Eight patients experienced HCMV disease , two patient experienced 
HCMV colitis/gastritis, four patients experienced proven HCMV 
pneumonitis with an HCMV positive BAL, and two patients experienced 
fatal pneumonitis during HCMV viraemia with a clinical picture consistent 
with HCMV pneumonitis, onset of HCMV viraemia immediately prior to 
sym ptom s but unsuccessful attem pt at BAL and persistent viraemia until 
death. Three patients recovered and five patients experienced a  fatal 
outcome, all due to HCMV pneumonitis. The clinical details of patients 
with HCMV d isease  are  shown in Table 3-2.
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Table 3-1 Clinical characteristics of 57 allogeneic stem cell transplant recipients 
experiencing HCMV infection between 1/1/01 and 31/12/04.
Number 57
Median Age yrs 29
(range) (3 - 63)
Gender Male 23
Female 34
Underlying Diagnosis ALL 7
AML 15
AA 6
CML 5
NHL 6
Hodgkin’s Disease 4
Other Malignant 5
Beta Thai 6
Other Non Malignant 3
Conditioning Regimen Myeloablative 36
Non-Myeloablative 21
Campath In Vivo Use In Vivo Campath 44
No In Vivo Campath 13
Campath Ex Vivo Use Yes 16
No 41
Donor Source HLA Identical Sibling 37
Non identical Related 3
Matched Unrelated 11
Mismatched Unrelated 6
Stem Cell Source BM 13
PBSC 44
GVHD Prophylaxis None 11
Tacrilimus 1
Ciclosporin 16
Methotrexate and 
Ciclosporin
30
HCMV Serostatus Negative/Positive 2
(Recipient/Donor) Positive/Negative 11
Positive/Positive 44
ALL, acute lymphoblastic leukaemia; AML acute myeloid leukaemia; AA aplastic 
anaemia; CML, chronic myeloid leukaemia; NHL, non-Hodgkin’s lymphoma; Beta Thai, 
beta thalassaemia; BM, bone marrow; PBSC, peripheral blood stem cell
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Table-3-2 Clinical characteristics of patients with HCMV viraemia and disease.
Age Sex HCMV Donor Stem Conditioning 
Serology Source Cell Regimen 
(R/D) Source _______
Campath Campath GVHD Steroid Site o f  Outcome
In Vivo Ex Vivo Prophylaxis Use Disease
Beta Thai 18 Male Pos/Pos
AA
CML
29 Male Pos/Pos
22 Male Pos/Pos
Hodgkin’s 18 Male Pos/Pos
Disease
NHL 36 Male Pos/Pos
NHL 55 Male Pos/Pos
NHL 14 Female Pos/Neg
NHL 55 Male Pos/Neg
HLA PBSC
identical
sibling
HLA BMT
identical
sibling
Non­ PBSC
identical
sibling
Non- PBSC
identical
sibling
Mismatch PBSC
Unrelated
Mismatch PBSC
Unrelated
HLA BM
identical
sibling
Mismatch PBSC
Unrelated
Busulfan
 TBI, Flu, cyclo
Yes
Yes
No
No
MTX and No Lung Fatal
CsA
MTX and No Lung Fatal
CsA
Yes Yes None No Lung Fatal
Yes Yes CsA No Lung Survived
Yes No MTX and 
CsA
Yes Lung Fatal
Yes No MTX and
CsA
Yes Colon Survived
Yes No CsA Yes Lung Fatal
Yes No CsA Yes Gastric
Retina
Survived
Beta Thai, beta thalassaemia; A A, aplastic anaemia; CML, chronic myeloid leukaemia; NHL, non-Hodgkin’s lymphoma; PBSC, peripheral blood stem cell;
BM, bone marrow; Flu, fludarabine; Cyclo, cyclophosphamide; TBI, total body irradiation; BEAM, carmustine, etoposide, cytarabine; melphalan; Mel, melphalan;
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3.3.2 Quantitative HCMV PCR Results
The median initial HCMV viral load w as 3.0 logio genom e copies/ml 
(range 2.4 to 4.3 logic genom e copies/ml). The distribution is shown in 
Figure 3-3. The median peak HCMV viral load during the first HCMV 
viraemia episode w as 3.8 logic genom e copies/ml (range of 2.4 to 5.3 
logic genom e copies/ml, Figure 3-4). In 12 cases, the peak viral load w as 
the initial viral load. The median frequency of sampling during viraem ia 
w as 2 sam ples per week, with a  range of 1 to 4.5 sam ples per week.
147
Figure 3-3 Frequency histogram of the initial HCMV viral load.
A frequency histogram of the initial logm genome copies/ml HCMV viral load from the first 57 
allogeneic stem cell transplant recipients experiencing HCMV infection is shown. The median 
initial viral load was 3.0 logio genome copies/ml (range 2.4 to 4.3 logio genome copies/ml).
?
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Figure 3-4 Frequency histogram of the peak HCMV viral load.
A frequency histogram o f the peak logio genome copies/ml HCMV viral load from 57 allogeneic 
stem cell transplant recipients experiencing HCMV infection is shown. The median peak viral 
load was 3.8 logio genome copies/ml (range 2.4 to 5.3 logio genome copies/ml)
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3.3.3 HCMV Replication Kinetics
The median Kmax w as 0.38 day'^ (mean 0,4505, with a  range of 0.05 to 
1.7 day Y  This corresponds to a  median initial HCMV viral doubling time 
of 1.82 days.
The median Kmean a s  determ ined by linear regression w as 0.32 day'^ 
(mean 0.35, with a  range of 0.05 to 0.9 day'^), corresponding to an HCMV 
doubling time of 2.17 days.
3.3.4 Predictors of Duration of Viraemia
The relationship betw een viral load dynam ics and total duration of 
therapy was exam ined. To a s se s s  if there w as a  significant correlation 
betw een the total duration of viraemia and viral load param eters a 
Spearm an rank correlation test was performed, Table 3-3. The log peak 
viral load had the strongest correlation with the total duration of viraemia 
(r=0.7953, p<0.0001), although the Kmax also show s a  significant 
correlation (r=0.2853, p=0.03). A scatter plot of the duration of viraemia 
versus log peak viral load with a linear regression line fitted is shown in 
Figure 3-5. Linear regression using the  least squares m ethod gave an r^  
value of 0.54. In order to identify the main factors determining the 
duration of viraemia, logistic regression analysis with a  binary outcom e of 
total duration of viraemia less than or greater than 14 days w as 
performed. Continuous variables entered into the model were log peak 
viral load, log initial viral load, Kmax and Kmean- Categorical variables 
entered into the model w ere an acute GVHD score g reater than I, in vivo
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use of Campath-1 H and steroid use during viraemia. The results of 
univariable analysis are  shown in Table 3-4. The results show that log 
peak viral load, log initial viral load and use  of Campath-1 H in vivo for 
conditioning predict the duration of viraemia. Using a  multivariable model, 
with backwards conditional selection and a  probability criteria for entry 
into the model of 0.05, and for removal of 0.1, both log peak viral load 
with a RH of 7.5 per quarter log increase in peak viral load (95% Cl 1.7 to 
32.5, p = 0.007) and Kmean viral replication rate with a  RH of 0.38 per 0.1 
day^ (95% Cl 0.15 to 0.99, p = 0.047) remain significant, although in vivo 
Campath-1 H use is of borderline significance, RH 20.6 (95% Cl 0.9 to 
474.3, p=0.06).
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Table-3-3 Correlation of initial viral load, peak viral load, Kmax and Kmean with total duration of HCMV viraemia in days.
The duration of viraemia for patients not clearing virus prior to death was defined as the difference between the date of the last HCMV PCR positive result prior to death and 
the first positive result.
initiât virai toad
log 10 genome copies/ml
Peak virai ioad
log 10 genome copies/ml
Kmax
day^
Kmean
day^
Number 57 57 57 57
Spearm an rank correlation 0.16 0.79 0.29 0.10
95% confidence interval -0.11 to 0.41 0.67 to 0.88 0.02 to 0.51 -0.08 to 0.43
p value (two-tailed) 0.24 P<0.0001 0.03 0.16
Table-3-4 Univariable logistic regression analyses of factors predicting a duration of viraemia of 14 days or more.
Variable Relative Hazard 95% Cl Significance 
(P value)
Peak Vira! Load (each quarter logio genom e copies/ml) 3.16 1.67-5.97 <0.0001
Initial Viral Load (each quarter logio genom e copies/ml) 1.55 1.03-2.33 0.03
Kmax (each 0.1 per day increase in viral replication rate) 1.26 0.5-1.68 0.1
Kmean (each 0.1 per day increase in viral replication rate) 1.1 0.83-1.46 0.52
Acute GVHD > 1 0.97 0.25-3.69 0.96
Campath-1 H in vivo 4.54 1.22-16.88 0.02
Steroid Use 0.69 0.21-2.32 0.55
Figure 3-5 Duration of viraemia versus peak viral load
A scatter plot of the duration of viraemia in days versus peak viral load (logmgenome copies/ml) 
is shown. A linear regression line is fitted and has a slope of 13.5 (95% Cl 10.14 -  16.85), with 
an r  ^of 0.542 (p<0.0001 ). The linear regression line is plotted in blue, with the 95% confidence 
interval plotted as dashed red lines.
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3.3.5 Predictors of HCMV Disease
The peak viral load w as significantly higher in those  patients with 
symptomatic HCMV infection com pared to non-symptomatic HCMV 
infection, with a median peak viral load in symptomatic patients of 4,45 
logio genom e copies/ml (range of 3.42 to 5.28) com pared to 3.82 logio 
genom e copies/ml in asym ptom atic patients (range of 2.38 to 5.14, 
p=0.02, Mann Whitney U test), Figure 3-6. There w as no significant 
difference in the initial viral load, the Kmax or the Kmean- Using logistic 
regression analysis, with a binary outcom e of the p resence  or ab sen ce  of 
d isease, for each quarter logio genom e copies/ml increase in peak HCMV 
viral load, the relative hazard of HCMV d isease  is 1.44 (95% Cl 1.05 to 
1.96, p=0.02). Neither donor nor recipient HCMV serology had an 
influence on the risk of developing HCMV disease.
Both the total duration of viraemia, and the duration of viraemia following 
initiation of therapy w ere significantly longer in patients with symptom atic 
HCMV infection com pared to the asymptom atic group. In the HCMV 
symptomatic group the m edian duration of viraemia w as 32 days and the 
median duration of viraemia foliov/ing initiation of therapy w as 20 days, 
while in the asym ptom atic group the median duration of viraemia w as 16 
days and the duration of viraemia following therapy w as 13 days (p 
values 0.003 and 0.04 respectively, Mann Whitney U test), Figure 3-7 and 
Figure 3-8. The duration of viraemia in the  HCMV sym ptom atic group is 
likely to be an underestim ate a s  the duration of viraemia in the  three 
patients failing to clear viraem ia prior to death w as defined a s  up to the
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last viral load before death. Neither the time to initiate antiviral therapy 
(median of 6 days in the asym ptom atic group and 7 days in the 
symptomatic group, p=0.40 Mann Whitney U test) or the Kdeciine rate 
(median of 0.37 day^ in the asymptom atic group and 0.25 day'^ in the 
symptomatic group, p=0.099) w as significantly different betw een the two 
groups.
If the log peak viral load, total duration of viraemia, Kmean and Kdeciine are 
entered into a  multivariable model, with a  binary outcom e of the p resence  
or absence  of d isease, then only the total duration of viraemia rem ains a 
statistically significant risk factor for symptomatic HCMV infection, with a 
RH of 1.12 per day of viraemia (95% confidence interval 1.04 to 1.22,
p=0.006).
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Figure-3-6 Peak viral load according to the presence or absence of HCMV disease.
A scatter plot of the peak viral load (logjogenome copies/ml) is plotted for patients with or 
without HCMV disease. The horizontal lines represent the median and the interquartile range. 
The median log peak viral load of patients with disease is 4.4 logm genome copies/ml, and for 
patients without disease is 3.7 logio genome copies/ml. The difference is statistically significant 
(p=0.02 Mann Whitney U test).
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Figure 3-7 Duration of viraemia according to the presence or absence of HCMV disease.
A scatter plot of the duration of viraemia for patients with or without HCMV disease is plotted. 
Duration of viraemia in patients not clearing virus was calculated to the last HCMV PCR result, 
therefore giving an underestimate of likely duration of viraemia. The horizontal lines represent 
the median value and the interquartile range. The median duration of viraemia in patients with 
disease is 32 days, and in patients without disease is 16 days. This difference is statistically 
significant (p=0.004, Mann Whitney U test).
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Figure 3-8 Time to viral clearance following initiation of therapy according to the presence 
or absence of HCMV disease.
A scatter plot of the time to viral clearance in days following initiation of therapy is plotted 
according to the presence or absence of HCMV disease. The horizontal lines represent the 
median value and the interquartile range. The median number of days to clear viraemia in 
patients experiencing HCMV disease is 21 days, and in patients not experiencing disease is 12 
days. This difference is statistically significant (P=0.02, Mann Whitney U test).
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3.3.6 Viral Decay Curves and Response to Therapy
The viral decline curves were evaluated in 57 patients. Two patients did 
not receive antiviral therapy but were able to clear the virus 
spontaneously. Both patients only had two positive HCMV PCR results. 
Another 6 patients cleared viraemia before or at the time antiviral therapy 
w as initiated. Among the remaining 49 patients, the group w as divided 
into those patients in whom the viral load continued to rise following 
initiation of therapy, defined as  the peak viral load occurring greater than 
two days after therapy (n= 21) and those patients in whom the viral load 
responded immediately to therapy, with the peak viral load less than or 
equal to two days following initiation of therapy (n= 28). Thus, based  on 
an intention to treat analysis, 38 percent (21 out of 55) of patients 
experienced a  peak viral load after the initiation of therapy, reflecting an 
increasing level of viraemia despite the initiation of therapy. In order to 
identify the risk factors for a  delayed peak viral load, a  com parison of the 
potential contributing factors known for each  group at the time antiviral 
therapy was initiated w as performed, using the Fisher exact test for 
categorical factors, and the Mann Whitney U (2 tailed) test for continuous 
variables. Table 3.5. A scatter plot of the factors found to be significantly 
different between the two groups is shown in Figure 3-9. A higher Kmax, 
higher Kmean and a higher baseline viral load at initiation of therapy were 
all predictive of a  delayed peak viral load after initiation of therapy, while 
an acute GVHD score of 2 or more w as of borderline significance 
(p=0.06). The type of treatm ent initiated did not influence the likelihood of
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response. Not surprisingly, patients that experienced a delayed rise in 
viral load after initiation of therapy are also significantly more likely to 
experience symptomatic d isease. When all the factors are  entered into a  
multivariable logistic regression model with a  binary outcom e of a  delayed 
peak viral load after initiation of therapy, using a  backw ards conditional 
selection criteria, only the Kmean (mean replication rate prior to therapy) 
rem ained an independently significant factor in predicting response  to 
therapy. Table 3-6. It w as possible to calculate the decay curves in the 
p resence and absen ce  of HCMV specific therapy in all but two patients 
(one due to viral load increasing at the time of death and the second  due 
to the inability to fit a  linear regression curve). The decline rate in the 
absen ce  of therapy w as calculated in eight patients who either did not 
receive therapy (n=2) or in whom viraemia cleared prior to initiation of 
therapy (n=6), with a  Kdeciine of 0.25 day^ (range 0.09 to 0.38 day "'), 
equivalent to a  half-life of 2.77 days. A further 41 patients had a  decline 
only in response to therapy, with a  median Kdeciine of 0.41 day^ (range 
0.14 to 1.48 day \  equivalent to a half-life of 0.69 days. This difference in 
the viral decay  rates w as significant (Mann Whitney U Test p=0.02,
Figure 3-10). In six c a ses , where therapy w as initiated after the viral load 
had started to decline, but before viral load w as undetectable it w as 
possible to com pare the decline rates pre and post therapy. Figure 3-11. 
This show ed an increase in the Kdeciine in 5 out of the 6 patients following 
initiation of therapy, with an average 4 fold increase in the rate of decline 
(mean of 0.19 day'^ prior to treatm ent vs. m ean of 0.74 day'^ following 
initiation of treatm ent, p=0.02. Paired T Test).
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Table-3-5 Characteristics of immediate responders versus delayed responders to HCMV specific therapy.
Factor Immediate Response to Therapy Delayed Response To Therapy Significance
(p value)
Number 34 21
Median age in yrs (range) 30(10-63) 29 (3, 55) 0.64
In Vivo Campath-1 H Use (%) 24 (70.6%) 19(90.5%) 0.10
GVHD score > 1 (%) 5(14.7%) 8(38.1%) 0.06
Steroid use (%) 9 (26.5%) 8 (38.1%) 0.39
Treatment
Ganciclovir 16 (47%) 10 (47.6%) 0.53
Foscarnet/Ganciclovir 14(41%) 10 (47.6%) 0.53
Foscarnet 3 (8.8%) 0 -
Valganciclovir 1 (2.9%) 1 (4.8%) -
Median Kmax day'^ (range) 0.34 (0.05-1.18) 0.42 (0.17-1.55) 0.04
Median Kmean day  ^ (range) 0.25 (0.05-0.75) 0.39 (0.18-0.90) 0.02
Median initial viral load logio genome 2.98 (2.38-4.3) 3.04 (2.48-4.33) 0.47
copies/ml (range)
Median baseline viral load logic 3.26 (2.30-5.07) 3.69 (2.41-5.14) 0.05
genome copies/ml (range)
Median time to initiate therapy from 7(1-38) 6(2-14) 0.44
1st PCR+ days (range)
Symptomatic Infection (%) 2 (5.9%) 6 (28.6%) 0.04
Table-3-6 Multivariable logistic regression analysis o f the risk factors for delayed response to therapy.
Factor Relative Hazard 95% Cl Significance
(p value)
GVHD score > 1 4.0 0.95-16.6 0.08
in vivo Campath-1 H 5.6 0.84-37.6 0.06
Kmnan (PGF 0.1 încreas© day'^) 1.4 1.02-1.87 0.004
Figure 3-9 K^ ax» Kmean, and baseline viral load according to immediate or delayed response 
to HCMV therapy.
Scatter plots of the difference in K^ax, K^ean and baseline viral load (logio genome copies/ml) at 
initiation of therapy between immediate responders (n=34) and delayed responders (n=21) to 
antiviral therapy are plotted. The horizontal lines indicate the median value and the interquartile 
range. The median K^ax in immediate responders is 0.34 day ’ and in delayed responders is 0.42 
day ' (p=0.04 Mann W hitney U Test). The median Kmean in immediate responders is 0.25 day ' 
and in delayed responders is 0.39 day * (p=0.02, Mann Whitney U Test). The median baseline 
viral load in immediate responders is 3.26 logio genome copies/ml and the delayed responders is 
3.69 login genome copies/ml (p=0.05, Mann Whitney U Test).
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Figure 3-10 Rate of decline in HCMV viraemia according to the absence or presence of 
antiviral therapy.
A scatter plot of the rate of decline in HCMV viraemia, determined by linear regression of the 
decay curve, is plotted according to the absence (8 patients) or presence (41 patients) of antiviral 
therapy. The horizontal lines represent the median value and the interquartile range. The median 
rate of decline in the absence of therapy is 0,25 day ’, and the median rate of decline in the 
presence of antiviral therapy is 0.41 day ’. The difference is statistically significant (p=0.02, 
Mann Whitney U Test).
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F igu re-3-ll HCMV decline rates before and after initiation of antiviral therapy.
A comparison of the HCMV decline rates in six patients in whom the effect of therapy on the 
decline rate could be calculated before and after initiation of antiviral therapy is shown. The 
mean rate of decline before treatment was 0.19 day ’, and after initiation of treatment was 0.74 
day ’. The difference is statistieally significant (p=0.02, Paired T Test).
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3.3.7 Comparison of Ganciclovir and Combination
Ganciclovir/Foscarnet for the Treatment of HCMV 
Viraemia
Using viral load dynamics it w as possible to com pare the efficacy of 
HCMV specific antiviral therapy at clearing viraemia. B ased on an 
intention to treat analysis, there w as no difference in the rate of viral 
clearance. However, six patients receiving ganciclovir m onotherapy were 
changed to combination therapy due to a perceived poor response to 
monotherapy. As the m edian time to change therapy (in those  patients 
not clearing the virus before therapy w as initiated) w as 12 days, and only 
one patient changed therapy before 7 days, the change in viral load in the 
first 7 days of therapy w as com pared, and is show in Figure 3-12. An 
alternative way of assessin g  the difference is to use  a  ‘crossover’ 
analysis, whereby patients that had a therapy change were put in the 
alternative group and  the serial decline in viral load and the 95% 
confidence intervals plotted at four day intervals, Figure 3-13. No 
difference betw een ganciclovir and combination ganciclovir/foscarnet 
therapy w as observed, although this was a  non-controlled, retrospective 
study.
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Figure 3-12 Comparison of change in viral load at day seven between ganciclovir 
monotherapy and combination ganciclovir/foscarnet therapy.
A scatter plot comparing the change in logjo genome copies/ml viral load at day 7 between 
patients receiving ganciclovir monotherapy (n=13) and combination ganciclovir/foscarnet 
therapy (n=20). The horizontal lines indicate the median value and the interquartile range. The 
median change in HCMV viral load at day 7 for ganciclovir monotherapy is 0.55 logio genome 
copies/ml, and for combination ganiclovir/foscarnet therapy is 0.66 logio genome copies/ml.
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Figure 3-13 Comparison of the change in viral load at four day intervals between ganciclovir monotherapy and combination therapy with ganciclovir/foscarnet.
The change in logm genome copies/ml viral load following initiation of therapy at four day intervals is shown for ganciclovir monotherapy (red) and foscarnet/ganciclovir 
combination therapy (blue). The triangle/square symbols indicate the mean values and the error bars the 95% confidence interval. Patients undergoing a change in therapy are 
crossed over into the other group. There is no difference in response to therapy between ganciclovir monotherapy and combination therapy with ganciclovir/foscarnet.
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3.3.8 Predictors of Recurrence of Infection
Seventeen of the 54 patients that cleared the initial HCMV infection 
experienced a  second  episode of infection, at a  m edian time of 20 days 
(range 4 to 119 days) following clearance of the first infection. The Kaplan 
Meier estim ate of the cumulative incidence of a second  HCMV infection 
after clearance of a  first episode of viraemia w as 37.9±7.8%, Figure 3-14. 
In order to identify the risk factors predicting a second infection, 
univariable Cox regression analysis was performed (with time to infection 
defined as  time from first negative HCMV PCR result to either the first of 
two consecutive positive PCR results or follow-up to the date of last PCR 
result) for donor HCMV serology, acute GVHD score greater than 1, ex 
vivo T-cell depletion, in vivo use  of Cam path, steroid use, log peak viral 
load, log initial viral load, Kmax, Kmean and viral half life of decline post first 
HCMV infection. Table 3-7. The only factor to predict an increased risk of 
further HCMV reactivation w as a  HCMV seronegative donor, with a 
relative hazard of 6.59 com pared to an HCMV seropositive donor (95%
Cl 2.49 to 17.4, p<0.001), and this remained significant when either ex- 
vivo T-cell depletion or in vivo Cam path use w as controlled for in a 
multivariable model. The cumulative incidence of second  HCMV infection 
in stem  cell recipients with an HCMV seronegative donor w as 80±12.7%, 
com pared to 28±8.7% for recipients with an HCMV seropositive donor 
(p<0.0001 Log Rank Score), Figure 3.15.
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Table 3-7 Univariable Cox regression analysis for the risk factors for second HCMV infection.
Factor Relative Hazard 95% Cl Significance (P value)
HCMV seronegative donor 6.59 2.49-17.41 <0.001
Acute GVHD score > 1 1.16 0.57-3.99 0.80
Ex vivo T-cell depletion 1.50 0.57-3.99 0.41
In vivo Campath-1 H Use 1.37 0.39-4.76 0.62
Steroid therapy 1.44 0.55-3.79 0.46
Peak viral load (each quarter logio genom e copies/ml) 0.72 0.35-1.45 0.35
Initial viral load (each quarter logic genom e copies/ml) 0.39 0.11-1.39 0.15
Kmax (each 0.1 per day increase in viral replication 0.12 0.01-1.51 0.1
rate)
Kmean (each 0.1 per day increase in viral replication 2.55 0.45-14.50 0.29
rate)
Half life of decline (days) 1.03 0 .9 7 -1 .1 0 0.32
T6&
Figure 3-14 Kaplan Meier estimate of the cumulative incidence of second HCMV infection.
The Kaplan Meier estimate of the cumulative incidence if second HCMV infection is plotted in 
54 patients who cleared the first episode of HCMV viraemia. Time to infection or follow-up was 
measured from the date of clearance of first viraemia. The cumulative incidence of second 
HCMV infection is 37.9±7.8%. The cross bars indicate censored data.
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Figure 3-15 Kaplan Meier estimate of the cumulative incidence of second HCMV infection
according to donor HCMV serostatus.
The Kaplan Meier estimate of the cumulative incidence of second HCMV infection in 54 patients 
who cleared the first episode of HCMV viraemia. Time to infection or follow-up was measured 
from the date of clearance of first viraemia. The cumulative incidence of second HCMV infection 
in patients with an HCMV seropositive donor (n=44, green line) is 28±8.7%, and in patients with 
a seronegative donor (n=10, blue line) is 80+12.7%. The difference is statistically significant 
(p<0.0001, Log Rank Score). The cross bars indicate censored data.
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3.4 Conclusions
This study confirms that in the era of pre-emptive therapy, peak viral load 
still significantly correlates with HCMV disease . However, in symptom atic 
patients, the duration of viraemia was twice that of non-symptomatic 
patients and it was the  most significant risk factor for d isease  in a 
multivariable model, suggesting that the total exposure to viraemia is 
more important. This is consistent with a  recent re-analysis of the 
influence of viral kinetics on the risk of HCMV pneumonitis, with the peak 
viral load contributing less to d isease  developm ent then periods of viral 
replication with equal quantity of viral turnover (R egoes e t al., 2006). 
Unlike the findings of Ljungman in a  study of 162 consecutive stem  cell 
recipients with donor and or recipient HCMV seropositivity (using ATG T- 
cell depletion for patients receiving m atched unrelated or m ism atched 
grafts) (Ljungman et al., 2006), neither GVHD nor HCMV serology were 
significant predictors of HCMV d isease  in a  model which incorporated 
viral kinetics. The difference seen  in this study may be due to the more 
intensive T-cell depletion resulting from in vivo Campath-1 H use  which 
also results in a  low incidence of GVHD.
It has been possible to use  viral kinetics to predict the duration of therapy 
required to clear viraemia, with both higher peak viral loads and faster 
viral replication rates pre-treatm ent predicting the need for a  longer 
duration of therapy. Eleven percent (6 out of 55 patients receiving 
therapy) of patients w ere initiated on therapy at a time when they w ere no 
longer viraemic. Real time viral load kinetics can be used to reduce
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unnecessary  antiviral therapy, in order to reduce the am ount of 
unnecessary  therapy, per-em ptive therapy w as only initiated when the 
viral load reached 3000 copies/ml. Verkruyse describes an effective 
alternative approach of only using ganciclovir (at a  dose  of 5 mg/kg OD) 
for HCMV viral loads equal or greater than 1 GOOD genom e copies/m l 
loads, although this does risk exposing patients to prolonged low level 
viraemia (Verkruyse et al., 2006), which has been shown in this study to 
be a  significant risk factor for d isease. A smaller Australian study of 46 
stem  cell transplant recipients identified either a high viral load (>5000 
copies/ml) or a  persistent viraemia as a  risk factor for d isea se  (Howden et 
al., 2003). Based on the findings of this study, the strategy of initiating 
antiviral therapy after a single high level (>3000 genom e copies/ml) or 
two or more consecutively PCR positive results at any level is the most 
appropriate to reduce the risk of HCMV disease. The question of w hether 
the dose  of antiviral therapy can  be reduced in patients with low level 
viraemia remains to be evaluated.
In many patients, the viral load w as observed to continue rising after 
initiation of therapy, and this w as often interpreted a s  a failure of antiviral 
therapy, when in fact it could be predicted from pre-therapy viral kinetics. 
G erna h as  described a similar phenom enon, with viral loads not falling 
until 5-10 days after initiation of antiviral therapy, and  this is m ore likely to 
occur in patients receiving steroid therapy for acute GVHD grade ll-IV 
(Gerna et al., 2005). The type of therapy initiated had no influence on a  
delayed reduction in viral loads. Patients with a  delayed reduction in viral 
loads were at g reater risk of HCMV disease, and th ese  patients may be
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appropriate for more intensive antiviral therapy or a s  priorities for 
adoptive immunotherapy.
Viral kinetics confirmed the equivalence in efficacy of ganciclovir 
monotherapy and combination ganciclovir/foscarnet therapy, consistent 
with the findings of Mattes in a random ised trial comparing ganciclovir 
and foscarnet/ganciclovir combination therapy in both solid organ and 
stem  cell transplant recipients (Mattes et al., 2004). In a  large multicentre 
trial of 213 stem  cell transplant patients random ised to either ganciclovir 
or foscarnet monotherapy, despite equivalence in efficacy, 11% of 
patients initiated on ganciclovir developed severe  neutropaenia (R eusser 
et al., 2002). Therefore, the choice of antiviral agent should be 
determ ined by clinical need (such a s  avoidance of cytopaenia or 
p resence of renal impairment). The efficacy of valganciclovir com pared to 
ganciclovir to control HCMV infection should also be evaluated using viral 
load kinetics a s  has been done for solid organ d isease  (M attes e t al., 
2005).
The strongest risk factor for a second episode of HCMV infection w as a 
seronegative donor, with a  cumulative incidence of second HCMV 
infection of 80 percent, dem onstrating the importance of immune 
regulation of viral replication. However, the rate of decline following first 
HCMV infection did not influence the risk of second reactivation, unlike 
Ljungman's findings (Ljungman et al., 2006), or the experience in solid 
organ transplant, w here a second infection is correlated with a  slower rate 
of decline (Humar et al,, 2002). The extensive use of Campath-1 H in this 
cohort of patients, due to its T-cell depleting effect and its relatively long
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half life (Morris et al., 2003), preventing donor immunity from influencing 
the first HCMV infection episode, but not later infections may account for 
th ese  findings. Despite HCMV seropositive patients with seronegative 
donors being at the g reatest risk of recurrent HCMV infections, adoptive 
immunotherapy is currently only available for recipients of HCMV 
seropositive donors. Ideally, an HCMV seropositive recipient should 
receive a  graft from a  seropositive donor, if such a  choice is available. 
Alternatively, clinical trials evaluating donor vaccination for HCMV should 
be carried out.
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Chapter 4 HOMV Specific Immune Recovery 
following Allogeneic Stem Cell Transplantation
4.1 Introduction
The role of cytotoxic T lymphocytes in protecting allogeneic stem  cell 
transplant patients from HCMV d isease  has been studied by R eusser 
who found that in the ab sen ce  of ganciclovir prophylaxis, patients with a 
detectable CTL response by three months did not develop HCMV 
pneum onia (R eusser et al., 1991). The use of tetram er technology for 
HCMV specific CD8+ T cells has now been widely applied in transplant 
patients and has shown the importance of pp65 specific CD8+ T cells in 
controlling HCMV infection following allogeneic transplantation (Aubert et 
al., 2001 : Cwynarski et al., 2001 ; Gratam a et al., 2001), with a level of 
two or more HCMV specific tetram er positive cells/p I being indicative of 
protection against HCMV d isease  in allogeneic stem  cell transplant 
recipients. However, tetram er technology does not predict the functional 
capacity of CD8+ T cells, such as  their ability to secre te  interferon gam m a 
in response to antigenic stimulation (Villacres et al., 2003). Early studies 
of HCMV specific CD4+ T cell helper function following stem  cell 
transplantation, based  on lymphoproliferation assay s  using ^H thymidine 
uptake, have dem onstrated that recovery of CD8+ CTL function is 
dependent on CD4+ T cell recovery (Li et al., 1994). W alters 
dem onstrated that following adoptive immunotherapy for HCMV following 
transplant, persistence of HCMV specific CD8+ CTLs were dependent on 
the p resence of HCMV specific CD4+ T cells (Walter et al., 1995). 
However lymphoproliferation responses are a  function of both the
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frequency and the activation status of the responding T cell. Although 
tetram ers can directly enum erate  the num ber of antigen specific cells 
p resent (for a known epitope), because  of the difficulty in producing MHC 
class II complexes, due to the difficulty in refolding polymorphic a  and p 
chains (Ferlin et al., 2000) a s  well a s  the low frequency of antigen specific 
CD4+ T cells, only a  limited num ber of C lass II tetram ers have been 
successfully produced, such a s  for Borrelia, influenza and hepatitis C 
(Day et al., 2003; Lucas et al., 2004; Meyer et al., 2000). HCMV specific 
class II tetram ers have now been described, such a s  the HLA DR3 
tetram er (Bronke et al., 2005), but unlike C lass I tetram ers, they remain 
relatively few. Therefore, alternative m ethods of monitoring HCMV 
specific CD4+ T cell responses that incorporate an a sse ssm en t of their 
functional capacity have been developed. Utilising Brefeldin A, a  fungal 
metabolite which disrupts the golgi apparatus and blocks export of newly 
produced proteins, following ex vivo antigen stimulation of T cells, it is 
possible to enum erate the cytokine response by enzym e linked 
immunospot (ELISPOT) a ssay  or flow cytometry using intracellular 
cytokine staining techniques (Waldrop et al., 1997). Flow cytometry has 
the advantage of directly characterising the immunophenotype of the 
responding cell by the use  of additional monoclonal antibodies and 
selective gating strategies. Up to 1-2 percent of the total CD4+ T cell 
population of normal HCMV seropositive individuals can be identified as 
having a  ThI response to HCMV (Waldrop et al., 1998; S es te r et al., 
2002). In HIV even higher frequencies of up to 5 percent HCMV specific 
CD4+ T cells can be identified (Pitcher et al., 1999; W aldrop et al., 1997).
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Relatively few authors have been  able to characterise the memory 
phenotype of HCMV specific CD4+ T cells although S este r et al reported 
in a subset of 11 percent of normal individuals, w here the HCMV 
response constitutes as  much a s  10-40 percent of the total response, the 
phenotype of th ese  cells constitute an activated/m em ory phenotype, 
(CD45RO^', CD27-, CD62L- and CCR7- expression) (Sester et al., 2002). 
Using an alternative technique, clonotypic oligonucleotide probing, 
W eekes has shown that pp65 peptide specific CD4+ T cells a re  both 
CD45RA"' CD45RO^° and CD45RA'-°CD45R0^' (W eekes et al., 2004), 
and Amyes has dem onstrated that HCMV specific CD4+ T cells lack 
CD27 expression and heterogeneity with respect to CD28, while up to 20 
percent of antigen experienced virus specific CD4+ cells can be both 
CD45RO+ and CD45 RA+ (Amyes et al., 2003).
The role for HCMV specific C D 4+ 1 cell immunity a s  determ ined by 
interferon gam m a production has been established in primary HCMV 
infection and also provides protection against HCMV d isease  in renal 
transplantation (Gamadia et al., 2003). Delayed recovery of HCMV 
specific CD4 function has been associated  with symptomatic d isease  in 
renal transplant patients despite the p resence of HCMV specific CD8+ 
cetls (Sester et al., 2001 ; G am adia et al., 2003), and may protect renal 
transplant recipients from high viral loads (R eusser et al., 1999). The role 
of HCMV specific CD4+ T cell functional a ssay s  in predicting patients at 
risk of HCMV infection following allogeneic stem  cell transplantation 
rem ains to be evaluated.
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4.2 Method
4.2.1 Patient Recruitment
Patients were recruited at the time of adm ission for allogeneic stem  cell 
transplantation. Patient information sh ee ts  were provided, and written 
informed consent obtained prior to entry into the study. In the ca se  of 
patients under the age of 18, informed consent w as obtained from the 
parents. For patients Gilleck com petent, consent w as obtained from both 
the patient and the parents. A copy of the consent form and patient 
information sheet is included in Appendix A. The Royal Free Hospital 
ethics committee approved the study.
4.2.2 Samples
20 ml of peripheral blood w as taken into a  universal container containing 
preservative free heparin at two weekly intervals whilst the patient w as an 
inpatient or at the time of an outpatient appointment. A full blood count 
sam ple and HCMV PGR sam ple were also obtained at the sam e time.
4.2.3 Viral Load Monitoring
HCMV PCR w as monitored from whole blood twice weekly whilst the 
patient w as an inpatient and then at each  subsequen t outpatient 
appointment. DNA w as extracted using the method described in section 
3.1.2, and TaqMan real time PCR for the HCMV viral load a s  per method 
described in section 3.1.3. Treatm ent of HCMV infection with either 
ganciclovir (5mg/kg BD), foscarnet (90mg/kg BD), combination 
ganciclovir (2.5mg OD)/foscarnet (90mg/kg OD) or valganciclovir (900mg 
BD) was initiated when the viral load w as greater than 3000 copies/ml or
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following two consecutive positive HCMV PCR results, and continued 
until two negative HCMV PCR results were obtained.
4.2.4 Conditioning Details and Infection Prophylaxis
Details of conditioning regim ens and infection prophylaxis are  detailed in 
section 2.2.2 and 2.2.3.
4.2.5 Clinical Data
Data on clinical outcom e was obtained from the patient notes, including 
conditioning details, p resence of GVHD, im m unosuppressive and steroid 
use  as  well a s  details of treatm ent of HCMV infection.
4.2.6 Mononuclear Cell Isolation
In a laminar flow HEPA filtered hood, 20ml of heparinised whole blood 
w as diluted 1:1 with Hank’s balanced salt solution (HBSS, Gibco) and 
layered over Lymphoprep (Nycomed, Norway) at a ratio of 15ml of 
lymphoprep to 20 ml of diluted blood. This was centrifuged at 400G for 25 
minutes with the brake off. The buffy layer w as removed using a  P asteur 
pipette, placed in a clean 50ml Falcon tub and diluted to 50ml with HBSS. 
The suspension was then centrifuged at 400G for 10 minutes, and the 
supernatant discarded. The pellet w as resuspended in 10ml of HBSS, 
mixed and lOpL removed for a  cell count. The cell suspension  w as m ade 
up to 50ml and centrifuged at 200G for 10 minutes. The supernatan t w as 
discarded, the pellet resuspended and sufficient RPMI 1640 culture 
medium with Glutamax (Gibco) containing lOOU/ml penicillin, lOOpg/ml
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streptomycin, and 10% heat inactivated Fetal Calf Serum  (PCS) w as 
added to m ake the suspension  to 1-2 X 10® PBMGs per ml.
A cell count was performed by adding 10pL of trypan blue 0.4% (Sigma) 
to the lOpL cell aliquot of cell suspension in a 1.5 ml eppendorf tube and 
vortexing for 2 seconds. Counting w as performed using a  N eubaeur 
counting cham ber.
4.2.7 Antigen Stimulation
Antigen stimulation of the m ononuclear cell suspension w as performed 
under sterile conditions in a laminar flow hood. In the ca se  of the HCMV 
ADI 69 whole viral lysate response, a  1ml aliquot of PBMCs su sp en d ed  in 
RPMI at a concentration of 1-2 X 10®/ml w as added to a  5ml 
polypropylene tube (Kendall). 5pg of commercially available sucrose  
gradient purified HCMV viral lysate (ABI) prepared from A D I69 infected 
hum an fetal foreskin fibroblasts (ABI) w as used as  the source of antigen 
stimulation. A control assay  using lysate prepared from uninfected hum an 
fetal foreskin fibroblasts w as also prepared. 2 pL (Ipg) of a  monoclonal 
antibody to CD28 (BD) (low azide) w as added for antigen co stimulation. 
After one hour incubation at a 5 “ slant, 37°C, 50% humidity and 5% COg 
in an incubator to allow m acrophage processing of the antigen protein, 2 
pL of GolgiStop (BD), containing brefeldin, was added to prevent 
interferon gam m a secretion by blocking intracellular protein export. The 
phorbol ester, PMA (phorbol 12-m yristate-13-acetate, Sigma) at a  
concentration of 50ng/ml (Sigma) with calcium ionophore [250ng/ml] 
(Sigma) was used a s  the positive control.
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IE1 and pp65 peptide pools were stored at -22° C in 1 pg aliquots 
dissolved in 2.5 pL of DMSO. For HCMV IE1 and pp65 peptide pool 
responses, 0.5mL of PBMCs suspended  in RPMI w as added to each  
polypropylene tube and 1 pg of the respective peptide pool w as added. A 
negative control without peptide w as included. The positive control used 
for the peptide antigen stimulation w as 0.5 pg of SEB (Staphylococcal 
enterotoxin B, Sigm a).1 pL of GolgiStop w as added to each tube and the 
cells were incubated at a 5° slant, 3 7 “C, 50% humidity and 5% CO 2 for 
betw een 12 and 14 hours.
4.2.8 Intracellular Staining
Following stimulation, the cells were w ashed by adding 2ml of HBSS, 
centrifuging at 200G for 5 minutes, and the supernatant w as discarded. 
After resuspending the cells, 5 pL of the appropriate conjugated 
monoclonal antibodies (BD) for surface markers: CD3 PerCP (peridin 
chlorophyll protein), CD69 PE (phycoerythrin) and CD4 or CD3 FITC 
(fluorescein isothiocyanin) for antigen responses, CD62L FITC, CD25 PE, 
CD45 RA FITC, CD45 RO FITC, and CD27 PE, for memory phenotype. 
HBSS 25 pL w as added to each  tube, vortexed for 2 seconds, and 
incubated in the dark for 10 minutes at room tem perature. lOOpL of 
intrastain reagent A (containing paraformaldehyde) (Dako) w as added in 
order to fix the sam ple. The suspension w as again vortexed, incubated 
for a  further 15 minutes in the dark at room tem perature, 2ml of HBSS 
w as added, centrifuged for 5 minutes at 2QGG and supernatan t was 
discarded, and the cell pellet w as resuspended. Intracellular staining for 
interferon gam m a w as then performed by adding interferon gam m a
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monoclonal antibody conjugated to APC (Allophycocyanin, BD) 1 pL, and 
100pL of reagent B (Dako) for cell permeabilisation. Following a  further 
15 minute incubation at room tem perature, the suspension  w as again 
w ashed in 2ml HBSS, centrifuged for 5 minutes at 200G, the supernatant 
w as discarded, and the cell pellet resuspended in SOOpL of FACS flow 
medium (BD).The sam ple w as then acquired in a four colour (six 
param eter) FACSCalibur (BD Bioscience) flow cytometer.
4.2.9 FACS Analysis
FACS analysis w as performed using CellQuest software (BD Bioscience). 
For analysis of intracellular interferon gam m a production, a  lymphocyte 
ga te  was drawn around the live lymphocyte population on the FCS 
(Forward Scatter, determ ined by cell volume) versus SSC  (Side scatter, 
determ ined by internal cell structure) plot. This gate w as used  to draw a 
density plot of CD3 versus CD4 or CD8, and the CD3+ CD4+ or CD3+ 
CD8+ populations were defined, taking care to include the CD3'°'" 
population to account for down regulation of CD3 by antigen stimulated 
cells. The proportion of CD3+ CD4+ or CD3+ CD8+ cells staining for 
interferon gam m a w as calculated from the CD69 versus Interferon 
gam m a plot, using CD69 upregulation to confirm interferon gam m a 
positive cells had undergone activation. In order to control for background 
interferon gam m a production, the percentage of interferon gam m a 
positive cells in the negative control for peptide stimulated cells and the 
uninfected lysate control for the HCMV lysate stim ulated cells w as 
subtracted from the result. A positive control using either PMA or SEB 
w as included. A target of acquiring 50,000 CD4 + cells w as m ade in order
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to acquire sufficient num ber of cells, but due to low CD4+ or CD8+ 
specific immune recovery following allogeneic stem  cell transplant, this 
w as not always possible in all patients.
The absolute CD4+ and CD8+ counts were calculated from the 
percentage of cells expressing CD3+ and CD4+ or CD3+ and CD8+ 
antigens on the live lymphocyte gate a s  a  proportion of the total 
lymphocyte population and multiplying this by the absolute lymphocyte 
count.
4.2.10 Statistical Analysis
Statistical analysis w as performed using S P S S  Version 12.1 and 
Graph Pad Prism.
4.3 Results
4.3.1 Patients and Clinicai Data
Twenty patients were recruited for monitoring of HCMV specific immune 
function following allogeneic stem  cell transplantation. The m edian age 
w as 45.5 years (range 9 to 60 years).The patient characteristics and 
conditioning details are  sum m arised in Table 4-1.
Twenty healthy HCMV seropositive volunteers (lab workers) w ere used  to 
establish a normal range of HCMV specific immune responses. Five 
HCMV seronegative volunteers were used as  negative controls.
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Table 4-1 Characteristics and conditioning details of patients recruited for HCMV specific 
immune function monitoring following allogeneic stem cell transplant.
P atient D isease Age,
years
Sex H C M V
sero logy
(R/D)
Stem cell 
source
C ond­
itioning
Cam path
-IH
in vivo/in  
the bag
G vH D
p ro p h y­
laxis
F ollow
-up
days
IP ALL 19 M pos/neg MUD
PBSC
Flu,
Cyclo
& T B I
No/Yes None 129
8P EP 60 M pos/neg MUD
PBSC
Flu & 
Melph
Yes/No None 299
2P MM 49 F pos/neg Sib Mini- 
allo PBSC
Plu & 
Melph
Yes/No None 336
15P AML 35 F pos/neg SibB M Cyclo
& T B I
No/No MTX &
CsA
362
3P AML 47 M pos/neg Sib PBSC Cyclo
& T B I
No/Yes None 208
17P NHL 56 M pos/neg MUD
Mini-allo
PBSC
Flu & 
Melph
Yes/No CsA 389
7P CML 57 F pos/pos MUD
PBSC
Flu & 
Melph
Yes/No CsA 473
19P ALL 27 M pos/pos Sib BM TBI No/No CsA 142
4P AML 32 M pos/pos Sib Mini- 
allo PBSC
Flu & 
Melph
Yes/No None 325
5P AML 9 M pos/pos Sib PBSC Cyclo
& T B I
No/No MTX &
CsA
256
12P HL 19 F pos/pos Sib Mini- 
allo PBSC
Flu & 
Melph
Yes/No None 188
IIP CLL 53 M pos/pos Sib Mini- 
allo PBSC
Flu & 
Melph
Yes/No None 114
13P AML 58 F pos/pos MUD
PBSC
F lu&
Melph
Yes/No None 417
6P ALL 17 M pos/pos Sib PBSC Cyclo
& T B I
No/No M T X &
CsA
166
18P AML 44 M pos/pos Sib PBSC Cyclo
& T B I
No/No M T X &
CsA
444
16P NHL 53 M neg/pos Sib Mini- 
allo PBSC
Flu & 
Melph
Yes/No CsA 188
22P FL 33 M pos/neg Sib Mini- 
allo PBSC
Flu and 
Melph
Yes/No CsA 353
21P AML 35 F neg/pos Sib Mini- 
allo PBSC
Flu & 
Melph
Yes/No CsA 160
20P AML 55 F pos/pos MUD
Mini-allo
PBSC
Flu & 
Melph
Yes/No CsA 60
23P CML 54 M neg/pos MUD
PBSC
Cyclo
& T B I
No/No CsA 78
AML acute myeloid leukaemia; ALL acute lymphoblastic leukaemia; NHL non-Hodgkin’s lymphoma; CML chronic 
myeloid leukaemia; HL Hodgkin’s lymphoma; CLL chronic lymphocytic leukaemia; MM multiple myeloma; EP 
erythropoietic porphyria; FL fas ligand deficiency; M UD matched unrelated donor; PB SC peripheral blood stem cell: 
Sib sibling; MTX methotrexate; CsA ciclosporin; Cycle cyclophosphamide; TBI total body irradiation; Flu fludarabine; 
Melph melphalan.
184
4.3.2 Results of FACS Analysis on Normal Controls
A typical FACS plot of the interferon gam m a response to HCMV antigen 
stimulation Is show in Figure 4-1.
In order to calculate the optimal quantity of HCMV ADI 69 viral lysate, a 
dose  response curve of the CD4-k T cell interferon gam m a response  of 6 
normal controls w as generated , with the concentration of HCMV viral 
lysate ranging from O.lug/ml to lOug/ml. The optimal concentration of the 
A D I69 HCMV viral lysate w as found to be 5ug/ml, with a  reduction in the 
response in three individuals when the lysate w as used at a  higher dose, 
Figure 4-2.
The intra-assay variability w as calculated by performing five replicates in 
two normal control subjects and w as found to be 5%. It w as not possible 
to calculate an inter-assay variability since deterioration in response  with 
storage occurs. The importance of processing and setting up sam ples for 
stimulation within 12 hours w as confirmed by the dem onstration that the 
response to HCMV lysate fell by 50% in two patients after a  24 hour delay 
prior to antigen stimulation.
HCMV lysate or peptide pools did not elicit a  significant response  in five 
HCMV seronegative healthy controls, with the maximum interferon 
gam m a response being 0.02% of CD4+ cells, which is the  lower limit of 
detection for this assay .
The CD4+ T cell Interferon gam m a responses to HCMV viral lysate w as 
obtained in 20 healthy control subjects, and the CD4-k and CD8+ T cell 
interferon gam m a responses to pp65 and IE1 peptide pools were 
obtained in 17 healthy HCMV seropositive control subjects and are
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sum m arised in Table 4.2. The median CD4+ T cell response  to the 
HCMV viral lysate w as 3.88 interferon gam m a secreting cells/pL, while 
the response to the pp65 peptide pool w as 1.98 interferon gam m a 
secreting cells/pL and to the IE1 peptide pool w as 0.26 interferon gam m a 
secreting cells/pL The median CD8+ CTL interferon gam m a response  to 
pp65 peptide pool w as 1.57 interferon gam m a secreting cells/pL and the 
IE1 peptide pool w as 0.5 interferon gam m a secreting cells/pL.
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Table 4-2 Interferon y response of normal controls to stimulation with HCMV lysate, pp65 
peptide pool, and lE l  peptide pool.
Median 
Interferon Gamma 
Response
Range
Absolute Lymphocyte Count (XIO^) 1.85 1.15-2.84
CD4 Response
Absolute CD4+ Count (XIO* )^ 0.84 0.41-1.53
% HCMV Lysate Response, N=20 0.49 0.03-2.74
HCMV Lysate Response cells/pL 3.88 0.11-30.84
% pp65 Peptide Pool Response, N =I7 0.22 0-0.51
pp65 Peptide Pool Response cells/pL 1.98 0-5.08
% lE l Peptide Pool Response, N=17 0.03 0-0.11
lE l Peptide Pool Response cell s/p L 0.26 0-0.97
CD8 Response
Absolute CD8+ Count (XIO'^) 0.47 0.26-1.08
% pp65 Peptide Pool Response, N=17 0.34 0.05-3.98
pp65 Peptide Pool Response cell s/p L 1.57 0-10.36
% lE l Peptide Pool Response, N=17 0.16 0-2.95
lE l Peptide Pool Response cell s/p L 0.50 0-10.94
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Figure 4-1 Representative FACS plots of intracellular staining for interferon y of CD4+ T cells following antigen stimulation.
R1 represents the live lymphocyte gate. R2 is gated around CD3+ CD4+ cells. CD3+CD4+ cells were defined by combining the R1 and R2 gates. The proportion of 
CD3+CD4+ cells producing interferon y in response to specific antigen stimulation was determined on a quadrant plot of CD69 PE versus interferon gamma AFC, with 
positive cells showing upregulation of CD69. Percentage of responding cells were defined as the proportion of cells in the right upper quadrant. Backgating on the interferon 
y positive cells (coloured blue), it can be seen on the CD3 PerCP versus CD4 FITC plot that the surface expression of both are down regulated in antigen responding cells. 
Plots are shown for uninfected (control) lysate, HCMV infected lysate, no peptide control, pp65 peptide pool, lE l peptide pool and SEB positive control.
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Figure 4-2 HCMV viral lysate dose response curve.
The percentage of CD4+ T cells producing interferon y in response to stimulation with HCMV 
viral lysate at the concentrations 0.1, 0.5, 1, 5 and 10 pg/ml is shown for the 6 normal controls. 
C l, C2, C6, C12, C13 and C17. The optimal concentration of HCMV viral lysate was determined 
to be 5 |ig/ml. In three healthy controls, a reduction in response was seen when 10 pg/ml was 
used.
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4.3.3 Immunophenotype of CD4+ T cells Responding to HCMV
The immunophenotype of CD4+ I  cells responding to HCMV AD169 viral 
lysate w as determ ined and a  representative plot from a  normal HCMV 
seropositive control is shown in Figure 4-3. The terminally differentiated 
m ature phenotype w as confirmed in 2 normal controls and 5 patients, 
showing that the interferon gam m a secreting cells are CD45RA-, 
CD45RO+, CD62L-, CD27-, and the majority are also negative for the 
m arker CD25 (12 hour stimulation is insufficient for up regulation of CD25 
as  an activation marker), Figure 4-4. The results are sum m arised in Table 
4-3.
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Figure 4-3 Representative FACS plot of the immunophenotype of CD4+ T cells responding to HCMV viral lysate.
The results of immunophenotyping of patient 2P following stimulation with HCMV viral lysate is shown. R1 represents the live lymphocyte population. R2 is gated around 
CD4+ lymphocytes, and CD4+ T cells are defined by combining R1 and R2. The second row shows the CD62L, CD25PE, CD45RA, and CD45RO versus intracellular 
interferon y plots for CD4+ T cells with positive cells coloured blue. The third row shows the respective frequency histograms for interferon y positive cells and the bottom 
row the frequency histograms for all CD4+ lymphocytes. The percentage positive (M l) and negative (M2) cells are indicated for each respective marker.
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Figure 4-4 Comparison of the immunophenotype of the total CD4+ T cell population and CD4 Ï+  cells responding to HCMV viral lysate.
Bar graphs of the immunophenotype of all CD4+ T cells, and CD4+ T cells producing interferon y in response to stimulation with HCMV viral lysate arc shown. The bar 
graph on the left shows the mean results for the five patients 2P, 12P, 13P, I5P, and 18P, and the bar graph on the right shows the mean results for the two normal controls IP 
and 2P. The hatched bars represent all CD4+ T cells and the solid bars represent CD4+ T cells producing interferon y in response to stimulation with HCMV viral lysate. The 
mean percentage of cells positive for the markers CD62L, CD25, CD45RA, CD45R0 and CD27 is shown, with the error bars indicating 1 standard deviation.
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Table 4-3 Immunophenotype of all CD4+ T cells and interferon gamma secreting CD4+ T cells in response to HCMV viral lysate, of patients and controls.
CD62L
AH CD4+ 
cells
CD62L
IFy+
cells
CD25
All CD4+ 
cells
CD25
IFy+
Cells
CD45RA
All CD4+ 
cells
CD45RA
IFy+
cells
CD45R0
AIICD4+
cells
CD45RO
IFy+
cells
CD27
All CD4+ 
cells
CD27
IFy+
cells
Patients, % 
(N=5)
52 6 27 8 23 10 47 67 52 14
Control, % 
(n=2)
65 11 28 10 29 18 27 43 81 37
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4.3.4 Results of HCMV Specific Immune Function Monitoring 
in Allogeneic Stem Cell Transplant Recipients
All twenty patients were monitored for CD4+ and CD8+ T-cell HCMV 
specific immune response by interferon gam m a secretion in response to 
stimulation with AD 169 HCMV viral lysate (CD4+ only), and the pp65 and 
IE1 peptide pools (CD4+ and CD8+ responses). Patients w ere monitored 
for a  median of 232 days post transplantation (range 60 to 444 days) .The 
m edian num ber of sam ples per patient w as 10.5 (range 3 to 17).
A representative plot of the recovery of the CD4+ T helper HCMV specific 
immune recovery (determ ined by interferon gam m a secretion in response 
to HCMV ADI 69 viral lysate) and CD8+ T cells (determined by interferon 
gam m a secretion in response to the IE1 and pp65 peptide pools), as  well 
a s  real time PCR HCMV viral load monitoring is shown in Figure 4-5.
A scatter plot of the percentage of the total and logio(interferon gam m a 
secreting ce I Is/p L) CD4+ T helper cells responding to HCMV viral lysate, 
pp65 peptide pool, and IE1 peptide pool versus time post transplant, 
along with the results from normal controls is shown in Figure 4-6. By 60 
days post transplant, the median percentage of the total CD4 T cell 
population responding to HCMV viral lysate exceeds that of normal 
controls, indicating that the HCMV specific response is a dom inant 
com ponent of early CD4+ T cell immune reconstitution post transplant. 
The absolute interferon gam m a response to HCMV viral lysate steadily 
increases following transplant, but only approaches similar levels to 
normal controls by 1 year post transplant. Although many of the
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allogeneic stem  cell transplant recipients achieve an absolute CD4+ T cell 
pp65 peptide pool response  similar to normal controls by day 90, 
recovery of IE1 peptide pool CD4 responses is slower, not reaching 
similar levels to normal controls until day 360 post transplant.
The Kaplan Meier estim ate of the cumulative incidence of HCMV specific 
CD4+ T cell response to HCMV viral lysate greater than one interferon 
gam m a secreting ce I I/p L is 57% of patients with a median time of 178 
days.
A scatter plot of the percentage of the total and logio(interferon gam m a 
secreting cells/pL) CD8 + T cells responding to pp65 and IE1 peptide 
pools versus time post transplant, and the results from normal controls is 
shown in Figure 4-7. The CD8  pp65 peptide pool response is recovered 
rapidly following transplantation, with som e patients having a  significant 
level of response a s  early a s  day 30 post transplant. The CD 8 + T cell 
response  to pp65 dom inates the early CD8  T cell immune response, with 
a  median of 4% of the total CD8 + T-cells responding to pp65 at Day 30 
post transplant, ranging from 0% to as  high a s  64.1%  in one patient. By 
day 90 post transplant, the median absolute CD8 + T cell response  to 
pp65 exceeds that of the normal control population, and rem ains greater 
than the normal controls at 1 year post transplant. Recovery of the CD8 + 
T cell response to the IE1 peptide pool is slower and although the m edian 
percen tage of the total CD8 + T cell population exceed s that of the normal 
control population by day 90, the absolute CD8  IE1 response does not 
reach similar levels to normal controls until day 270 post transplant. The 
Kaplan Meier estim ate of the cumulative incidence of the CD 8 + T cell
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response to pp65 peptide pool greater than 1 interferon gam m a secreting 
cell/pL is 84.6% with a  m edian recovery time of 94 days.
A bar graph of the median and interquartile range of the absolute 
interferon gam m a response to HCMV viral lysate (CD4+ T cells) a s  well 
a s  the pp65 and IE1 peptide pools (CD4+ and GD8 + cells T cells) versus 
time post transplant is shown in Figure 4-8. This graph confirms that pp65 
dom inates the early HCMV response  for both CD4-h and CD 8 -1- T cells.
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Figure 4-5 Representative plot of the HCMV specific immune response and viral load monitoring following transplant.
The FACs plots show the percent of CD4+ T cells producing interferon j  (upper right quadrant) in response to stimulation with HCMV viral lysate. The red line on the line 
graph shows HCMV viral load monitoring (logio genome copies/ml) versus time post transplant. The blue (CD4+ T cells), green (CD8+ T cells) and black (CD8+ T cells) 
lines show the number of interferon y producing cells/pL following stimulation with HCMV viral lysate , pp65 and lE l peptide pools respectively.
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Figure 4-6 Scatter plots of the CD4+ T cell response to HCMV versus time post transplant
The results of the CD4+ T cell interferon y response to stimulation with HCMV viral lysate, pp65 and lE l peptide pools in 20 allogeneic transplant recipients at risk ol 
HCMV infection are plotted. The top row of scatter plots shows the response as a percentage of the total CD4+ lymphocyte population, and the bottom row of scatter plots 
shows the absolute interferon gamma response expressed as login(interferon y producing cells/mL).
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Figure 4-7 Scatter plots of CD8+ T cell response to HCMV versus time post transplant.
The results of the CD8+ T cell interferon y response to stimulation with HCMV viral lysate, pp65 
and lE l peptide pools in 20 allogeneic transplant recipients at risk of HCMV infection are 
plotted. The top row of scatter plots shows the response as a percentage of the total CD4+ 
lymphocyte population, and the bottom row of scatter plots shows the absolute interferon gamma 
response expressed as logio(interferon y producing cells/mL).
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Figure 4-8 The CD4+ and CD8+ T cell interferon gamma response to HCMV post transplant.
The median and interquartile range of the CD4+ and CD8+ T cell interferon y response to HCMV specific antigen stimulation for 20 allogeneic transplant patients is shown 
at 30, 60, 90, 180, 270 and 360 days post transplant. The results of 20 normal controls are plotted on the right hand side for comparison. Results are expressed as log,o 
(interferon y producing cells/mL). The error bars indicate the interquartile range.
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4.3.5 Correlation of Immune Function with HCMV Infection
Eleven of the twenty stem  cell transplant recipients experienced 19 
sep ara te  episodes of HCMV infection (as defined by two consecutive 
HCMV PCR positive results), Table 4-4. The median time to the first 
ep isode of HCMV infection w as 46 days (range -1 to 134 days). The 
median peak HCMV viral load was 3.42 logio genom e copies/ml (range 
2.38 to 4.95 logio genom e copies/ml). All the patients experiencing 
viraemia were seropositive for HCMV. Of the 7 patients with a 
seronegative donor, 4 out of 4 receiving Campath-1 H in vivo experienced 
infection, and 2 out of the 3 not receiving Campath-1 H in vivo (although 
one patient received Campath-1 H ex vivo) experienced infection. Of the 
10 patients with a  seropositive donor, none of the 4 patients without 
Campath-1 H in vivo experienced infection, while 5 out of the 6 that 
received Campath-1 H in vivo had infection. Seven patients experienced a 
second  HCMV infection, and all but one of th ese  patients had a  
seronegative donor. Only patient (patient 17P) developed symptom atic 
HCMV infection, with HCMV retinitis, with no recovery of either CD4-k or 
CD8+ T cell function by 1 year post transplant.
The CD4+ T cell interferon gam m a response to HCMV ADI 69 viral lysate 
w as less the one cell per pL in all but one patient at the time of initial 
detection of HCMV viraemia, with a  m edian HCMV specific immune 
response of 0.02 interferon gam m a secreting cells per pL. The CD8+ T 
cell interferon gam m a response to pp65 peptide pool at the time of HCMV 
viraemia was 0.13 interferon gam m a secreting cells per pL, with a CD8+
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T Cell response of g reater than 1 per pL occurring In 5 ep isodes of 
viraemia. Kaplan Meier estim ates of the time to recovery of a  CD4+ T cell 
HCMV viral lysate response  greater than one cell per pL according to the 
p resence or ab sen ce  of HCMV infection show s that although the overall 
recovery of HCMV specific CD4+ T cell immune responses is similar 
(55±34.2% for patients experiencing infection versus 58+33.9%  for 
patients not experiencing infection, p=0.72 Log Rank Score), recovery is 
slower in patients who experience infection, Figure 4-9. The median time 
to HCMV specific CD4+ T cell recovery w as 94 days in the group without 
infection, and 178 days in the group with infection, with none of the 
patients with infection experiencing a  recovery of HCMV specific CD44- T 
cell function until day 68. Although a  greater proportion of patients in the 
HCMV infection group recovered an HCMV specific CD8+ T cell immune 
response  to pp65 of greater than one cell per pL, the difference w as not 
significant (87.9±21.6% for the patients experiencing infection versus 
58.3±33.9%  for the patients not experiencing infection, p=0.86 Log Rank 
Score), Figure 4-10. The median time to HCMV specific CD8 T cell 
recovery was 94 days in the group without infection and 101 days in the 
group with infection.
The median and interquartile range of the immune resp o n ses  to HCMV 
viral lysate (CD4+ only), pp65 peptide pool and 1E1 peptide pool at days 
30, 60, 90, 180, 270 and 360 post transplant according to the p resence  or 
ab sen ce  of HCMV infection are shown for CD4-r T cells in Figure 4-11 
and Figure 4-12, and for CD8+ T cells in Figure 4-13. Patients 
experiencing HCMV infection had a  lower HCMV specific CD4+ T cell
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lysate response prior to day 180 post transplant, with a  similar but less 
marked trend for pp65 and IE1. In contrast, there w as no difference in the 
CD8+ T cell pp65 and IE1 responses betw een patients experiencing 
HCMV infection com pared to patients not experiencing infection.
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Table 4-4 Viral kinetics and HCMV specifîc immune response at time of infection of the allogeneic transplant patients experiencing HCMV infection.
Patient HCMV Serology 
(R/D)
Campath-1 H  
In vivo
Time to 
Infection 
(days)
Log 1 0  Peak 
Viral Load 
(genome copies/ml)
Log JO Initial 
Viral Load 
(genome copies/ml)
Kmax 
(day s'
CD4 Lysate 
Response 
(IFy/pl)
CDS pp65  
response 
(IFy/pl)
Recurrent
Infection
IP pos/neg
*
no 28 3.19 2.84 0.14 0.03 0.29 yes
2P pos/neg yes 50 2.94 2.50 0.23 # # yes
3P pos/neg no 84 2.71 2.71 0.16 0 0.13 yes
7P pos/pos yes 134 3.42 2.80 0.24 3.6 3.57 no
8P pos/neg yes 110 3.47 2.73 0.57 0 0.09 yes
IIP pos/pos yes 20 3.87 2.61 0.21 0.47 2.2 yes
12P pos/pos yes 20 4.95 2.65 0.52 0 0.02 no
13P pos/pos yes 46 3.82 3.07 0.36 0 0 no
17P pos/neg yes 71 3.42 2.79 0.19 0 0 yes
20P pos/pos yes 29 3.85 2.66 0.42 # # no
22P pos/neg yes -1 2.38 2.38 0.06 0 0 yes
# Immune response at the time of infection not available
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Figure 4-9 Kaplan Meier estimate of the cumulative incidence of CD4+ T cell immune
recovery to HCMV.
The Kaplan Meier estimate of the cumulative incidence of patients achieving a CD4+ T cell 
interferon y response to HCMV viral lysate of greater than 1 eell/pL is shown. The cumulative 
incidence for the group experiencing HCMV infection (n=l 1, red line) is 55±34.2%, and for the 
group not experiencing infection (n=9, blue line) is 58.3±33.9%. The difference is not significant 
(p=0.4 Log Rank Score). Dotted lines indicate the 95% confidence intervals and censored events 
are indicated by the cross bars.
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Figure 4-10 Kaplan Meier estimate of the cumulative incidence of CD8+ T cell immune
recovery to HCMV.
The Kaplan Meier estimate of the cumulative incidence of patients achieving a CD8+ T cell 
interferon y response to the pp65 peptide pool of greater than 1 cell/pL is shown. The cumulative 
incidence for the group experiencing HCMV infection (n=l 1, red line) is 87.9±21.6%, and for the 
group not experiencing infection (n=9, blue line) is 58.3+33.9%. The difference is not significant 
(p=0.85 Log Rank Score). Dotted lines indicate the 95% confidence intervals and censored events 
are indicated by the cross bars.
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Figure 4-11 CD4+ T cell response to HCMV viral lysate according to the presence or
absence of HCMV infection.
The logio CD4+ T Cell interferon y response versus time post transplant is plotted following 
stimulation with HCMV viral lysate. The results of patients experiencing infection (n=l 1) are 
plotted in red and patients not experiencing infection (n=9) are plotted in blue. The 
triangles/square boxes indicate the median values, and the error bars indicate the interquartile 
range.
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Figure 4-12 CD4+ T cell response to pp65 and lE l peptide pools according to the presence
or absence of HCMV infection.
The logio CD4+ T Cell interferon y response versus time post transplant is plotted following 
stimulation with the pp65 (top graph) and lE l (bottom graph) peptide pools. The results of 
patients experiencing infection (n=l 1) are plotted in red and patients not experiencing infection 
(n=9) are plotted in blue. The triangles/square boxes indicate the median values, and the error 
bars indicate the interquartile range.
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Figure 4-13 CD8+ T cell response to pp65 and lE l peptide pools according to the presence
or absence of HCMV infection.
The logio CD8+ T cell interferon y response versus time post transplant is plotted following 
stimulation with the pp65 (top graph) and IE] (bottom graph) peptide pools. The results of 
patients experiencing infection (n=l 1) are plotted in red and patients not experiencing infection 
(n=9) are plotted in blue. The triangle/square boxes indicate the median values, and the error bars 
indicate the interquartile range.
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4.3.6 Effect of Campath-1 H Use on HCMV Immune Recovery
The u se  of Campath-1 H in vivo w as strongly associa ted  with HCMV 
infection, with 9 out of the 10 patients (90%) who received Campath-1 H in 
vivo experiencing infection, com pared to only 2 out of 10 patients (20%) 
not receiving Campath-1 H (p=0.006, Fisher's exact test). Kaplan Meier 
survival curves of the cumulative incidence of CD4+ T cell recovery to 
HCMV (as determ ined by interferon gam m a response to HCMV viral 
lysate) and CD8+ T cells (as determ ined by interferon gam m a response  
to the pp65 peptide pool) according to Cam path In Vivo use  are shown in 
Figure 4-14 and  Figure 4-15. Similar to the com parison betw een the 
group experiencing HCMV infection or not, m edian time to CD4+ T cell 
recovery occurred w as faster in the non Campath-1 H in vivo group 
(m edian time to recovery of 53 days for the non Campath-1 H group 
versus 94 days for the Campath-1 H in vivo group) but the overall 
cum ulative incidence of CD4+ T cell recovery was not statistically 
significant (54.2±29.5% in the Campath-1 H group versus 75±38.7%  in the 
Non Campath-1 H group, p=0.33 Log Rank Score). Median time to CD8+
T cell specific immune recovery w as also faster in the non Campath-1 H in 
vivo group (67 days for the non Campath-1 H group versus 94 days for 
th e  Campath-1 H group) but the cumulative incidence of CD8+ T cell 
recovery w as not significantly different (83.3±26.7% in the Campath-1 H 
group versus 75±38.7% in the non Campath-1 H group, p=0.83 Log Rank 
Score). The median and interquartile range of the logio(IFy producing 
cells/pl) CD4+ T cell response to HCMV lysate and the CD8+ T cell
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response to pp65 over time post transplant according to Campath-1 H in 
vivo use is shown in Figure 4.15 and Figure 4.16, and the statistical 
analysis is shown in Table 4.5. Although the median CD4 response is 
lower at all time points post transplant in patients receiving Campath-1 H 
in vivo, the difference is only significant at Day 30 (0.0 IFy secreting 
cel Is/p L for the Campath-1 H group and 0.7 IFy secreting cells/pL for the 
non Campath-1 H group, p=0.04 Mann Whitney U test). A similar analysis 
for CDS responses to pp65 did not show any significant difference at any 
s tag e  post transplant.
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Table 4-5 Comparison of the median HCMV speciHc interferon gamma responses in allogeneic transplant recipients according to use of Campath-IH in vivo at 
different time points post transplant.
Days Post Transplant 30 60 90 180 270 360
Median CD4+ T cell Viral Lysate Response (cells/pL)
Campath-IH 0 0.0 0.2 0.7 1.8 2.3
(Range) (0, 0.2) (0, 114) (0, 38.8) (0, 9.4) (0.7, 20.3) (0.0, 14.5)
No Campath-IH 0.70 0.9 3.8 5.0 10.7 2.3
(Range) (0.0, 8.9) (0, 16.0) (0.1, 11.1) (1.1,5.0) (7.1, 14.2) (1.9, 2.8)
p value (Mann Whitney) 0.04 0.08 0.17 0.37 0.38 0.86
Median CD8+ T cell pp65 Response (cells/pL)
Campath-IH 0.1 0.0 0.6 2.4 6.2 2.4
(Range) (0,3.1) (0, 14.8) (0, 28.6) (0,41.5) (0, 40.6) (0,41.5)
No Campath-IH 1.0 0.8 4.7 3.7 29.4 8.9
(Range) (0.1, 2.1) (0, 12.6) (0, 8.8) (1.5, 11.9) (13.2,45.7) (3.8, 13.9)
p Value (Mann Whitney) 0.2 0.14 0.69 0.69 0.19 0.36
212
Figure 4-14 Kaplan Meier estimate of the cumulative incidence of CD4+ T cell immune
recovery to HCMV according to Campath-IH use.
Kaplan Meier estimate of the cumulative incidence of patients achieving a CD4+ T Cell 
interferon y response greater than 1 cell/pL to HCMV viral lysate is plotted. The cumulative 
incidence for the Campath-IH group (n= 12, red line) is 54.2+29.5%, and for the non Campath- 
IH  group (n-8, blue line) is 75±38.7%. The difference is not significant (p=0.33 Log Rank 
Score). Dotted lines indicate the 95% confidence intervals and censored events are indicated by 
the cross bars.
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Figure 4-15 Kaplan Meier estimate of the cumulative incidence of CD8+ T cell immune
recovery to HCMV.
The Kaplan Meier estimate of the cumulative incidence of patients achieving a CD8+ T Cell 
interferon y response greater than 1 cell/pL in response to the pp65 peptide pool is plotted. The 
cumulative incidence for the Campath-IH group (n=12, red line) is 83.3±26.7%, and for the non 
Campath-IH group (n=8, blue line) is 75±38.7%. The difference is not significant (p=0.33 Log 
Rank Score). Dotted lines indicate the 95% confidence intervals and censored events are 
indicated by the cross bars.
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Figure 4-16 CD4+ T response to HCMV according to use of Campath-IH in vivo.
The logio CD4+ T cell interferon gamma response to stimulation with HCMV viral lysate is 
shown. The results of patients that received Campath-IH in vivo (n=12) are plotted in red, and 
for patients that did not receive Campath-IH in vivo (n=8) are plotted in blue. The 
triangles/square boxes represent the median values and the error bars show the interquartile 
range.
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Figure 4-17 CD8+ T Response to HCMV according to use of Campath in vivo.
The logio CD8+ T cell interferon gamma response to stimulation with the pp65 peptide pool is 
shown. The results of patients that received Campath-IH in vivo (n= l2) are plotted in red, and 
for patients that did not receive Campath-IH in vivo (n-8) are plotted in blue. The 
triangles/square boxes represent the median values and the error bars show the interquartile 
range.
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4.3.7 Effect of Donor Serostatus on HCMV Immune Recovery
Kaplan Meier survival curves of the cumulative incidence of CD4+ T cell 
recovery to HCMV (as determ ined by the interferon gam m a response to 
HCMV viral lysate) and CD8+ T cells (as determ ined by the  interferon 
gam m a response  to the pp65 peptide pool) according to HCMV serology 
are  shown in Figure 4-18 and Figure 4-19. None of the 3 HCMV 
seronegative patients with a  seropositive donor recovered either CD4+ or 
CD8+ T cell HCMV specific immune function, although two of th ese  
patients received C am path-IH  in vivo. The cumulative incidence of CD4+ 
T cell recovery greater than 1/pL w as 76±28.5%  for R+D+ patients and 
61.9+39.1%  for R+D- patients. The difference in the curves w as not 
significant (p=0.17 Log Rank Score). The cumulative incidence of CD8+ T 
cell recovery greater than 1/pL w as 90+18.6% for R+D+ patients and 
81 ±32.8% for R+D- patients. The difference in the curves w as significant 
(p=0.02 Log Rank Score), with earlier recovery of CD8+ T cell HCMV 
immunity in patients with a  seropositive donor.
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Figure 4-18 Kaplan Meter estimate of the cumulative incidence of CD4+ T cell immune
recovery to HCMV according to the HCMV serology of the donor and recipient.
The results of the Kaplan Meier estimate of the cumulative incidence of HCMV viral lysate 
CD4+ T cell interferon gamma response greater than 1/pL according id plotted. The cumulative 
incidence for R+D+ (n=10, blue line) is 76+28.5%, for R+D- (n=7, red line) is 61.9±39.1%, and 
for R-D+ (n=3, green line) is 0%. The hatched lines indicate 95% confidence interval. The p 
value for the log rank score is 0.17, indicating no significant difference between the curves.
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Figure 4-19 Kaplan Meier plot of the cumulative incidence of CD8+ T cell immune recovery
to HCMV according to the HCMV serology of the donor and recipient.
The results of the Kaplan Meier estimate of the cumulative incidence of HCMV viral lysate 
CD4+ T cell interferon gamma response greater than 1/pL according id plotted. The cumulative 
incidence for R+D+ (n=10, blue line) is 90±18.6%, for R+D- (n=7, red line) is 81+32.8%, and for 
R-D+ (n=3, green line) is 0%. The hatched lines indicate 95% confidence interval. The p value 
for the log rank score is 0.02 indicating that the curves are significantly different.
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4.4 Conclusions
The HCMV specific CD4+ T cell immune response  constitutes a  large 
com ponent of the early antigen specific T cell response  following 
allogeneic stem  cell transplantation. This is likely to be due to the  fact that 
HCMV is one of the earliest antigens to which a  transplant patient is 
exposed  to following transplantation. The im m unophenotype of CD4+ T 
cells responding to HCMV antigens is of a  m ature memory phenotype. 
This is simillar to the immunophenotype found in normal controls in this 
study a s  well a s  by other workers (Amyes et al., 2003; S es te r et al., 2002; 
W eekes et al., 2004), and suggests  that HCMV specific CD4+ T cell 
im m une recovery is likely to be derived from m ature donor T cells.
Overall, 84.6 percent of patients achieved a significant CD8+ T cell 
re sp o n se  to pp65, with half the patients doing so  by 3 m onths post 
transplant, similar to the finding in R eussers study (R eusser et al., 1991). 
However, only 57 percent of patients achieved a  significant CD4+ T cell 
re sp o n se  to HCMV viral lysate, although this difference w as not 
statistically significant due to insufficient study num bers. Even by one 
year, the absolute CD4+ T cell response did not attain similar levels to 
norm al controls, despite the HCMV specific CD8+ T cell response  
exceed ing  normal control levels. This suggests that CD4+ T helper 
function may be a  major limiting factor in the recovery of an HCMV 
specific immune response following allogeneic stem  cell transplant. A low 
ab so lu te  CD4+ T cell count less than 100 X 10® has been reported by
220
Hakki et al. to be associated  with delayed recovery of HCMV specific 
CD4+ T cell function (Hakki et al., 2003).
In this study, an HCMV specific CD4+ T cell response  greater than 1 
cell/pL w as associa ted  with protection against viraemia in all but one 
patient, while a  protective level of HCMV specific CD8+ T cell response 
could not be established. One possible explanation is that antigen 
experienced m ature HCMV specific CD8+ T cells (derived from the 
donor) may proliferate in response  to exposure to an HCMV antigen, 
perhaps at a subclinical level, but without HCMV specific CD4+ T helper 
function, be insufficient to control viral replication and prevent clinically 
detectab le  infection. This situation may have parallels to the observation 
of im m unosenescence in HCMV seropositive elderly patients, w here high 
levels of HCMV tetram er positive CD8+ T cells are associa ted  with a 
terminally differentiated phenotype and functional impairment (Khan et 
al., 2002b; Guyang et al., 2003). Although only one ca se  of HCMV 
d ise a se  w as observed in this cohort of patients, it is likely that CD4+ I  
cell function is also essential to prevent HCMV d isease. Further work to 
a s s e s s  the functional capacity of HCMV specific CD8+ T cells following 
transplantation is warranted.
The lack of recovery of an HCMV specific immune response  in 
seronegative  recipients with a seropositive donor may be to the ab sen ce  
of antigenic stimulation of mature donor derived T cells. Alternatively, as  
th ere  is evidence that early T cell recovery in patients T-cell depleted with 
Cam path-1 has a  significant recipient com ponent (Roux et al., 1996), it 
m ay be the absen ce  of HCMV experienced recipient T-cell recovery that
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accounts for this. Recovery of HCMV specific CD8 + T cells w as 
significantly faster in seropositive recipients of seropositive donors when 
com pared to seronegative donors. Although recovery of HCMV specific 
CD4+ T cells w as also faster with a  seropositive donor, this difference did 
not reach statistical significance, although that may be due to small study 
num bers, and the impact of Campath-1 H use.
The use  of C am path - 1  H in vivo however w as associated  with a  
significantly delayed recovery of HCMV specific CD4-I- T cells, although 
the  overall likelihood of recovery of HCMV specific CD4+ T cell function 
w as not affected. No difference w as seen  in the recovery of HCMV 
specific CD8 4 - T cell function. A recent study of 38 patients transplanted 
with a  reduced intensity conditioning regimen using alem tuzum ab show ed 
tha t reconstitution of HCMV specific CTLs a s  m easured  by tetram ers was 
rapid, with a  five fold rise in HCMV specific CTLs observed following 
HCMV infection (Lamba et al., 2005). The difference in recovery of HCMV 
specific CD4 4 - T helper function is likely to be a significant factor in 
explaining the high incidence of HCMV infection seen  with the use  of 
Cam path-1 H both in this study a s  well a s  other studies (Chakrabarti et al., 
2 0 0 2 a).
R ecovery of HCMV specific CD4-i- T cells is predictive of a  low risk of 
further HCMV infection. Although monitoring of CD4-i- T cell function two 
weekly post transplant is labour intensive, restricting analysis to Day 50 
an d  Day 100 may be a useful way of identifying patients that remain at 
risk of HCMV infection, and require continued monitoring for HCMV 
viraem ia, a s  well a s  identifying potential candidates for immunotherapy.
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Chapter 5 Identification of HLA Class II
Restricted Epitopes for the HCMV Proteins pp65 
andIE1
5.1 Introduction
The identification of immunodominant HLA class II restricted epitopes for 
the HCMV proteins pp65 and IE1 could provide antigenic peptides to 
assis t in the monitoring of HCMV specific CD4+ T cell function and may 
facilitate the generation of HCMV reactive cells for immunotherapy. Using 
the Vp typing of HCMV specific CD4 cells, it has  been dem onstrated that 
there  is a  clonotypic structure to the CD4 memory response  to HCMV, 
with 1-3 clones predominating, a s  well as  a  cohort of subdom inant clones 
and num erous minor clones (Bitmansour et al., 2001). By molecular 
clonotypic analysis and limiting dilution assays, th ese  clones have been 
show n to be stable over time and may com prise a s  much a s  0.3 -  1.5% 
of all CD4+ T cells (W eekes et al., 2004). A similar p rocess of clonal 
focusing is exhibited by HCMV specific CD8+ T cells (W eekes et al.,
1999). Identification of the epitope specificity of th ese  clones may be 
useful to facilitate immune function monitoring and also have therapeutic 
potential in the generation of HCMV specific cell lines and peptide 
vaccines (Paston  et al., 2004).
The first HCMV C lass I epitopes were identified by generating cytotoxic 
c lones and  dem onstrating peptide specific cytotoxic activity (Diamond et 
al., 1997). Using intracellular cytokine staining combined with flow 
cytom etry following antigen stimulation ex vivo, the antigenic potential of 
a  large num bers of peptides can be screened  (Kern et al., 1998), and this
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approach has already been used  to identify C lass I epitopes as  well a s  a 
num ber of G lass II epitopes for pp65 and IE1 (Kern et al., 1999; Kern et 
al., 2002). As the specificity of an epitope for a  particular HLA molecule is 
determ ined by anchoring residues within the peptide chain, it is possible 
to predict C lass I specific epitope on the basis of the binding affinity of 
each  possible peptide within a  protein using com puter algorithms such as  
SYFPEITHI (R am m ensee et al., 1999). B ecause proteosom e cleavage 
and  TAP transport also influences the selection of peptides generated  for 
binding to HLA class I m olecules, algorithms have been refined to 
incorporate th ese  factors into the T-cell epitope prediction algorithms 
(Doytchinova and Flower, 2006; D onnes and Kohlbacher, 2005; Larsen et 
al., 2005; R eche and Reinherz, 2005).
With respect to HLA C lass II molecules, becau se  of the m ore relaxed 
nature of epitope binding and the influence of flanking seq u en ces  
(Fleckenstein et al., 1999), epitope prediction algorithms are less useful, 
although they continue to be refined (Cui et al., 2007; Salom on and 
Flower, 2006; Xiao and Segal, 2005; Nielsen et al., 2004; Tong et al., 
2006). Khattab generated pp65 specific CD4+ T cell lines to identify two 
HLA C lass II restricted epitopes to DR11 and DR3 (Khattab et al., 1997). 
As already d iscussed, Kern has identified a small num ber of HLA Class II 
ep itopes to pp65 using overlapping peptides and intracellular cytokine 
staining (Kern et al., 2002). W eekes identified 3 HLA class-11 restricted 
ep itopes by sequencing the TCR beta-chain of peptide specific CD4-H T 
cell clones (W eekes et al., 2004). Other authors have described epitopes 
for gB (Elkington et al., 2004) and pp150 (La Rosa et al., 2005), while
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only one C lass II restricted epitope to IE1 has been described to date 
(Gautier et al., 1996). Recently Li Pira reported the results of a  pp65 
specific C lass II peptide mapping study using immunomagnetic CD4+ T 
cell selection and ELIspot (Li Pira et al., 2004a). A sum m ary of the C lass 
II HCMV specific epitopes identified to date is shown in Table 5-1. The 
feasibility of using overlapping peptide pools to generate  CTL for 
im m unotherapy h as  been evaluated and this technique is also capable of 
generating CD4 responses (Trivedi et al., 2005) and has been  used to 
g en era te  CTLs. With respect to the generation of HCMV specific cell lines 
for the use  in immunotherapy, clinical trials in the past have utilised either 
autologous fibroblasts infected with HCMV ADI 69 or whole HCMV 
ADI 69 protein derived from an infected fibroblast cell line. However the 
problem is that CTLs derived from this method may not reflect the sam e 
epitope response that is seen  in vivo and thus may not be fully effective.
A CD4 helper response to HCMV using proliferation a ssa y s  has been 
described  for pp65, gB, gH, IE1, IE2, and UL69 (Beninga et al., 1995), 
with the response to pp65 and IE1 being am ong the most frequent. 
Individual epitopes to gB (Elkington et al., 2004; Liu et al., 1993) , gH 
(Elkington et al., 2004), IE1 (Alp et al., 1991; Gautier et al., 1996) and 
pp65 (Bitmansour et al., 2001 ; Gallot et al., 2001 ; Kern et al., 2002; 
K hattab et al., 1997; Trivedi et al., 2005; W eekes et al., 2004; Davignon 
et al., 1996; Li Pira et al., 2004b) have been described..
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Table 5-1 HLÂ Class II HCMV specific epitopes previously published for pp65 and lEI.
Protein Epitope site Sequence HLA
seroloftic
HLA
m olecular
R ef
pp65 361 to 376 PQYSEHPTFTSQYRIQ D R ll D R B l^ ll (Khattab et al., 1997)
pp65 485 to 499 PPWQAGILARNLVPMV ?DR3 DRB1*03 (Khattab et al., 1997)
pp65 509 to 524 KYQEFFWD ANDIYR IF DR3 DRB1=*=03 (Khattab et al., 1997)
pp65 364 to 386 SEHPTFTTSQYRIQGKLEYHTWD DR 1302 DRB 1*1302 (Gallot et al,, 2001)
pp65 34 to 56 VLPHETRLLQTGIHVRVSQPSLI DQ0602 DQB 1*0602 (Gallot et al., 2001)
pp65 364 to 386 SEHPTFTTSQYRIQGKLEYHTWD D R ll D R B l* ll (Gallot et al., 2001)
pp65
pp65
pp65
pp65
34 to 56 
509 to 523
511 to 522
47 to 58
VLPHETRLLQTGIHVRVSQPSLI DQ0602
7
7
7
DQB 1*0602 (Gallot et al., 2001) 
(Bitmansour et al., 
2001)
(Bitmansour et al,, 
2001)
(Bitmansour et al., 
2001)
pp65 41 to 55 LLQTGIHVRVSQPSL DR15
(DQ6)
DRB1*15 (Kem et al., 2002)
pp65 281 to 299 IIKPGKISHIMLDVAFTSH DR53
(DQ3)
DRB4*01 (Kern et al., 2002)
pp65 361 to 383 PQYSEHPTFTSQYRIQGKLEYRH D R ll DRB1*11 (Kem et al., 2002)
pp65 509 to 527 KYQEFFWDANDIYRIFAEL DR52 DRB3*01 
or 02
(Kem et al., 2002)
pp65 489 to 507 AGILARNLVPMVATVQGQN 7 (Kem et al., 2002)
pp65 41 TO 60 LLQTGIHVRVSQPSLILVSQ DQ6 DQB 1*06 (Weekes et al., 2004)
pp65 259 to 273 NPQPFMRPHERNGFT DR 13 DRB1*13 (Weekes et al., 2004)
pp65 367 to 380 PTFTDQYRIQGKLE D Q ll DQB 1*06 (Weekes et al., 2004)
pp65 41 to 55 LLQTGIHVRVSQPSL DR15 DRB1*15 (Li Pira et al., 2004b)
pp65 117 to 131 PLKMLNIPSINVHHY DR3 DRB1*03 (Li Pira et al., 2004b)
pp65 117 to 131 PLKMLNIPSINVHHY DR 3 DRB1*03 (Li Pira et al., 2004b)
pp65 169 to 183 TRQQNQWKEPDVYYT DRl DRB1*01 (Li Pira et al., 2004b)
pp65 177 to 191 EPDVYYTSAFVFPTK DR7 DRB1»07 (Li Pira et al., 2004b)
pp65 225 to 239 KVYLESFCEDVPSGK DR15 DRB1*15 (Li Pira et al., 2004b)
pp65 245 to 259 TLGSDVEEDLTMTRN DR3 DRB1*03 (Li Pira et al., 2004b)
pp65 261 to 275 QPFMRPHERNGFTVL DRl 3 DRB1*13 (Li Pira et al., 2004b)
pp65 281 to 295 IIKPGKISHIMLDVA DR4 DRB1*04 (Li Pira et al., 2004b)
pp65 281 to 295 IIKPGKISHIMLDVA DR7 DRB1*07 (Li Pira et al., 2004b)
pp65 365 to 379 EHPTFTSQYRIQGKL D R ll D R B F l l (Li Pira et a l, 2004b)
pp65 373 to 387 YRIQGKLEYRHTWDR DR3 DRB1*03 (Li Pira et a l , 2004b)
pp65 413 to 427 TERKTPRVTGGGAMA DR14 DRB1*14 (Li Pira et a l , 2004b)
pp65 429 to 443 ASTSAGRKRKSASSA D R ll DRBI*11 (Li Pira et a l, 2004b)
pp65 445 to 459 ACTSGVMTRGRLKAE D R l DRB1*01 (Li Pira et a l , 2004b)
pp65 489 to 503 AGILARNLVPMVATV D R ll DRB1*11 (Li Pira et a l, 2004b)
pp65 489 to 503 AGILARNLVPMVATV DR3 DRB1*03 (Li Pira et a l , 2004b)
pp65 509 to 523 KYQEFFWDANDIYRIF DRl DRB1*01 (Li Pira et a l , 2004b)
pp65 509 to 523 KYQEFFWD ANDIYRIF DR3 DRB1*03 (Li Pira et a l , 2004b)
pp65 513 to 523 FFWD ANDIYR 1 DRl 301 D R B *I30I (Trivedi et a l ,  2005)
pp65 513 to 523 FFWD ANDIYR 1 DQ05xx DQB 1*05 (Trivedi et a l , 2005)
pp65 513 to 523 EHPTFTSQYRIQGKL D R llO l DRBI*1101 (Trivedi et a l , 2005)
lE l 162 to 175 DKREMWMACIKELH DR8 (Gautier et a l ,  1996)
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5.2 Methods
5.2.1 Patient Population
Normal controls w ere recruited from healthy HCMV seropositive 
laboratory workers. Ten HCMV seropositive stem  cell transplant 
recipients were recruited from the HCMV specific immune reconstitution 
study described in C hapter 4, including nine allogeneic stem  cell 
transplant recipients and one autologous transplant recipient. Only 
patien ts who had recovered sufficiently both an absolute CD4+ T cell 
count and HCMV specific CD4+ T cell responses w ere included in the 
study of HLA C lass II HCMV specific epitopes. The details of the patient 
recruited and sam ple processing are described in sections 4.2.1 and
4.2.2
5.2.2 Antigen Stimulation and Intraceiiuiar Cytokine Staining
The m ethod for m ononuclear cell preparation is described in section 
4.2.6. The method for antigen stimulation in section 4.2.7 and for 
intracellular cytokine staining is described in section 4.2.8. The antigens 
u sed  for the C lass II epitope identification study were HCMV A D I69 viral 
lysate  (ABI, Columbia, USA) at a  concentration of 5 pg per 1 ml of cell 
su sp en sio n  (containing 1X10® PBMCs), pp65 and IE1 peptide pools 
(Jerini Peptide Technologies, Germany) at a concentration of Ip g  per 1 ml 
(1X10® PBMCs) of cell suspension, Ipg  of each peptide mapping pool for 
IE1 and  pp65 (Jerini Peptide Technologies, Germany) per 1ml (1X10® 
PBM Cs) of cell suspension for low resolution mapping, and 1 pg of each
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individual 15 mer peptide suspension  (Alta Biosciences, Birmingham, UK) 
for high resolution mapping.
The low resolution mapping pools used for identifying candidate sites for 
immunodominant C lass II epitopes each  contained 15 to 17 consecutive 
15 m er peptides, each  peptide seq u en ce  overlapping the preceding 
peptide seq u en ce  by 11 amino acids. Eight peptide pools spanning the 
entire seq u en ce  of IE1 and  9 pools spanning the entire sequ en ce  of pp65 
w ere used. The composition of the low resolution mapping pools is 
detailed in Appendix B. For high resolution epitope mapping, all the 
individual 15 m er peptides from a  reactive pool were tested  individually. 
All peptides were m anufactured by Fmoc solid phase  peptide synthesis. 
M onoclonal antibodies (BD Biosciences, Oxford, UK) used  for low 
resolution mapping w ere CD4 FITC, CD3 PerOP, CDS PE (surface 
staining) and Interferon y APC (intracellular staining). For high resolution 
m apping, the monoclonal antibodies CD4 FITC, CD3 PerCP, CD69 PE 
(surface staining) and Interferon G am m a APC (intracellular staining) were 
used .
HCMV specific CD4+ T cell responses were screened  using HCMV viral 
lysate, and IE1 and pp65 peptide pools and the low resolution mapping 
pools for IE1 and pp65. In order to identify the peptide seq u en ce  of the 
im m unodom inant epitope, a  second PBMC sam ple from patients reacting 
to a  low resolution mapping pool w as stimulated with the individual 
constituent peptides of that pool in order to identify the immunodominant 
15 m er peptide chain.
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5.2.3 FACS Analysis
Following surface and intracellular staining, the fixed cell suspensions 
were acquired using a  FACSCalibur four colour flow cytom eter (BD 
Bioscience, Oxford, UK). FACS analysis w as performed using CellQuest 
softw are (BD Bioscience, Oxford, UK). Initial gating to identify the 
lymphocyte population w as performed using forward and side scatter. A 
secondary  gate w as placed around the CD3+ CD4+ population to identify 
CD4+ T Cells. The threshold fluorescence intensity for interferon y APC 
positive cells w as se t using unstim ulated control cells. The sam e gating 
stra tegy  w as used  for the identification of CD4+ T cells for high resolution 
mapping. Interferon y reactivity was confirmed by the dem onstration of 
upregulation of the activation marker, CD69 on an Interferon y versus 
CD69 plot, with reactivity calculated by quadrant analysis.
5.2.4 Epitope Prediction Modelling
In order to define the HLA C lass II restriction of immunodominant regions 
identified by high resolution, the amino acid sequ en ce  w as entered into 
the  epitope prediction program, SYFPEITHI, maintained by Prof. Hans- 
G eorg R am m ensee at the Departm ent of Immunology, University of 
Tuebingen, Germany, and accessed  by the website www.svfpeithi.de 
(R am m ensee  et al., 1999). Epitope prediction is only available for the 
HLA C lass II molecules: DRB1*0101, DRB1*0301, DRB1*0401, 
DRB1*0701, and DRB1*1501. Anchoring and binding residues are 
predicted from previously published motifs. The program performs a  
sequentia l analysis of each  15 m er peptide of the entered sequence, and
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assigns a  score based  on the p resence of ideal anchors, auxiliary 
anchors and preferred residues, with negative values for amino acids 
excluded at a particular site for the selected  HLA molecule. The 
maximum score predicts the most likely epitope. B ecause the program 
calculates epitope binding affinity for 15 mer peptides and the binding 
groove contains 9 residues, the first anchoring residue is the fourth amino 
acid of the peptide.
5.2.5 HLA Typing
HLA typing w as perform ed by the Anthony Nolan Trust. Low resolution 
C lass  I and II HLA typing w as performed by serology and high resolution 
typing w as perform ed by PGR using sequ en ce  specific oligonucleotides.
5.3 Results
5.3.1 HLA Typing
A total of 22 normal controls and 10 stem  cell transplant recipients were 
studied. The HLA C lass I and II tissue types for normal controls are 
show n in Table 5-2 and for the stem  cell recipients in Table 5-3.
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Table 5-2 HLA class I and II molecular typing results of normal controls.
Code Gender HLA Class I Class II HLA Class 11
A and B D RBl HLA D Q B l
C l Female A 1 ,A 1 ,B 7 ,B 8 0301,0401
C2 Female A2, A2, B15, B39 0401, 1101
C3 Female A l l ,  A 30 ,B 13 ,B 58 0301,0701
C4 Male A l, A 24,B15, B27 1301
C5 Male A 26 ,B 38 ,B 27 0401, 1301
C6 Male A2, B15 4, 13 06*
C7 Male A32, A33, B52, B58 1502, 1302
C8 Female A l, A68, B35, B51 1101, 1301 0603, 0301
C9 Male A24, A31, B56 11, 15
CIO Female A l, A26, B8, B55 0301, 1401
C l l Female A3, A l l ,  B35, B42 1501,0801 06*, 03*
C12 Male A24, A35, B35, B44 16*, 13*,
C13 Female A2, A29, B27, B44 0101, 1101 0501, 0301
C14 Female A2, A29, B7, B44 1501 06*
C15 Male A2, A l l ,  B7, B40 1501 1
C16 Female A l, A 3,B 35, B37 0101, 1501
C17 Male A l, A2, B35 1303, 1401 0301, 0503
C18 Female A l, A2, B 15,B 38 0301 0201
C19 Female Al l ,  A 68,B 35 0405, 0805
C20 Female A2, A3, B 7,B 18 1501,0401 0302, 0602
C21 Female A2, A24, B7, B35 2 ,4
C22 Female A24, A68, B I5, B27 0101, 1103 0501, 0301
* unresolved at allele level
Table 5-3 HLA class I and II molecular typing results of stem cell transplant patients.
Code Gender HLA Class I 
A and B
Class I I  HLA 
D R B l
Class II 
HLA D Q B l
PI Female A24, A31, B51, B27 0401,0408 03*, 03*
P2 Male A l, A2, B7 0103, 1501 0501,0602
P3 Female A2, A32, B51 1104, 1301 0603, 0301
P4 Male A29, A68, B49, B50 0102, 1001 0501
P5 Male A2, A31,B50,B35 1501,0701 06*, 02*
P6 Male A2, A2, B50, B35 1104, 1001 0501, 03*
P7 Female A24, A 11,B 15, B35 0101, 1103 0501,03*
P8 Female A24, A 11,B 51,B 27 1202, 0912 03*, 0303
P9 Female A 1,B 8 1107, 0701 02*, 03*
PIO Female A l, A2, B8, B40 0101,03011 0501,02*
* unresolved at allele level
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5.3.2 Results of HCMV Lysate and Peptide Pool Responses
The patient and control CD4+ T cell IFy responses to HCMV AD169 viral 
lysate, pp65 and IE1 peptide pools are shown in Table 5-4. The 
percen tage of the total CD4+ T cells of the patient population responding 
to HCMV viral lysate (1.34%) and the IE1 peptide pool (0.06%) 
significantly exceeded  the percentage of CD4+ T cell response of the 
normal controls (0.45% for HCMV viral lysate and 0.03%  for the IE1 
peptide pool, p = 0 . 0 1  and 0.03 respectively, Mann Whitney U test). The 
difference in the percen tage response to the pp65 peptide pool between 
the  patients and the  controls did not reach statistical significance (0.41% 
for the  patient population and 0 .2 1 % for the normal controls, p=0 . 1 1 
Mann W hitney U test). The percentage pp65 response  of the normal 
controls contributed to just less than half the percentage HCMV viral 
lysate response.
For normal controls, the absolute response to the HCMV viral lysate was 
3.65 IFy producing cells per pL, with the median absolute response to the 
pp65 peptide pool (1.97 IFy producing cells per pL) accounting for just 
over half the viral lysate response, while the median IE1 response (0.27 
IFy producing cells per pL) accounted for seven percent of the  viral lysate 
response . For the post transplant patient population, the absolute HCMV 
viral lysate response w as 3.99 IFy producing cells per pL, with the pp65 
peptide pool response (0.81 IFy producing cells per pL) accounting for 
tw enty percent of the viral lysate response, and the IE1 peptide pool 
re sp o n se  (0.24 IFy producing cells per pL) accounting for six percent.
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There w as no significant difference in the absolute IFy resp o n se  for any 
of the antigens.
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Table 5-4 CD4+ T cell interferon gamma response of patients and controls to HCMV viral 
lysate, and the pp65 and lE l  peptide pools.
Code
%
HCMV
Lysate
Response
Absolute
Lysate
Response
(IFy/pl)
%
lE l
response
Absolute
lE l
response
(IFy/pl)
%
pp65
response
Absolute
pp65
Response
(IFy/pl)
C l 0.93 7.12 0.03 0.26 0.28 2.17
C2 0.21 1.84 0.01 0.12 0.12 1.04
C4 0.41 2.56 0.00 0.00 0.00 0.00
C5 0.45 3.22 0.08 0.59 0.38 2.75
C6 0.77 5.98 0.07 0.51 0.25 1.96
C7 0.27 2.04 0.03 0.26 0.04 0.29
C8 1.81 20.49
C9 0.03 0.11 0.01 0.05 0.05 0.22
CIO 0.53 4.78 0.11 0.97 0.41 3.73
C l l 0.19 2.49
€ 1 2 0.22 1.22 0.05 0.28 0.07 0.38
€1 3 0.55 3.65 0.02 0.11 0.30 1.98
€ 1 4 1.23 12.28 0.03 0.29 0.51 5.08
€1 5 0.55 6.01 0.03 0.38 0.19 2.01
€ 1 6 0.97 14.91 0.00 0.05 0.19 2.89
€1 7 0.54 4.11 0.08 0.60 0.23 1.77
€1 8 0.06 0.47 0.03 0.27 0.03 0.27
€ 2 0 0.08 0.72
€ 2 2 0.38 5.77 0.00 0.06 0.22 3.34
M edian 0.45 3.65 0.03 0.27 0.21 1.97
Control
PI 0.22 0.20 0.01 0.01 0.04 0.03
P2 6.59 7.59 0.06 0.07 0.69 0.80
P3 1.13 3.82 0.06 0.20 0.66 2.23
P4 2.09 3.99 0.55 1.05 0.22 0.42
P5
P6 1.34 7.09 0.03 0.14 0.15 0.81
P7 0.64 2.74 0.14 0.58 0.41 1.77
P8 6.83 14.53 1.03 2.18 5.06 10.76
P9 9.26 35.54 0.84 3.23 2.12 8.13
PIO 0.26 1.19 0.05 0.24 0.10 0.43
M edian 1.34 3.99 0.06 0.24 0.41 0.81
Patients
P  value 0.01 0.52 0.03 0.52 0.11 0.95
M ann Whitney
Lysate and peptide data for C l9 and C21 unavailable
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5.3.3 Low Resolution Mapping
Low resolution mapping w as performed on all 32 individuals in the study. 
Representative plots of the FACS analysis of a  normal control response 
to pp65 and IE1 low resolution mapping pools is shown in Figure 5-1 and 
Figure 5-2. The percen tage of CD4-i- T cells producing interferon y in 
re sp o n se  to stimulation with the pp65 mapping pools is shown in Figure 
5-3 and for IE1 m apping pool is shown in Figure 5-4. Applying a threshold 
resp o n se  of 0.05% , 30 of the 32 (94 percent) individuals in the study had 
a resp o n se  to at least one pp65 peptide pool a s  illustrated in Figure 5-5. 
The m edian resp o n se  w as to two pp65 peptide pools (range 0 to 7), and 
although all the peptide pools elicited at least one response, the most 
im m unogenic regions of pp65 w ere identified a s  pools 1 (aa 1 to 71), 4-7 
(181 to 431) and pool 9 (aa 481 to 561). Tw enty-one out of 32 (55%) 
individuals responded to at least one peptide pool from IE1, with 9 out of 
10 (90%) patients having a  response. Figure 5-6. The m edian response 
w as to 1 peptide pool, with a  range of 0  to 7. The m ost immunogenic 
regions of IE1 were pools 1 (aa 1 to 71) and 6  (aa  301 to 371), although 
the  patient cohort also  show ed a significant response  to pool 4 (aa 181 to 
251) and pool 5 (aa 241 to 311).
P atien ts w ere significantly m ore likely to respond to  a  greater num ber of 
pp65 and IE1 mapping pools than the normal controls, with a  m edian 
re sp o n se  of 3.5 pools for both pp65 and IE1 com pared to a  median 
re sp o n se  of only 1 pool for pp65 and IE1 for the controls (p=0.03 for pp65 
and  p=0.04 for IE1 , Mann Whitney U Test), Figure 5-7. Thus the CD4 +
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immune response of transplant recipients is characterised  by greater 
diversity than normal controls. As the total CD4+ resp o n se  a s  
characterised  by the response  to HCMV lysate is similar betw een  the two 
groups, the m agnitude of the individual epitope resp o n ses  in transplant 
recipients is likely to be lower.
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Figure 5-1 Representative FACS plots of the CD4+ T Cell interferon gamma response to pp65 low resolution mapping pools.
The interferon y response of CD4+ T cells following stimulation with the pp65 low resolution mapping pools is shown for the normal control, C14. IFy APC vesus FSC is 
plotted for CD4+CD3+ cells for each mapping pool. The percentage positive cells are defined as the percentage of cells in the right upper quadrant.
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Figure 5-2 Representative FACS plots of the CD4+ T Cell interferon gamma response to lE l low resolution mapping pools.
The interferon y  response of CD4+ T cells following stimulation with the lE l low resolution mapping pools is shown for the normal control, C l4. IFy APC vesus FSC is 
plotted for CD4+CD3+ cells for each mapping pool. The percentage positive cells are defined as the percentage of cells in the right upper quadrant.
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Figure 5-3 Results of low resolution pp65 mapping of normal controls and patients.
The results of low resolution mapping of normal controls (n=21) and patients (n=10) with the pp65 low resolution mapping pools is illustrated as a three dimensional bar 
graph. The results are expressed as the percentage of the total CD4+ T cells producing interferon gamma in response to stimulation with each of the nine mapping pools.
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Figure 5-4 Results of low resolution lE l mapping of controls and patients.
The results of low resolution mapping of normal controls (n=21) and patients (n-10) with lE l low resolution mapping pools is illustrated as a three dimensional bar graph. 
The results are expressed as the percentage of the total CD4+ T cells producing interferon gamma in response to stimulation with each of the eight mapping pools.
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Figure 5-5 Percentage of patients and controls responding to each low resolution pp65 
mapping pool.
The percentage of the overall group (green, n=32), normal controls (red, n=22) and patients (blue, 
n=10) responding to each of the low resolution mapping pools of pp65 is shown as a bar graph. A 
response is defined as a CD4+ T cell interferon gamma response of greater than 0.05%.
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Figure 5-6 Percentage of patients and controls responding to each low resolution lE l  
mapping pool.
The percentage of the overall group (green, n=32), normal controls (red, n=22) and patients (blue, 
n=10) responding to each of the low resolution mapping pools of lE l is shown as a bar graph. A 
response is defined as a CD4+ T cell interferon gamma response of greater than 0.05%.
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Figure 5-7 Comparison of the number of IEI and pp65 peptide pool responses between patients and controls.
A scatter plot of the number of peptide pools eliciting a CD4+ T Cell interferon gamma response of greater than 0.05% for patients and normal eontrols is shown. The 
horizontal line indicates the median value. Each blue square represents the number of pp65 or lE l pools eliciting a response for the normal controls (n=22) and the red 
triangle for the patients (n=10). The difference was statistically significant for both IEI and pp65 (p=0.04 and 0.03 respectively, Man Whitney U Test)
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5.3.4 High Resolution Mapping
High-resolution m apping w as performed in 15 individuals (9 normal 
controls and 6  patients) to define HLA C lass II restricted pp65 and IEI 
ep itopes. High-resolution mapping identified thirteen individual HLA C lass 
II ep itopes, and they are  shown along with their likely HLA C lass II 
associations, Table 5.5. Six of th ese  epitopes, including one for IEI have 
not been  described previously. A representative plot of the FACS analysis 
of a  normal control response  to peptide num bers 9 to 12 from the pp65 
peptide pool 1 is illustrated Figure 5-8. The results of peptide pool 1 high 
resolution m apping of normal controls C l 4, C l 5 and Cl 6  is shown in 
Figure 5-10, dem onstrating a  maximal response to peptide num ber 11, 
with the  seq u en ce  LLQTGIHVRVSQPSL. This epitope h as  previously 
b een  described by Khattab and Li Pira, but ascribed to HLA DR15 
(Khattab et al., 1997; Li Pira et al., 2004b). Although all three responding 
individuals are HLA DRB1*15, based  on predicted anchoring residues the 
m ost likely HLA C lass II restriction for this epitope is HLA 
DQA 1 *0103/DQB1*0602 (Ettinger and Kwok, 1998), Figure 5-10, 
consis ten t with W eekes da ta  dem onstrating an HLA DQ6  restriction for 
this epitope (W eekes et al., 2004).
For patient P 1 , the immunodominant pp65 epitope was found to be 
HVLKAVFSRGDTPVLPHETRLLQ (pp65 a a  21 to 33), with equal 
re sp o n se s  to peptides num ber 7, 8 , and 9 of pp65 pool 1. The most likely 
HLA restriction is HLADRB 1*0401 a s  predicted by anchoring residues 
previously defined for this C lass II molecule (Friede et al., 1996), with F 
in position 1 of the nonam er binding groove. W hen this sequence  was
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en tered  into the SYFPEITHI epitope prediction program for HLA 
DRB1*0401, the 15 m er peptide, KAVFSRGDTPVLPHE achieved the 
maximum binding sco re  of 22, Table 5-5.
For control C l 3, the epitope does seem  likely to be DRBl *1101, and 
co rresponds with the predicted anchoring residues with F in position 1 of 
th e  binding groove (Verreck et al., 1996), and the predicted epitope from 
SYFPEITHI with a  sco re  of 26 is HPTFTSQYRIQGKLWE (auxiliary and  
main anchoring residues in bold), and this concurs with Li Pira findings. 
T he  epitope YRHTWDRHDEGAAQG does not appear to be an HLA 
DRBl *1501 epitope a s  the binding score following SYFPEITHI analysis is 
only 4. A DQBl *06 restriction may be possible but a s  this epitope w as 
only identified in one individual, this cannot be confirmed.
T he epitope PPWQAGILARNLVPMVATV (pp65 aa  485 to 503) ap p ea rs  
to be restricted to either DRBl *1101 or D Q B l*0301. Interestingly La P ira 
su g g ested  that the epitope could be p resen ted  by either DRB1*11 or 
DRBl *0301 but an alternative explanation is that the epitope is in fact 
p resen ted  by a  DQBl molecule shared  by th ese  individuals, a s  La Pira 
d o e s  not report the results of HLA C lass II DQ typing in her patient 
population. Analysis of the epitope by SYFPEITHI support a  non-DRB1 
restriction for this epitope, a s  the binding score for DRBl *0301 Is 13 
(Table 5-7) and DRBl *1101 is 15 (Table 5-8).
It ap p ea rs  likely that the  IEI epitope, MESSAKRKMDPDNPD (aa 1 to 15) 
is HLA DQBl *06 restricted, although this is based  on only two individuals. 
It w as not possible to attribute a  likely association to the pp65 epitopes 
SVLGPISGHVLKAVFSRGD (aa 13 to 31), VALRHVVCAHELVCS (aa
2 4 4
193 to 207), YRHTWDRHDEGAAQG (aa 381 to 395), 
TERKTPRVTGGGAMA (aa  413 to 427), GQNLKYQEFFWDANIYRI (aa 
517  to 531) and ANDIYRIFAELEGVW (aa 517 to 531).
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Table 5-5 HLA class II epitopes identified at high resolution.
(results in
Protein Site Sequence Code HLA DR HLA Association Previously Described
IEI 1 to 15 MESSAKRKMDPDNPD C17 DR13.14DQ 3,5 DQ5 No
IEI 1 to 15 MESSAKRKMDPDNPD P2 D R L15D Q 5.6 DQ5 No
pp65 13 to 31 SVLGPISGHVLKAVFSRGD PS DR9,12 DQ3 No
pp65 21 to 43 HVLKAVFSRGDTPVLPHETRLLQ PI DR4 DQ3 DR4 No
pp65 41 to 55 LLQTGIHVRVSQPSL C14 DR15DQ6 DQ6 (Li Pira et a i , 2004h) DRI5, (Kem et al., 2002) im i5 ,
pp65 41 to 55 LLQTGIHVRVSQPSL C15 m t \ 5 D Q m DQ6
(Weekes et al., 2004) DQ6
pp65 41 to 55 LLQTGIHVRVSQPSL C16 DRL15 DQ6
pp65 193 to 207 VALRHVVCAHELVCS Cl DR3,4 No
pp65 361 to 383 PQYSEHPTFTSQYRIQGKLEYRH C13 D R l,11 DQ3,5 D R ll (Li Pira et al., 2004b) D R /7
pp65 381 to 395 YRHTWDRHDEGAAQG C14 DR15DQ 6 No
pp65 413 to 427 TERKTPRVTGGGAMA C13 DR 1,11 DQ3,5 (Li Pira et al., 2004b) DR14
pp65 485 to 503 PPWQAGILARNLVPMVATV C13 DRL 11 D R ll orDQ3 (Li Pira et al., 2004b) D R U  or DR3
pp65 485 to 503 PPWQAGILARNLVPMVATV C22 DR 1,11 DQ3,5 D R ll orDQ3
pp65 485 to 503 PPWQAGILARNLVPMVATV P3 DR11,13DQ3,6 D R ll orDQ3
pp65 485 to 503 PPWQAGILARNLVPMVATV P6 DR10,11 DQ3,5 D R ll orDQ3
pp65 485 to 503 PPWQAGILARNLVPMVATV P7 D R L ll DQ3,5 D R ll orDQ3
pp65 489 to 503 AGILARNLVPMVATV C18 DR3 DQ2 DR3 (Li Pira et al., 2004b) D R ll or DR3, (Khattab et al., 
1997) 1DR3, (Kem et al., 2002) Not ascribed
pp65
pp65
pp65
505 to 523 
505 to 523 
505 to 527
GQNLKYQEFFWDANIYRI 
GQNLKYQEFFWDANIYRI 
GQNLK YQEFFWDANIYR IFAEL
P6
P7
C22
D R lO .ll DQ3,5 
D R L ll DQ3.5 
D R L ll DQ3,5
(Li Pira et al., 2(K)4b) D R l or DR3
pp65 509 to 523 KYQEFFWDANDIYRI CIS DR3 DR3 (Li Pira et al., 2004b) DR3 A D R l, (Trivedi et ai., 
2005) DQ5, (Kem et al., 2002) DR52, (Bitmansour et 
al., 2001) Not Ascribed
pp65 509 to 531 KYQEFFWDANDIYRIF AELEGVW CIO D R 3,\4D Q 3,4
pp65
pp65
517 to 531 
517 to 531
ANDIYRIFAELEGVW
ANDIYRIFAELEGVW
P6
P7
D R 10,U D Q 3,5
DR1,10DQ3,5
(Trivedi et al., 2005) DRl 1
Table 5-6 SYFPEITHI epitope prediction for HLA D R B l*0401 for the pp65 
immunodominant sequence, H VLK AVFSRG DTPVLPH ETRLLQ  (aa 21 to 33).
Position
o /r^
Peptide
Peptide Number 
1 2 3 4 5  67 8 9 0  1 2 3 4 5
score
4 K A V F S R G D T P V L P H E 22
1 H V L K A V F S R G D T P V L 18
8 S R G D T P V L P H E T R L L 12
9 R G D T P V L P H E T R L L Q 12
3 L K A V F S R G D T P V L P H 9
5 A V F S R G D T P V L P H E T 6
2 V L K A V F S R G D T P V L P 0
6 V F S R G D T P V L P H E T R 0
7 F S R G D T P V L P H E T R L 0
(Anchoring residues in bold)
Table 5-7 SYFPEITHI epitope prediction for HLA DRB1*0301 for the pp65 
immunodominant sequence, PPW Q AG ILARNLPM VATV (aa 485 to 503).
Position
Peptide
Peptide Number 
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5
s c o r e
4 Q A G I L A R N L V P M V A T 13
5 A G I L A R N L V P M V A T V 11
1 P P W Q A G I L A R N L V P M 10
3 W Q A G I L A R N L V P M V A 9
2 P W Q A G I L A R N L V P M V 8
(Anchoring residues in bold)
Table 5-8 SYFPEITHI epitope prediction for HLA DRB1*1101 for the pp65 
immunodom inant sequence, PPW Q AG ILARNLVPM VATV (aa 485 to 503).
Position Peptide Number s c o r e
o fT '
Peptide 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5
2 P W Q A G I L A R N L V P M V 15
1 P P W Q A G I L A R N L V P M 7
3 W Q A G I L A R N L V P M V A 7
4 Q A G I L A R N L V P M V A T 6
5 A G I L A R N L V P M V A T V 6
(Anchoring residues in bold)
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Figure 5-8 Representative FACS plots of high resolution peptide mapping for the identification of an immunogenic epitope from pp65 peptide pool 1.
Representative FACS plots o f the CD4+ T cell response to high resolution mapping for the normal control C 15 are shown, illustrating the response to stimulation with the 
individual mapping peptides 9 through to 12 from pp65 mapping pool 1. The interferon y  response is defined as the percentage of cells in the right upper quadrant.
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Peptide pp65 Pool 1
No.
1 M ESRGRRCPEM ISVL
2 GRRCPEM ISVLGPIS
3 PEMISVLGPISGHVL
4 SVLGPISGHVLKAVF
5 PISGHVLKAVFSRGD
6 HVLKAVFSRGDTPVL
7 AVFSRGDTPVLPHET
8 RGDTPVLPHETRLLQ
9 PVLPHETRLLQTGIH
10 HETRLLQTGIHVRVS
11 LLQTGIHVRVSQPSL
12 GIHVRVSQPSLILVS
13 RVSQPSLILVSQYTP
14 PSLILVSQYTPDSTP
15 LVSQYTPDSTPCHRG
Figure 5-9 Interferon gamma response as a percentage of total CD4+ T Cells following 
stimulation with individual peptides from pp65 peptide pool 1.
A three dimensional bar graph of the percentage of CD4+ T cells producing interferon y  in 
response to the individual mapping peptides from pp65 pool 1 is shown for normal controls 014  
(brown), €15  (blue), and 0 1 6  (green). The maximal response is to peptide 11 (aa 41 to 55) with 
the sequence LLQTGIHVRVSQPSL.
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Figure 5-10 Predicted anchoring residues o f the pp65 epitope, LLQTGIHVRVSQPSL for 
DQA1 *0103/DQB 1 *0602.
The predicted anchoring residues for the pp65 epitope, LLQTGIHVRVSQPSL (aa 45 to 55) is 
shown for the HLA class II molecule, DQA 1*0103/DQB 1*0602, with glutamine (Q) occupying 
the position of the binding groove.
DQB1*0602
4 6 92 3 7 81 5
T V
P
Q T G H V R V S
’ Dominant anchoring residue is in bold
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5.4 Conclusions
The results of this study confirm that in HCMV seropositive patients, the 
specificity of early CD4+ T cell recovery post allogeneic stem  cell 
transplantation is dom inated by HCMV, similar to the  findings in HIV 
infected patients (Pitcher e t al., 1999; W aldrup et al., 1997). The immune 
response to pp65 w as found to account for over half the total CD4+ T cell 
response  to HCMV in healthy normal controls, with IE1 contributing to 
approximately seven percent of the response. However the skewing of 
the  immune response tow ards pp65 w as less prominent in the post 
transplant patients, accounting for only twenty percent of the resp o n se  to 
HCMV viral lysate. Som e of this difference is due to a  proportionately 
g reater immune response  to IE1, but this study su g g ests  that o ther 
antigens, such as  gB and pplSO may also m ake significant to the  immune 
response . The specificity of HCMV reactive CD4+ T cells to an tigens 
o ther than pp65 and IE1 n eed s  to be further characterised  in allogeneic 
stem  cell transplant recipients.
Low resolution mapping of the  CD4+ T cell response  to the 
immunodominant HCMV proteins, pp65 and IE1 in both patients and  a  
large cohort of normal controls did not reveal any single im m unodom inant 
region of either pp65 or IE1, unlike the immune response  to CD 8  which 
tends to be charactised by one or a  few strongly dom inant ep itopes 
(Diamond et al., 19997; Kern e t al., 1999). This finding con trasts  with 
th o se  of Bitmansour (Bitm ansour et al., 2001) who found that the  CD4+ T 
cell response to HCMV w as dom inanted by 1 to 3 clones. However this
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work w as done using T cell lines generated  following prolonged 
stimulation with HCMV antigen in vitro, w hereas by a ssess in g  the 
functional response of unexpanded T cells dircectly from the patient, this 
study is m ore likely to reflect the  true nature of the HCMV specific 
im m une response  in vivo. Among stem  cell transplantation recipients, the 
im m une response  w as characterised  by a  broader range of epitopes than 
th e  normal controls, suggesting that the immune response is less 
focused . W eekes found in normal controls by clonotypic analysis that the 
CD4+ T cell immune response  to HCMV show ed a  focused but stable 
pattern  overtim e (W eekes et al., 2004). Thus the broader range of 
re sp o n ses  seen  in the allogeneic transplant recipient may represent 
face ts  of the early immune response  to HCMV. Alternatively, reactivation 
of HCMV in the allogeneic transplant setting may increase the frequency 
of HCMV specific subdom inant CD4+ T cell clones. It is not clear if a 
b roader antigenic response with multiple epitopes is required to control 
HCMV infection in the stem  cell transplant setting or if a  resp o n se  to a  
few  dom inant epitopes are sufficient. Analysis of HCMV specific C 8 + T 
cell resp o n ses  in HIV patients using overlapping peptides su g g est that 
patien ts with a  broader antigenic repertoire are  better able to control 
replication and prevent d isease , despite having a  similar abso lu te  
re sp o n se  (Sacre et al., 2005). In healthy individuals, there  is evidence 
th a t in order to mount and sustain a  functional immune resp o n se  to 
HCMV, both a  diversity in antigen specificity and a  persistent CD4+ T cell 
re sp o n se  are required for protective immunity (Sinclair et al., 2004). A 
com prehensive assessm en t of the CD4 + T cell immune resp o n se  to
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HCMV in a  larger num ber of a llogeneic  s tem  cell tran sp lan t recip ien ts 
over a  longer time period and  correlation with HCMV viral load d a ta  is 
required to clarify this question . This is su e  a lso  h a s  im portant practical 
im plications a s  restricting th e  range of HCMV reactive  c lo no types w hen 
gen era tin g  HCMV specific CD4+ T cells line for im m unotherapy , su ch  a s  
using  peptide pools from a  single protein su ch  a s  pp65  (R a u se r  e t al., 
2004) m ay com prom ise efficacy. In con trast, s tra teg ie s  th a t g e n e ra te  
HCMV specific CD4+ T cells with a  broad ran g e  of specificities su ch  a s  
th rough  the  u se  of HCMV infected au to logous fib rob lasts or w hole viral 
ly sa te  (W alter et al., 1995; P eg g s  e t al., 2001) would o v e rco m e  this issu e . 
This d a ta  a lso  su g g e s ts  tha t monitoring im m une reconstitu tion  by HCMV 
specific  c la ss  II te tram ers will have significant limitations d u e  to th e  b road  
an tigen ic  repertoire observed  in stem  cell tran sp lan t rec ip ien ts an d  th e  
low frequency  of individual ep itopes.
In this chap ter, high resolution m apping w as successfu lly  u se d  to  identify 
im m unodom inant ep itopes in both normal controls an d  p a tien ts. H ow ever, 
th e  attribution of c lass  It HLA restrictions to th e  ep ito p es  identified proved 
m ore  problem atic. D espite the  poor specificity in em pirically predicting 
C la ss  II ep itopes, prediction algorithm s su ch  a s  SYFPEITHI (R a m m e n se e  
e t al., 1999) w ere useful in attributing an im m unodom inant pep tide  
s e q u e n c e  to an  HLA DRB1 m olecule b a se d  on pred ic ted  binding motifs, 
a s  well a s  helping to  to narrow  down the  m ost likely s e q u e n c e . H ow ever, 
for HLA DR there  is only a  single a lpha  chain  allele, so  all th e  
polym orphism s a re  determ ined by the  b e ta  chain , simplifying ep ito p e  
prediction for DRB1. For HLA DP and  DO, both th e  a lp h a  an d  th e  b e ta
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chain  a re  highly polym orphic an d  both contribute to th e  pep tid e  binding 
specificity. The asso c ia tio n  of DRB2, 4 an d  5 a lle les  in a sso c ia tio n  with 
certa in  DRB1 types a d d s  an o th er level of com plexity to  th e  problem  of 
defining c lass  II ep itopes.
In a  num ber of c a se s , the  resu lts  of HLA C la ss  II a sso c ia tio n  of th e  
identified ep itopes d isag reed  with previously published  HLA a sso c ia tio n s  
(Kern e t al., 2002; W eek es  et al., 2004; Li Pira e t al., 2004b). O n e  
explanation  is tha t so m e  of the  authors, including Li Pira, did not c o n sid e r 
p ep tid e  p resen ta tion  through HLA DQB1 (Li Pira e t al., 2004b). All th ree  
HLA c la ss  II fam ilies (DP, DQ and  DR) h av e  previously b e e n  show n to be  
im portant for CD4+ helper T cell re sp o n se s  (G ehrz e t al., 1987). T he 
re su lts  of my study support the  im portance of DQ in HCMV an tigen  
p resen ta tio n . P resen tation  through DQ m ay acco u n t for th e  a p p a ren t 
ability of an  epitope to be  p resen ted  by m ore th an  o n e  DRB1 allele 
s u g g e s te d  by o ther w orkers (Burrows e t al., 2003). C o m p ared  to  DR, 
th e re  a re  only a  limited num ber of DQ alleles which ten d  to b e  relatively 
c o n se rv e d  am ong different populations. It is p o ssib le  th a t infection with 
HCMV h a s  exerted  selective p re ssu re  in th e  spec trum  of DQ a lle les  over 
tim e, a s  HCMV is known to have  co-evolved with h u m an s  (M cG eoch e t 
al., 1995). Further work is required to confirm which HLA C la ss  II family 
(DP, DQ or DR) an ep itope is restricted to by perform ing blocking 
ex p erim en ts  using m onoclonal an tibodies which block th e  C la ss  II binding 
s ite  a t th e  tim e of incubation of PBM Cs with th e  ta rg e t pep tide .
In a  recen t study using overlapping pep tides ex tend ing  a c ro ss  th e  en tire  
HCMV genom e, a t least 151 O R Fs containing im m unogenic  pep tid e
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s e q u e n c e s  for both CD8+ an d  CD4+ T-cells h av e  b e e n  d e sc rib ed  
(S ylw ester e t al., 2005). As th e  investigators u sed  p ep tid es  overlapping 
by 10 am ino acids, they  w ere not ab le  to a c c u ra te  define all ep ito p es  but 
did find prom inent re sp o n se s  to both th e  I E l an d  pp65  O R Fs. H ow ever, 
th e s e  w orkers a lso  show ed  in o rder to obtain  a  co m p arab le  CD 4+ T cell 
re s p o n se  to  a  peptide pool spanning  th e  entire  HCMV g en o m e, p ep tid es  
from  a  minimum of 6 of the  m ost im m unogenic O R F s n e ed  to  b e  u sed . 
T herefo re , restricting antigen re sp o n se s  to only pp65  an d  1E1 m ay limit 
th e  im m une re sp o n se  g en era ted  in so m e  individuals, an d  th e  
im m unogenicity of additional HCMV proteins n e e d s  to  be  s tud ied , for 
p o ssib le  inclusion a s  a  so u rce  of antigenic stimuli for im m unotherapy.
A s a  result of the  findings from this study, thym idine proliferation a s s a y s  
sh o u ld  be  perform ed to confirm that the  identified ep ito p es  a re  c ap a b le  of 
stim ulating CD4+ T cell proliferation. Furher work is n e e d e d  to  define the  
clonotypic natu re  of the  responding CD4+ T cell by analysing  V beta  
u s a g e . Following peptide stimulation, V beta u sa g e  could b e  a s s e s s e d  
e ith e r by flow cytom etry using fluorescen t labelled V beta  specific  
m onoclonal antibodies (lOTEST B eta Mark kit, Im m unotech, M arseille), 
o r alternatively by PCR, using V beta specific prim er s e ts  following 
se lec tio n  of reactive cells by cell sorting or gam m a cap tu re  tech n iq u e  
(Miltenyi). The results could be com pared  to a  c lonogram  derived  
following stim ulation with the  whole HCMV viral lysate  to a s s e s s  for o th e r 
dom inan t or subdom inant c lones. This information would fu rther e n h a n c e  
th e  understand ing  of the  role of HCMV specific CD4+ T cells in p ro tecting  
a llogeneic  s tem  cell transplant patien ts from HCMV infection.
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Chapter 6 General Discussion
T h e  p u rp o se  of this th e s is  w as to in crease  u n d ers tan d in g  of HCMV 
infection an d  th e  role of th e  im m une system  in controlling HCMV infection 
in a llogeneic  s tem  cell transplantation , in order to find w ays of reducing  
th e  morbidity and  mortality a sso c ia ted  with HCMV d is e a se . T h e  risk 
fac to rs  for HCMV infection w ere identified in a  large cohort of a llogeneic  
tra n sp lan t pa tien ts  and  a re  described  in C h ap ter Two of this th esis . T he 
ability of HCMV replication kinetics derived from real tim e PC R  m onitoring 
of HCMV viral load to predict HCMV d ise a se  and  th e  re sp o n se  to  antiviral 
th e ra p y  is described  in C hap ter T hree. A p rospective  s tudy  of th e  
reco v ery  of CD4+ and  CD8+ T cell immunity to HCMV following 
a llo g en e ic  s tem  cell transplan tation  is desc rib ed  in C h ap te r Four. A study  
to  ch a rac te rise  the  CD4+ T cell re sp o n se  to HCMV an d  identify c la s s  II 
HLA ep ito p es  for the  HCMV proteins pp65 and  IE1 in s tem  cell tran sp lan t 
p a tie n ts  and  norm al controls is described  in C h ap te r Five.
In th e  large cohort of patien ts described  in the  sec o n d  c h ap te r  of this 
th e s is , neither recipient or donor HCMV sero logy h a s  a  significant im pact 
on  survival, and  this provides indirect ev idence  for th e  efficacy of th e  
com bination  of high d o se  prophylactic aciclovir an d  a  pre-em ptive 
s tra teg y  to  prevent HCMV d ise a se  while limiting th e  a d v e rse  
c o n se q u e n c e s  of antiviral therapy, su ch  a s  th e  in c reased  ra te s  of 
infection a sso c ia ted  with ganciclovir u se  (Boeckh e t al., 1996; S a lzb e rg e r 
e t al., 1997). T he a b se n c e  of viraem ia in th e  R-D- g roup  su p p o rts  th e  
ap p ro a ch  of HCMV seronegative  blood p roducts for th is g roup  of pa tien ts.
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In th e  e ra  of un iversal leukodepletion the  n ecess ity  of this m ay  be  
d isp u ted , but a s  th e re  is ev id en ce  of g rea te r HCMV d is e a s e  following 
tran sfu sio n  of non-HCM V sero n eg a tiv e  leukodepleted  red cells (B ow den 
e t  al., 1995), this ap p ro ach  should  rem ain. The low incidence  of HCMV 
infection s e e n  in a llogeneic  transp lan t recipients with R-D+ HCMV 
sero lo g y , s u g g e s ts  tha t th e  acquisition of HCMV infection from a  positive 
d o n o r  is not inevitable. T herefore, although th e se  pa tien ts  a re  a t a  h igher 
risk  of HCMV infection than  R-D- patien ts, and  n e ed  HCMV su rveillance  
w ith pre-em ptive th e rap y  for viraem ia, they  a lso  require HCMV 
s e ro n e g a tiv e  blood products.
C h a p te r  Two a lso  identified the u se  of C am path-1 in vivo, but not ex  vivo, 
a s  a  m ajor risk fac to r for HCMV infection. T he im pact of in vivo C am p ath  
u s e  on HCMV infection w as g rea te s t in the  R-i-D- group co m p ared  to 
R + D - pa tien ts  not receiving C am path  in vivo, m ost likely d u e  to  th e  effect 
o n  pre-existing  recip ient HCMV specific immunity. T he finding th a t HCMV 
in fection  o ccu rs  significantly earlier in pa tien ts receiving C am path-1  G or 
C am p a th -1  H co m p ared  to patien ts not receiving C am path  in vivo 
s u p p o r ts  the  h y p o th esis  tha t the  u se  of C am path  in vivo h a s  th e  g re a te s t 
im p a c t on th e  recovery  of early HCMV specific im m une function. T he  fact 
t h a t  th e  m edian tim e  to o n se t of HCMV infection in pa tien ts  receiving 
C am p a th -1  H w as 30 .5  d ays and  the  very long half life of th e  an tibody  h a s  
im p o rtan t im plications for Im m unotherapy, a s  th e  prophylactic infusion of 
H C M V  specific  im m une com peten t cells could be  n eu tra lised  by th e  anti- 
C D 5 2  activity of C am path-1  H.
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This s tu d y  h a s  a lso  show n th a t th e  ch an g e  from C am path-1  G to 
C am path -1  H h a s  re su lted  in an  in c rease  in HCMV infection, an d  this is 
m ost likely d u e  to th e  longer half life of th e  h u m an ised  form of C am p ath  
(Morris e t al., 2003). T he s a m e  in vivo d o se  w as  u s e d  for both C am p ath - 
1G a n d  C am path-1  H in th e  pa tien ts  d esc rib ed  in C h ap te r  Two, th e re fo re  
p a tien ts  receiving C am path-1  H ex p erien ced  a  far g re a te r  level of in vivo 
T-cell depletion . A reduction in the  d o se  of C am path-1  H in vivo m ay  
re d u c e  th e  risks of e x ce ss iv e  T-cell depletion su ch  a s  in c re a se d  HCMV 
infection, an d  su ch  d o s e  d e -esca la tio n  s tu d ie s  a re  underw ay. In a  recen t 
s tudy , 30 m illigram s of C am path-1  H given for th re e  d ay s  p re -tran sp lan t 
re su lted  in significantly d e lay ed  recovery  of CD4+, CD8+, CDIO-k an d  NK 
cells co m p ared  to ATG (Thym oglobulin 2m g/kg for 3 days), but a  
reduction  of th e  d o se  of C am p ath  to  a  single d o s e  of 30m g w as  show n  to 
co rrec t th is d e lay  w ithout com prom ising im m une su p p re ss io n  (Ju liusson  
e t al., 2006). Initial re su lts  of th e  UK C am path-1 H d e -esca la tio n  trial, 
pu b lished  In a b s trac t form, h av e  show n that, co m p ared  to  BOmg of 
C am p ath , red u ced  d o s e s  a re  not a s so c ia te d  with in c re a se d  mortality 
(C hakraverty  e t al., 2006). The timing of C am path-1  H is a lso  critical, a s  a  
g re a te r  inc idence  of GHVD is s e e n  if C am path-1  H in vivo is u se d  7-8 
d a y s  prior to  s tem  cell tran sp lan t co m p ared  to 24-48  hours prior to 
tran sp lan t.
Ex vivo u se  of C am path-1  H for T-cell depletion  w as not a s so c ia te d  with a  
significantly in c reased  risk of HCMV infection in this study, an d  m ay 
re p re se n t an  a lternative ap p ro ach  to reducing  graft v e rsu s  h o st d is e a s e  
w ithout com prom ising im m une reconstitu tion  (C hakrabarti e t al., 200 3 a ;
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Novitzky e t al., 2004). This ap p ro a ch  an d  its im pact on th e  recovery  of 
HCMV specific im m unity w arran ts  further investigation.
T he study  of risk fac to rs  for late  HCMV infection d e sc rib ed  in C h ap te r 2 is 
su b jec t to se lec tion  b ia s  a s  only p a tien ts  perce ived  to b e  a t risk of HCMV 
infection underw en t e x ten d e d  HCMV PC R  surveillance. In this high risk 
cohort, pa tien ts  ex p erien c in g  HCMV infection before  100 d a y s  w ere 
identified a s  being  a t th e  g re a te s t risk for late HCMV infection on 
univariable Cox reg re ss io n  an alysis . H ow ever, in a  m ultivariable analysis , 
this factor w as no longer significant, while increasing  recipient a g e , a cu te  
GVHD, and  a  low C D 34 d o se  w ere  significant. T h e se  fac to rs all im pair 
th e  long term  recovery  of im m une function following a llogeneic  s tem  cell 
transp lan tation . U se of C am p ath  in vivo w as no longer a  significant fac to r 
after 100 days, su g g es tin g  th a t th e  g re a te s t im pact of C am p ath  is on 
HCMV infection risk early  p o st transp lan t. D ue to  th e  inheren t selec tion  
b ias  of this study, th e se  resu lts  m ust be  in terp re ted  with caution  an d  can  
only b e  applied  to pa tien ts  clinically perceived  to b e  a t high risk of HCMV 
infection. N ev erth eless, o lder pa tien ts, th o se  with a  poor s tem  cell d o se  
an d  p a tien ts  experiencing  GVHD, a s  well a s  p a tien ts  with HCMV infection 
a n d  a  se ro n eg a tiv e  d o nor shou ld  all h av e  ex ten d ed  m onitoring for HCMV 
viraem ia  beyond  100 d ays.
R eal tim e PC R  m onitoring of HCMV viral loads can  be  u se d  to  gu ide  p re ­
em ptive therapy, an d  h a s  th e  a d v an ta g e  of being a  very rapid te s t, with a  
tu rnaround  tim e of only 2 4  h o u rs  com p ared  to th e  minim um  two d ay  
tu rnaround  tim e using  a g a ro s e  gel b a se d  PC R  tech n iq u es . It h a s  b e e n
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show n th a t viral load  kinetics provides useful p rognostic  inform ation, 
predicting th e  likely re sp o n se  to  the rap y  an d  the  risk of d is e a s e . T he p e ak  
viral load, a  fa s te r  viral replication, and  a  pro longed  duration of viraem ia 
w ere  all found to  b e  significant predictors of p a tien ts  a t in c re a se d  risk of 
HCMV d is e a s e , an d  th e s e  pa tien ts  n e ed  to b e  ta rg e ted  for m ore  in tensive 
th e rap y  and  m onitoring. A lthough th e  p eak  viral load a n d  fa s te r  viral 
replication ra te s  h av e  previously  b e en  recogn ised  a s  risk fac to rs  for 
HCMV d is e a s e  (E m ery e t al., 2000; G or e t al., 1998), th e  resu lts  from 
C h ap te r T h ree  confirm th a t they  rem ain significant w hen a  s tra teg y  of 
pre-em ptive th e rap y  for HCMV infection is em ployed. B e c a u se  th e  resu lts  
a re  availab le in real tim e, th ey  c an  b e  u sed  for clinical m a n a g e m e n t of 
pa tien ts  with HCMV infection. T he ra te  of viral replication can  easily  b e  
calcu la ted  from th e  first two co n secu tiv e  PC R  positive resu lts  or th e  last 
negative  an d  the  first positive PC R  result, an d  prov ides th e  clinician with 
useful information, if sufficiently frequen t viral m onitoring, ideally tw ice 
w eekly  is perform ed. In a  m ultivariable analysis , it w as  found th a t the  
duration of viraem ia is th e  m ost significant risk fac to r for HCMV d ise a se , 
an d  th is is co n sis ten t with R e g o e s ’ recen t finding th a t th e  risk of d is e a s e  
h a s  a  b e tte r correlation with th e  total viral tu rnover ra ther th en  a  single 
p e a k  viral load (R eg o es  e t al., 2006). T hus, th e  goal of p re-em ptive 
th e rap y  should  be  to re d u c e  th e  total ex p o su re  of s tem  cell tran sp lan t 
p a tien ts  to HCMV viraem ia, ra th e r than  simply reducing  p e a k  viral loads.
A new  finding from th is s tu d y  is th a t a  de layed  re sp o n se  to therapy , with a  
p e a k  viral load occurring a fte r initiation of th erapy  a lso  p red ic ts  an  
in c re ase d  risk of d is e a s e , an d  this is likely to  reflect th e  m ore rapid viral
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replication rate , p robab ly  d u e  to  an  a b s e n c e  of HCMV specific immunity 
s e e n  in th e s e  p a tien ts.
T he s tra teg y  of im plem enting HCMV specific antiviral th e rap y  w hen th e  
viral load rises  ab o v e  a  level of 3000  g en o m e co p ies  of HCMV p e r ml, or 
two co n secu tiv e  HCMV PC R  positive resu lts, resu lted  in a  sub stan tia l 
num ber of p a tien ts  receiving th e rap y  unnecessarily , a s  ev id en ced  by th e  
a b se n c e  of v iraem ia a t th e  tim e th erapy  w as initiated. U sing viral 
replication ra tes, th e s e  p a tien ts  can  b e  identified, an d  further m onitoring 
con tinued  before initiating th e rap y . T he m ost app rop ria te  th resho ld  for th e  
initiation of therapy , a s  well a s  w hen to  d iscon tinue th e rap y  rem ain s  to  be  
determ ined , an d  fu rther clinical s tu d ie s  to estab lish  this a re  required .
Viral load dynam ics h av e  a lso  d em o n stra ted  th e  eq u iv a len ce  in efficacy 
of ganciclovir and  com bination  th e rap y  with ganciclovir/foscarnet. T he 
s a m e  app ro ach  should  b e  u se d  to  ev a lu a te  th e  efficacy of new  th e ra p ies  
for HCMV, su ch  a s  valganciclovir.
HCMV viral load kinetics by real tim e PC R  w as  not ab le  to  predict th e  risk 
of recu rren ce  of HCMV infection. T he only fac to r ab le  to  significantly 
predict an  in c reased  risk of recu rren ce  in pa tien ts  experiencing  a  first 
e p iso d e  of HCMV infection w as  th e  receip t of s tem  cells from an  HCMV 
se ro n eg a tiv e  donor. U nfortunately, a lthough th e s e  pa tien ts  a re  a lso  m ost 
likely to  benefit from adoptive im m unotherapy, this is only p o ssib le  if they  
h av e  an  HCMV seropositive  donor. HCMV vaccination  of se ro n eg a tiv e  
d o n o rs  could be  ev a lu a ted  a s  an  a lternative p reven tative s tra teg y  in 
th e s e  patien ts, a lthough th is d o e s  ra ise  ethical is su e s .
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T he pheno type of HCMV specific CD4+ T cells in pa tien ts  following 
allogeneic tran sp lan t w as found to be  of an  an tigen  ex p erien ced  m atu re  
pheno type and  sim ilar to  th e  pheno type  of HCMV specific CD4+ T cells in 
th e  norm al contro ls u se d  in this s tudy  an d  d esc rib ed  by o th ers  (A m yes e t 
al., 2003; S e s te r  e t al., 2002; W ee k e s  e t al., 2004). In this s tudy  HCMV 
specific CD4+ T cell recovery  a s  de term ined  by th e  re sp o n se  to th e  
HCMV viral lysate  w as found to be a  dom inant co m p o n en t of early  
im m une recovery p o s t transp lan t, but ab so lu te  levels tak e  a t le a s t a  y ea r 
to reach  the  s a m e  levels a s  norm al controls. T he re sp o n se  to  HCMV viral 
lysate  gave th e  b e s t indication of th e  s ta tu s  of HCMV specific immunity in 
th e  transp lan t recipient. pp65 specific re sp o n se s  recover early  post 
transp lan t, c losely mirroring viral lysate  re sp o n se s , while th e  IE1 recovery  
w as slow er. An HCMV specific T cell re sp o n se  of g re a te r  th an  o n e  cell 
p e r pL w as a sso c ia te d  with a  low risk of HCMV infection, while no 
protective level for HCMV specific CD8+ T cells by functional an a ly sis  
could be d em o n stra ted , in co n tra st to th e  findings using HCMV specific  
CD8+ te tram ers  in a llogeneic  s tem  cell tran sp lan t pa tien ts  (A ubert e t al.,
2001). B ec a u se  HCMV infection only occurred  in th e  a b s e n c e  of 
significant HCMV specific CD4+ T cell function, it w as  not p o ssib le  to 
a s s e s s  th e  im pact of th e  level of immunity on th e  replication rate.
It w as found tha t HCMV specific CD4+ T cell recovery w as s low er than  
CD 8+ T cell recovery. P a tien ts  with HCMV infection had  a  de lay ed  
recovery  of HCMV specific CD4+ T cell function but not CD8+ T cell 
function com p ared  to  p a tien ts  without infection, su g g es tin g  th a t CD4+ T 
cell immunity m ay be  a  m ajor limiting factor for th e  recovery  of functional
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HCMV immunity an d  pro tection  ag a in s t infection. C am path-1  H a lso  
correla ted  with d e lay ed  CD4+ T cell HCMV function, but not CD 8 -1- T cell 
function, and  this m ay  b e  th e  m echan ism  by which C am p a th -1 H 
in c rease s  the  risk of HCMV infection, a s  show n in C h ap te r O ne  of this 
th esis  and  this h a s  b e e n  repo rted  by o th er w orkers (C hakrabarti e t al.,
2002). Further s tu d ie s  a re  indicated  to ch a rac te rise  th e  recovery  of 
HCMV specific immunity, to  a s s e s s  if early  HCMV specific  T cells a re  of 
recipient or donor origin in pa tien ts  tran sp lan ted  a n d  a s s e s s  cytokine 
re sp o n se s  to HCMV o th er th an  interferon gam m a, su ch  a s  IL2 an d  TN Fa. 
T he central role of HCMV specific CD4+ T he lper cells m ay acco u n t for 
th e  beneficial effect s e e n  with im m unotherapy using polyclonal virus 
specific T cell c lones g e n e ra te d  by th e  sho rt term  culture of donor 
lym phocytes with m onocyte  derived dendritic cells pu lsed  with w hole viral 
lysate  (P eg g s  e t al., 2001), resulting in large n u m bers of HCMV specific 
CD4+ I  cells (P eg g s  e t al., 2003). Adoptive th e rap y  targeting  only CD 8 + 
HCMV specific T cells, su ch  a s  th o se  ob ta ined  by te tram er selec tion  
(C obbold e t al., 2005) m ay  not be  a s  effective. T he  u se  of a  viral lysate  
derived  from HCMV infected  cell cu ltu res is no longer feasib le , a s  this 
p rac tice  d o e s  not confirm to good  m anufacturing  p rac tices.
Incorporating an  a s s e s s m e n t  of HCMV specific im m une function using 
intracellular cytokine stain ing  p rov ides additional clinically re levan t 
inform ation in s tem  cell tra n sp lan t recipients. T he m onitoring of HCMV 
CD 4+ T cell specific im m une function by intracellular cytokine stain ing 
two w eekly following a llo g en e ic  s tem  cell transp lan tation  is labour 
in tensive and  not p ractical for routine practice. Restricting an a ly s is  to  day
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50 and day  100 p o st tran sp lan t m ay b e  a  m ore practical w ay of identifying 
patien ts at high risk of HCMV infection, and  requiring ex ten d ed  real tim e 
PCR monitoring for HCMV viraem ia, a s  well a s  identifying potential 
can d id a te s  for im m unotherapy.
T he investigation of th e  CD4+ T cell im m une re sp o n se  to HCMV viral 
lysate  and  to the  HCMV pro te ins pp65 and  IE1 sh o w ed  th a t am o n g  s tem  
cell transp lan t pa tien ts, th e  re sp o n se  to pp65 contribu ted  le ss  to  th e  total 
re sp o n se  to HCMV than  the  total re sp o n se  to  HCMV in norm al controls. 
T he pp65 and  IE1 specific im m une re sp o n se  of s tem  cell tran sp lan t 
pa tien ts  w as ch arac te rised  by a  b ro ad e r range  of ep ito p es  w hen 
co m p ared  to norm al controls. T h ere  is ev id en ce  th a t a  b road  an tigen ic  
re sp o n se  is im portant to  control HCMV infection in HIV pa tien ts  (S ac re  e t 
al., 2005), and  this m ay a lso  b e  th e  c a s e  following s tem  cell 
transp lan tation . This finding is a lso  particularly re levan t for HCMV specific 
im m unotherapy, a s  te ch n iq u es  tha t focus on a  few  im m unodom inant 
ep ito p es, su ch  a s  CD8+ te tram er selec tion  (Cobbold e t al., 2005) or u se  
of few  stim ulating p ep tid es  (R a u se r e t al., 2004) m ay not b e  a s  effective 
a s  tech n iq u es  that u se  HCMV viral lysate  (E insele e t al., 2002; P e g g s  e t 
al., 2001) or overlapping pep tide  pools of im m unodom inant p ro te ins 
(Trivedi e t al., 2005).
T he  study  of the  c la s s  II re sp o n se  to th e  HCMV pro teins pp65 an d  IE1 in 
norm al controls and  s tem  cell tran sp lan t pa tien ts h a s  identified 13 
ep ito p es  for pp65 an d  o n e  ep ito p e  for IE1, including six e p ito p e s  which 
hav e  not previously b e e n  d esc rib ed . Further work is required  to g e n e ra te  
ep itope  specific T cell lines, an d  a s s e s s in g  V beta restriction to  confirm
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clonality. T he im portance  of c la ss  II m olecu les o th e r th en  HLA DR in 
p resen ting  HCMV an tig e n s  to GD4+ T cells h a s  b e en  d e m o n stra ted  by 
show ing tha t so m e  of th e  identified pp65 ep ito p es  a re  p re sen te d  by HLA 
DQ m olecules. This finding in c re a se s  th e  level of com plexity in predicting 
th e  likely HCMV ep ito p e  re sp o n se  of allogeneic  tran sp lan t recip ien ts, a s  
this requires know ledge a t a  m olecu lar level of both th e  a lp h a  (for HLA 
DQ an d  DP) and  b e ta  ch a in s . A lthough HCMV specific ep ito p es  for which 
th e  c la ss  II HLA restriction is known c an  be  u sed  for m onitoring of 
im m une recovery following a llogeneic  s tem  cell transp lan ta tion , th e  
com plexity of c la ss  II HLA p resen ta tio n  p re se n ts  a  s trong  a rg u m en t for 
th e  app ro ach  of using overlapping  pep tide  pools to g e n e ra te  HCMV 
reactive T cell lines for im m unotherapy  irrespective of th e  tis su e  type of 
th e  donor. In the  light of S y lw este r’s  findings th a t p ro te ins from a t leas t six 
O R F s from HCMV a re  required to  rep licate  th e  total re sp o n se  (S y lw ester 
e t al., 2005), evaluation of th e  re sp o n se  to  pep tide  pools of 
im m unodom inant pro teins o th e r than  pp65 an d  IE1 for stim ulation of 
d o nor cells for im m unotherapy  is required . T he  optim al ap p ro ach  to 
im m unotherapy tha t a lso  conform s to  GM P s ta n d a rd s  would be  
stim ulation of donor derived  PBM Cs with overlapping pep tide  pools from 
a  n um ber of the  m ost im m unogenic  HCMV proteins, an d  the  selec tion  of 
reactive  CD4+ a n d  CD8+ T cells by a  tech n iq u e  su ch  a s  th e  interferon 
g am m a  cap tu re  tech n iq u e  d e sc rib e d  by R au se r e t al (R au se r e t al.,
2 0 0 4 ).
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This th esis  h a s  in c re a se d  th e  know ledge of HCMV infection in a llogeneic  
s tem  cell transp lan t rec ip ien ts. This study h a s  show n th a t th e  u se  of 
C am path-1 H in vivo but not ex  vivo significantly in c reased  th e  risk of 
HCMV infection in a llogeneic  tran sp lan t pa tien ts. T he study  of real tim e 
PC R  for quantitation of viral load confirm ed tha t a  h igher p e a k  viral load 
an d  fa s te r viral replication rem ain  risk fac to rs  for HCMV d is e a s e  w hen 
pre-em ptive th erapy  for HCMV infection is u sed , but the  to tal duration  of 
v iraem ia is now th e  m ost significant risk factor. T hrough p ro sp ec tiv e  
monitoring of HCMV specific im m une function in s tem  cell tran sp lan t 
recipients, the  central role of HCMV specific CD4-i- T cells in controlling 
HCMV infection h a s  b e en  identified. A n um ber of new  HCMV specific  
c la s s  II ep itopes with potential u se  In im m une m onitoring following 
transp lan tation  have  b e en  desc rib ed , an d  th e  im portance  of c la s s  II 
m olecu les o ther then  HLA DB1 in p resen tin g  HCMV an tig e n s  to  CD4+ T 
cells h a s  b een  highlighted. A s a  resu lt of th e  work in th is th e s is , a  num ber 
of new  questions h av e  b e e n  g e n e ra te d  which require fu rther 
investigation. Clinical trials a re  required  to identify th e  m ost ap p ro p ria te  
th resho ld  to initiate HCMV specific antiviral th e rap y  a n d  to d iscon tinue  
antiviral therapy. Further p ro spective  s tu d ie s  of HCMV specific  im m une 
recovery  following a llogeneic  transp lan ta tion  should  b e  perform ed, 
including the  cytokine re sp o n se  o th e r than  interferon g am m a  to  HCMV, 
a n d  w hether early HCMV specific  T cell recovery  is of donor o r recipient 
origin. Further work is requ ired  to  ch a rac te rise  th e  specificity a n d  
functional s ta tu s  of th e  CD 4+ T cell im m une re sp o n se  to HCMV in 
allogeneic s tem  cell tran sp lan t recipients, including clonotypic he irachy  of
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responding  T cells, proliferation potential in re sp o n se  to  identified 
ep itopes, an d  ep ito p e  m app ing  of p ro te ins o th e r than  pp65 an d  IE1.
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Appendix A
Patient Consent for HCMV Immune Reconstitution Study
PARTICIPANT CONSENT FORM
TITLE OF PRO JECT
Monitoring of CMV antigen specific T cells in Bone marrow transplant patients 
before and after transplant.
The patient should complete the whole of this sheet themselves.
Have you read the Patient Information Sheets? YES / NO
Have you had an opportunity to ask questions and discuss YES/NO
this study?
Have you received satisfactory answers to all your questions? YES / NO
Have you received enough information about the study? YES / NO
Who have you spoken to? Dr / Mr / Mrs______________________________
Do you understand that you are free to withdraw from the 
study at any time, without having to give a reason for
withdrawing and without affecting your future medical care? YES / NO
Do you agree to enter your this study and in doing so give 
permission for the researchers to have access to your
medical notes? YES / NO
Do you give permission for us to notify your GP that you have
entered this study? YES / NO
Do you agree to enter in this study? YES / NO
Patient s name   ____
(in block letters)
Signature______________________   Date_I________ I_________ I_______ 1
Dr’s signature .___________________   Date_I ___ I i____ I
Dr’s name ______________________________________________________
(in block letters)
F i t e  one copy Ti patien ts notes, one copy in CRF and one copy to patient
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Patient Information Sheet
Monitoring of CMV antigen specific T cells in Bone Marrow 
transplantpatiens before and after transplant.
We at the Anthony Nolan Research Institute and Haematology Dept of the RFH 
are currently embarking on a project to investigate the reconstitution of the 
immune system after bone marrow transplantation. As you are aware, the 
immune system is severely depleted after pre-transplant conditioning. Research 
has shown that specific cells in the normal immune system are responsible for 
combating many virus infections but of specific importance to transplant patients 
is CMV. The precise details of how fast these cells regenerate and how effective 
they are in fighting CMV virus in Bone marrow transplant patients still remains 
unclear. This project uses newly developed techniques which will provide 
valuable information about the levels and activity of these cells in patients after 
bone-marrow transplantation.
To help us carry out this work we require 20mls of blood. These samples would 
be taken at the same time as the regular checks occurring at the hospital and will 
not require additional venepuncture.
TRANSPLANT RECIPIENTS- blood is required prior to transplant and then 
subsequently at the same times when blood is being taken for routine monitoring 
of CMV status, this is usually twice weekly during the early phase post 
transplant. Monitoring will continue at outpatient appointments.
DONORS- blood is required once at the pre-donation health check.
The cells extracted from these samples will only be used for the research project 
that the patients has agreed to take part in.
The proposed study will use class I soluble HLA molecules in the form of 
tetramers. These will be used to specifically detect the presence of circulating 
antigen specific T cells in the peripheral blood of patients who reactivate CMV 
following BMT.
CMV viraemia is a significant problem in immunosuppressed patients following 
BMT and before their new haemopoietic system has been able to fully develop to 
provide appropriate level of immune response to counteract the occurrence of 
CMV infection de novo or through the reactivation of pre-existing CMV. 
Monitoring the immune potential of a patient to mount a specific immune 
response to a virus such as CMV, will allow us to obtain a better understanding 
of what is happening to the CMV specific T cells in patients who reactivate 
CMV post BMT or who develop de-novo CMV viraemia following BMT. The 
acquisition of such data will allow us to correlate the ability of patients to resolve 
CMV with the concurrent expansion or development of CMV specific CD8 T 
cells in their peripheral circulation. The analysis of such imformation has 
implications for improved therapy or clinical intervention at specific time points 
resulting in improved treatment of patients developing CMV disease post BMT.
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The role of CMV specific CD8+ T cells in the resolution of CMV viraemia is 
well documented. However specific details about the dynamics of expanded 
CMV +ve populations, the relative relecance of CD4+ T cells to the action of 
CD8 antigen.
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Appendix B
pp65 Peptide Pool Composition
Peptide# Sequence
1 MESRGRCPEMISVL
2 GRRCPEMISVLGPIS
3 PEMISVLGPISGHVL
4 SVLGPISGHVLKAVF
5 PISGHVLKAVFSRGD
6 HVLKAVFSRGDTPVL
7 AVFSRGDTPVLPHET
8 RGDTPVLPHETRLLQ Pool 1
9 PVLPHETRLIQTGIH
10 HETRLLQTGIHVRVS
11 LLQTGIHVRVSQPSL
12 GIHVRVSQPSLILVS
13 RVSQPSLILVSQYTP
14 PSLILVSQYTPDSTP
15 LVSQYTPDSTPCHRG
16 YTPDSTPCHRGDNQL
17 STPCHRGDNQLQVQH
18 HRGDNQLQVQHTYFT
19 NQLQVQHTYFTGSEV
20 VQHTYFTGSEVENVS
21 YFTGSEVENVSVNVH
22 SEVENVSVNVHNPTG
23 NVSVNVHNPTGRSIC Pool 2
24 NVHNPTGRSICPSQE
25 PTGRSICPSQEPMSI
26 SICPSQEPMSIYVYA
27 SQEPMSIYVYALPLK
28 MSIYVYALPLKMLNI
29 VYALPLKMLNIPSIN
30 PLKMLNIPSINVHHY
31 LNIPSINVHHYPSAA
32 SINVHHYPSAAERKH
33 HHYPSAAERKHRHLP
34 SAAERKHRHLPVADA
35 RKHRHLPVADAVIHA
36 HLPVADAVIHHASGKQ
37 AD A VIH AS GKQMWQ A
38 IHASGKQMWQARLTV Pool 3
39 GKQMWQARLTVSGLA
40 WQARLTVSGLAWTRQ
41 LTVSGLAWTRQQNQW
42 GLAWTRQQNQWKEPD
43 TRQQNQWKEPDVYYT
44 NQWKEPDVYYTSAFV
45 EPDVYYTSAFVFPTK
46 YYTSAFVFPTKDVAL
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47 AFVFPTKDVALRHVV
48 PTKDVALRHVVCAHE
49 VALRHVVCAHELVCS
50 HVVCAHELVCSMENT
51 AHELVCSMENTRATK
52 VCSMENTRATKMQVI
53 ENTRATKMQVIGDQY Pool 4
54 ATMQVIGDQYVKVY
55 QVIGDQYVKVYLESF
56 DQYVKVYLESFCEDV
57 KVYLESFCEDVPSGK
58 ESCEDVPSGKLFMH
59 EDVPSGKLFMHVTLG
60 SGKLFMHVTLGSDVE
61 FMHVTLGSDVEEDLT
62 TLGSDVEEDLTMTRN
63 DVEEDLTMTRNPQPF
64 DLTMTRNPQPFMRPH
65 TRNPQPFMRPHERNG
66 QPFMRPHERNGETVL
67 RPHERNGFTVLVPKN Pool 5
68 RNGFTVLCPKNMIIK
69 TVLCPKNMIIKPGKI
70 PKNMIIKPGKISHIM
71 IIKPGKISHIMLDVA
72 GKISHIMLDVAFTSH
73 HIMLDVAFTSHEHFG
74 DVAFTSHEHFGLICP
75 TSHEHFGLICPKSIP
76 HFGLLCPKSIPGLSI
77 LCPKSIPGLSISGNL
78 SIPGLSISGNLIMNG
79 LSISGNLLMNGQQIF
80 GNLLMNGQQIFLEVQ
81 MNGQQIFLEVQAIRE
82 QIFLEVQAIRETVEL
83 EVQAIRETVELRQYD Pool 6
84 IRETVELRQYDPVAA
85 VELRQYDPVAALFFF
86 QYDPVAALFFFDIDL
87 VALFFFDIDLLLQR
88 FFFDIDLLLQRGPQY
89 IDLLLQRGPQYSEHP
90 LQRGPQYSEHPTFTS
91 PQYSEHPTFTSQYRI
92 EHPTFTSQYRIQGKL
93 FTSQYRIQGKLEYRH
94 YRIQGKLEYRHTW DR
95 GKLEYRHTW DRHDEG
96 YRHTW DRHDEGAAQG
97 W DRHDEGAAQGDDDV
98 DEGAAQGDDDVW TSG Pool 7
99 AQGDDDVW TSGSDSD
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100 DDVWTSGSDSDEELV
101 TSGDSDEELVTTER
102 DSDEELVTTERKTPR
103 ELVTTERKTPRVTGG
104 TERKTPRVTGGGAMA
105 TPRVTGGGAMAGAST
106 TGGGAMAGASTSAGR
107 AMAGASTSAGRKRKS
108 ASTSAGRKRKSASSA
109 AGRKRKSASSATACT
110 RKSASSATACTSGVM
111 SSATACTSGVMTRGR
112 ACTSG VMTRGRLK AE
113 GVMTRGRLKAESTVA Pool 8
114 RGRLKAESTVAPEED
115 KAESTV APEEDTDED
116 TVAPEEDTDEDSDNE
117 EEDTEDSDNEIHNP
118 DEDSDNEIHNPA VET
119 DNEIHNPAVFTWPPW
120 HNPAVFTWPPWQAGI
121 VFTWPPWQAGILARN
122 PPWQAGILARNLVPM
123 AGILARNLVPMVATV
124 ARNILPMVATVQGQN
125 VPMVATVQGQNLKYQ
126 ATVQGQNLKYQEFFW
127 GQNLKYQEFFWDAND
128 KYQEFFWDANDIYRI Pool 9
129 FFWDANDIYRIFAEL
130 ANDIYRIFAELEGVW
131 YRIFAELEGVWQPAA
132 AELEGVWQPAAQPKR
133 GVWQPAAQPKRRRHR
134 PAAQPKRRRHRQDAL
135 PKRRRHRQDALPGPC
136 RHRQDALPGPCIAST
137 DALPGPCIASTPKKH 
13 8 LPGPCIASTPKKHRG
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IE1 Peptide Pool Composition
Peptide^ Sequence
1 MESSAKRKMDPDNPD
2 AKRKMDPDNPDEGPS
3 MDPDNPDEGPSSKVP
4 NPDEGPSSKVPRPET
5 GPSSKVPRPETPVTK
6 KVPRPETPVTKATTF
7 PETPVTKATTFLQTM
8 VTKATTFLQTMLRKE Pool 1
9 TTFLQTMLRKEVNSQ
10 QTMLRKEVNSQLSLG
11 RKEVNSQLSLGDPLF
12 NSQLSLGDPLFPFPELA
13 SLGDPLFPELAEESL
14 PLFPELAEESLKTFE
15 ELAEESLKTFEQVTE
16 ESLKTFEQVTEDCNE
17 TFEQVTEDCNENPEK
18 VTEDCNENPEKDVLA
19 CNENPEKDVLAELVK
20 PEKDVLAELVKQIKV
21 VLAELVKQIKVRVDM
22 LVKQIKVRVDMVRHR
23 IKVRVDMVRHRIKEH Pool 2
24 VDMVRHRIKEHMLKK
25 RHRIKEHMLKKYTQT
26 KEHMLKKYTQTEEKF
27 LKKYTQTEEKFTGAF
28 TQTEEKFTGAFNMMG
29 EKFTGAFNMMGGCLQ
30 GAFNMMGGCLQNALD
31 MMGGCLQNALDILDK
32 CLQNALDILDKVHEP
33 ALDIDKVHEPFEEM
34 LDKVHEPFEEMKCIG
35 HEPFEEMKCIGLTMQ
36 EEMKCIGLTMQSMYE
37 CIGLTMQSMYENYIV
38 TMQSMYENYIVPEDK Pool 3
39 MYENYIVPEDKREMW
40 YIVPEDKREMWMACI
41 EDKREMWMACIKELH
42 EMWMACIKELHDVSK
43 ACIKELHDVSKGAAN
44 ELHDVS KGAANKLGG
45 VSKGAANKLGGALQA
46 AANKLGGALQAKARA
47 LGGALQAKARAKKDE
48 LQAKARAKKDELRRK
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49 ARAKKDELRRKMMYM
50 KDELRRKMMYMCYRN
51 RRKMMYMCYRNIEFF
52 MYMCYRNIEFFTKNS
53 YRNIEFFTKNSAFPK Pool 4
54 EFFTKNSAFPKTTNG
55 KNSAFPKTTNGCSQA
56 FPKTTNGCSQAMAAL
57 TNGCSQAMAALQNLP
58 SQAMAALQNLPQCSP
59 AALQNLPQCSPDEIM
60 NLPQCSPDEOMAYAQ
61 CSPDEIMAYAQKIFK
62 EIMAYAQKIFKILDE
63 YAQKIFKILDEERKDK
64 IFKILDEERDKVLTH
65 LDEERDKVLTHIDHI
66 RDKVLTHIDHIFMDI
67 LTHIDHIFMDILTTC Pool 5
68 DHIFMDILTTCVETM
69 MDILTTCVETMCNEY
70 TTCVETMCNEYKVTS
71 ETMCNEYKVTSDACM
72 NEYKVTSDACMMTMY
73 VTSDACMMTMYGGIS
74 ACMMTMYGGISLLSE
75 TMYGGISLLSEFCRV
76 GISLLSEFCRVLCCY
77 LSEFCRVLCCYVLEE
78 CRVLCCYVLEETSVM
79 CCYVLEETSVMLAKR
80 LEETSVMLAKRPLIT
81 SVMLAKRPLITKPEV
82 AKRPLITKPEVISVM
83 LITKPEVISVMKRRI Pool 6
84 PEVISVMKRRIEEIC
85 SVMKRRIEEICMKVF
86 RRIEEICMKVFAQYI
87 EICMKVFAQYILGAD
88 KVFAQYILGADPLRV
89 QYILGADPLRVCSPS
90 GADPLRVCSPSVDDL
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91 LRVCSPSVDDLRAIA
92 SPSVDLRAIAEESD
- 93 DDLRAIAEESDEEEA
94 AIAEESDEEEAIVAY
95 ESDEEEAIVAYTLAT
96 EEAIVAYTLATAGVS
97 VAYTLATAGVSSSDS
98 LATAGVSSSDSLVSP Pool 7
99 GVSSSDSLSPPESP
100 SDSLVSPPESPVPAT
101 VSPPESPVPATIPLS
102 ESPVPATIPLSSVIV
103 PATIPLSSVIVAENS
104 PLSSVIVAENSDQEE
105 VIVAENSDQEESEQS
106 ENSDQEESEQSDEEE
107 QEESEQSDEEEEEGA
108 EQS DEEEEEGAQEER
109 EEEEEGAQEEREDTV
110 EGAQEEÏŒDTVSVKS
111 EEREDTVSVKSEPVS
112 DTVSVKSEPVSEIEE
113 VKSEPVSEIEEVAPE Pool 8
114 PVSEIEEVAPEEEED
115 lEEVAPEEEEDGAEE
116 APEEEEDGAEEPTAS
117 EEDGAEEPTASGGKS
118 AEEPTASGGKSTHPM
119 TASGGKSTHPMVTRS
120 GKSTHPMVTRSKADQ
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